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adequately and supportthe dataandresults giveninthis
Technical Report.
Conclusions: Under the conditions of these 2-year
gavage studies, there was some evidence of car-
cinogenic activity for male F344/N rats that received
100 mg/kg 2-amino-5-nitrophenol, as shown by the
increased incidence of acinar cell adenomas ofthe pan-
creas. Reduced survival of male F344/N rats that
received 200 mg/kg decreased the sensitivity of this
group for detecting a carcinogenic response. There was
no evidence of carcinogenic activity for female rats
that received 100 or 200 mg/kg per day. Marginally
increased incidences of preputial or clitoral gland ade-
nomas or carcinomas (combined) occurred in male and
female F344/N rats administered 200 mg/kg 2-amino-5-
nitrophenol. There was no evidence of carcinogenic
activity for B6C3F1 mice that received 400 mg/kg
2-amino-5-nitrophenol; reduced survivalofB6C3F1 mice
that received 800 mg/kg caused this group to be consid-
ered inadequate for detecting a carcinogenic response.
Report Date: February 1988
TR-335 lTxicology and Carcinogenesis
Studies ofC.I. Acid Orange 3 (CAS No.
6373-74-6) in F344/N Rats and B6C3F
Mice (Gavage Studies)
C.I. Acid Orange 3 is a dinitrodiphenylamine deriva-
tive used exclusively as adye (up to 0.2%) in semiperma-
nent hair coloring products. This study was one of a
series on semipermanent hair dyes, which included HC
Blue No.1 (NTP TR 271), HC Blue No. 2 (NTP TR 293),
HC Red No. 3 (NTP TR 281), and C.I. Disperse Blue 1
(NTP TR 299). Toxicology and carcinogenesis studies of
C.I. Acid Orange 3 (90% pure, containing 10% water for
short-term studies and containing 6%-8% water and
2%-4% acetone for 2-year studies) were conducted by
administering the dye in corn oil by gavage to F344/N
ratsandB6C3F1 miceofeachsexfor14days,13weeks, or
2 years.
Fourteen-Day and Thirteen-Week Studies: In the 14-
daystudies (at94-1,500mg/kginratsand62-1,000mg/kg
in mice), no compound-related deaths or body weight
changes were observed and no adverse effects were
observed at necropsy.
In the 13-week studies (at 94-1,500 mg/kg in rats and
31-2,000mg/kginmice), compound-relatedkidneylesions
were observedinrats andmice ofeach sex.Theselesions
includedvariabledegreesofdegenerationandnecrosisof
epithelial cells in the proximal convoluted tubules,
regeneration oftubularepithelium, andgranularcastsin
the tubules. In a few female rats of the highest dose
group, necrosis of the renal papillae and suppurative
inflammation were also observed. Mean body weights
were generally comparable among groups of rats and
mice. Mice receiving 2,000 mg/kg had body weights
11%-12% lower than those ofvehicle controls. Five of10
female ratsthatreceivedthehighestdoseof1,500mg/kg
diedbeforetheendofthe study,butnocompound-related
deaths occurred in male rats or mice ofeither sex.
Based on these results, 2-year studies of C.I. Acid
Orange 3 were conducted by administering the dye by
gavage in corn oil at 0, 375, or 750mg/kgto groups of50
F344/N rats ofeach sex, 5 days perweek for 103 weeks.
Groups of 50 male B6C3F1 mice were administered 0,
125, or 250 mg/kg C.I. Acid Orange 3 on the same
schedule, and groups of 50 female B6C3F1 mice were
administered 0, 250, or 500 mg/kg. These doses were
selected on the basis of the nature and severity of the
renal lesions in both species.
Body Weights and Survival in the Two-Year Studies:
Mean body weights of high dose rats were generally
more than 10% lowerthan those ofvehicle controls after
week 52 for males and week 70 for females. Mean body
weights forlowdose groupswere comparable to those of
vehicle controls. The survival of high dose male (after
week 33) and female (after week 14) rats was lower
(P<0.05)thanthatofvehicle controls andwasattributed
to nephrotoxicity (final survival-male: vehicle control,
36/50; low dose, 30/50; high dose, 0/50; female: 43/50;
34/50; 7/50). Mean body weights of dosed male and
female mice were lower than those of vehicle controls
(high dose, 5%-11% after week 74; low dose, 7%-17%
afterweek 48). Survival ofboth the lowdose (afterweek
102) and high dose (afterweek 100) groups ofmale mice
waslowerthanthatofthevehiclecontrols (finalsurvival:
38/50; 25/50; 26/50). Although survival was lower than
usual, no notable differences in survival were observed
between groups of female mice (final survival: 23/50;
23/50; 24/50).
Nonneoplastic and Neoplastic LesionsintheTwo-Year
Studies: For both species, the kidney was the major
target organ for C.I. Acid Orange 3. These findings are
summarized in the accompanying table. The incidences
of renal pelvic epithelial hyperplasia were increased in
dosed rats of each sex. No renal neoplasms were
observed in dosed male rats, but atubular cell adenocar-
cinoma was observed in a vehicle control male rat. Six
transitioilal cell carcinomas ofthe kidneywere observed
in high dose female rats; kidney transitional cell neo-
plasms have not been observed in 1,697 corn oil vehicle
control female F344/N rats.
Nonneoplastic lesions characteristic of secondary
renal hyperparathyroidism or secondary to uremia also
occurred in dosed rats. The lesions included parathyroid
hyperplasia, fibrous dysplasiaofbone, erosion andulcers
oftheglandularstomach, andmineralization ofthe aorta
and glandular stomach.
Epithelial hyperplasia of the urinary bladder was
observed in one low dose and three high dose female
mice.Asquamous cell carcinomawas seenintheurinary
bladder of one low dose female mouse. Even though no
squamous cell urinary bladder neoplasms have been
observed in 1,665 corn oilvehicle control female B6C3F1
mice, this single neoplasm in a low dose animal was not
considered toberelated totheadministration ofC.I.Acid
Orange 3.4NTP/NIEHS
Genetic Toxicology: C.I. Acid Orange3was mutagenic
with and without exogenous metabolic activation in Sal-
monella typhimurium strains TA97; TA98; andTA100;
no mutagenicity was observed for strain TA1535.
Audit: The data, documents, and pathology materials
from the 2-year studies ofC.I. Acid Orange 3 have been
audited. The audit findings show that the conduct ofthe
studies is documented adequately and support the data
and results given in this Technical Report.
Conclusions: Under the conditions of these 2-year
gavage studies, there was no evidence ofcarcinogenic
activity of C.I. Acid Orange 3 for male F344/N rats
administered 375 mg/kg; because ofamarked reduction
in survival and no indication ofcarcinogenicity, the 750
mg/kggroupwasconsideredtobeinadequateforassess-
ment ofcarcinogenic activity. There was clear evidence
ofcarcinogenicactivity ofC.I.AcidOrange3forfemale
F344/N rats as shown by the occurrence oftransitional
cellcarcinomasofthekidneyinthe750mg/kggroup;this
group had reduced survival and chemically related non-
neoplastic lesions ofthe kidney. There was no evidence
ofcarcinogenic activity ofC.I. Acid Orange 3 for male
B6C3F1 mice administered 125 or 250 mg/kg or for
female B6C3F1 mice administered 250 or 500 mg/kg.
Nonneoplastic lesions of the kidney were observed in
both dose groups ofboth sexes ofrats and mice.
Synonyms: 2-anilino-5-(2,4-dinitroanilino)-benzene-
sulfonic acid, monosodium salt; 5[(2,4-dinitrophenol)-
amine]-2-(phenylamine)-benzenesulfonic acid,
monosodium salt; C.I. 10385; Tetracid Light Yellow 2R
Report Date: December 1988
TR-336 Ibxicology and Carcinogenesis
Studies ofPenicillin VK (CAS No. 132-98-9)
in F344/N Rats and B6C3F1 Mice (Gavage
Studies)
PenicillinVK, awidelyused antibioticfortreatment of
gram-positive coccalinfections,was nominated forstudy
by the National Cancer Institute because rodent car-
cinogenicity studies for this drug had not been per-
formed.Thechemical (94%or98%pure,USPgrade)was
administered orally (by gavage in corn oil) because oral
administration is the primary route used to treat infec-
tionsinhumans. Fourteen-day,13-week, and2-yearstud-
ies were conducted in F344/N rats and B6C3F1 mice.
Additionalstudieswereperformedtoevaluatethepoten-
tial forgenetic damage inbacteria and mammalian cells.
Fourteen-Day and Thirteen-Week Studies: In the 14-
day studies, penicillin VK was administered at doses of
150-2,400 mg/kg. No compound-related deaths or dose-
related histopathologic lesions were seen in rats ormice.
Final mean body weights of dosed male rats were
5%-17%lowerthanthatofcontrols;weights ofdosedand
control female rats were comparable. Final mean body
weights of dosed mice were 5%-9% lower than those of
controls. Diarrhea was observed in all dosed groups of
rats and mice.
In the 13-week studies, male and female rats received
doses of 180-3,000 mg/kg and male and female mice
receiveddoses of250-3,000mg/kg. Nocompound-related
deaths were seen in rats or mice. Final mean body
weightsofratsthatreceived3,000mg/kgwere11%lower
thanthoseofthevehiclecontrolsformalesand 6%lower
for females. For mice, mean bodyweights were compar-
able. Diarrhea occurred inmale rats at doses of750 mg/
kg and above and in female rats at doses of 1,500 and
3,000 mg/kg. Mucous cell metaplasia of the glandular
stomachwas observed in male and female rats receiving
1,500 and3,000mg/kg. Lesions oftheglandular stomach
(inflammation, mucous cell metaplasia, and eosinophilic
cytoplasmic change) and the forestomach (papillary
hyperplasia and hyperkeratosis) were seen in all groups
of dosed mice. The severity oflesions at 1,000 mg/kg or
below was considered minimal. Based on these results,
doses selected for rats and mice in the 2-year studies
were 0, 500, or 1,000 mg/kg.
Body Weight and Survival in the Two-Year Studies:
Meanbodyweightsofdosedandvehiclecontrolmaleand
female rats and male micewere comparable. Mean body
weights of dosed female mice were 4%-16% lower than
those ofthe vehicle controls from week 28 to the end of
the study. Diarrhea was observed for dosed male and
female rats and for dosed male mice. Survival oflow and
high dose male rats and high dose female rats was
reduced(malerats:vehiclecontrol,34/50;lowdose,19/50;
high dose, 16/50; female rats: 29/50; 26/50; 16/50). Sur-
vival ofmale and female mice was comparable to that of
the vehicle controls (male mice: 24/50; 36/50; 26/50;
female mice: 36/50; 32/50; 32/50).
Nonneoplastic and Neoplastic Effects in theTwo-Year
Studies: Nonneoplastic lesions occurred at low inci-
dences in the nasal mucosa, lung, and forestomach of
dosed male rats and in the nasal mucosa and lung of
dosedfemale rats. Congestion and aspirationpneumonia
occurring in dosed rats dying before week 104 was the
principal cause ofdeath in these animals.
Nonneoplastic lesions of the gastric fundal gland
(eosinophilic cytoplasmic change and dilatation) and
glandular stomach (cyst, chronic focal inflammation,
hyperplasia, fibrosis, and squamous metaplasia) were
seen in dosed male and female mice, and lesions of the
gallbladder (eosinophilic cytoplasmic change) were seen
in male mice.
Slight increases in the incidences of adenomas ofthe
pituitary gland in high dose male rats and of fibro-
adenomas or adenomas (combined) of the mammary
glandinlowdosefemaleratswere observed. Thesewere
not considered to be compound-related lesions.
The incidence of hepatocellular adenomas was
decreased in high dose male mice (14/50; 15/49; 4/49).




or TA1537 with or without exogenous metabolic activa-
tion. The chemical was mutagenic onlywith activation in
the mouse lymphoma L5178Y/TK+/- forward mutation
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assay. Incubation of Chinese hamster ovary cells with
penicillin VK resulted in increased frequencies ofsister
chromatid exchanges and chromosomal aberrations in
the absence ofmetabolic activation under the conditions
of delayed harvest to compensate for chemical-induced
cell cycle delay, no effects from penicillin VK exposure
were observed in these cells in the presence ofS9.
Audit: The data, documents, and pathology materials
from the 2-year studies of penicillin VK were audited.
Theauditfindings showthattheconductofthestudiesis
documented and support the data and results given in
this Technical Report.
Conclusions: Under the conditions of these 2-year
gavage studies, there was no evidence ofcarcinogenic
activity ofpenicillin VK for F344/N rats or for B6C3F1
mice administered 500 or 1,000 mg/kg penicillin VK in
cornoil gavage, 5daysperweekfor2years. Nonneoplas-
tic lesions were seen in the glandular stomach of dosed
mice. Decreased survival oflowand high dose male rats
and of high dose female rats reduced the sensitivity of
the studies for determining the presence or absence ofa
carcinogenic response in this species.
Synonyms: 4-thia-1-azabicyclo(3.2.0)heptane-2-
carboxylic acid, 3,3-dimethyl-7-oxo-6-(2-phenoxy-
acetamide)-, monopotassium salt; penicillinVpotassium;
penicillin V potassium salt; D-ot-phenoxymethylpenicil-
linate K salt; phenoxymethylpenicillin potassium; PVK
Trade Names: Antibiocin; Apsin VK; Aracil; Arcasin;
Aspin VK; Beromycin; Beromycin 400; Betapen VK;
Calciopen K; Cliacil; Compocillin VK; Distakaps V-K;
Distaquaine V-K; DowpenV-K; DQV-K; Fenoxypen; Ici-
pen; Isocillin; Ispenoral; LedercillinVK; Megacillinoral;
Oracil-VK; Orapen; Ospeneff; Pedipen; Penagen; Pen-
compren; Pen-Vee K; Pen-V-K powder; Penvikal;
Pfizerpen VK; Qidpen VK; Robicillin VK; Rocillin-VK;
Roscopenin; SK-Penicillin VK; Stabilin VK Syrup 125;
Stabilin VK Syrup 62.5; Sumapen VK; Suspen; Uticillin
VK; V-Cil-K; V-Cillin K; Veetids; Vepen
Report Date: June 1988
TR-337 Toxicology and Carcinogenesis
Studies ofNitrofurazone (CAS No. 59-87-0)
in F344/N Rats and B6C3F1 Mice (Feed
Studies)
Nitrofurazone is a synthetic furan derivative, active
against a broad spectrum of bacteria, which has been
widely used in veterinary and human medicine. Toxicol-
ogy and carcinogenesis studies were conducted by feed-
ing diets containing nitrofurazone (99% pure) to groups
ofF344/N rats and B6C3F1 mice ofeach sexfor14 days,
13 weeks, or 2 years.
Fourteen-Day and Thirteen-Week Studies: Groups of
fivemales and five females ofeach specieswerefed diets
containing0, 630, 1,250, 2,500, 5,000, or10,000ppmfor14
consecutive days. Early deaths occurred in all groups of
rats receiving 5,000 or 10,000 ppm nitrofurazone. The
surviving rats in the lower two dose groups gained
weight, but weight gain was decreased as the dose of
nitrofurazone was increased. Feed consumption by rats
ofeach sexwas decreased at all doses above 630ppm. In
all dosed groups, clinical signs oftoxicityincluded rough
haircoats andlethargy.Atdoses of2,500ppmandabove,
rats of each sex exhibited intermittent episodes of sei-
zures and lethargy.
All mice that received 2,500, 5,000, or 10,000 ppm
nitrofurazone and3/5malesthatreceived1,250ppm died
before the end ofthe 14-day studies; the surviving dosed
mice (except females at 630 ppm) lost weight. A dose-
related decrease infeed consumptionwas observed at all
doses above 630 ppm. Clinical signs included rough hair
coats and convulsive seizures.
In the 13-week studies, groups of 10 rats of each sex
weregivendietscontaining0,150, 310,620,1,250, or2,500
ppm nitrofurazone. No deaths were observed and all
animals gainedweight, butthemagnitude ofweightgain
was dose dependentwith decrements in final mean body
weightforthe highestdose groupreaching55% inmales
and 36% in females. Otherevidence ofchemically related
toxicity included convulsive seizures, osteoporosis,
degenerative arthropathy, and gonadal hypoplasia in
both sexes at the two highest doses.
Groups of10mice ofeach sexweregiven diets contain-
ing 0, 70, 150, 310, 620, or 1,250 ppm nitrofurazone for 13
weeks. Early deaths were observed in the two highest
dose groups ofeach sex. The final mean bodyweights of
maleandfemalemiceinthe1,250-ppmgroupswereabout
20% lowerthanthose ofthe controls;weightgains ofthe
other dosed mice were comparable to those of the con-
trols. Stimulus-induced convulsive seizures were
observed for all mice in the two highest dose groups.
Testicular hypoplasia was observed in the two highest
dose groups ofmale mice.
Body Weight and Survival in the Two-Year Studies:
Dietaryconcentrationsforthe2-yearstudieswere0,310,
or 620 ppm for rats and 0, 150, or 310 ppm for mice (50
animalsperdosegroup).Meanbodyweightsofhighdose
male rats were lower than those of the controls after
week39; meanbodyweights oflowdosemale rats and of
the controls were comparable throughout the study.
Final mean body weights of low and high dose female
rats were 9% and 21% lower than those ofthe controls.
Dosedratsconsumedlessfeedthan didthecontrols. The
average amount ofnitrofurazone consumed per daywas
approximately 11-12 or 24-26 mg/kg by low or high dose
maleandfemalerats.Thesurvivalofthehighdosegroup
of male rats was lower than that of the controls after
week 92 (final survival-male: control, 33/50; low dose,
30/50; high dose, 20/50; female: 28/50; 37/50; 31/50).
Mean body weights of dosed mice were similar to or
somewhat greater than those of controls throughout
most ofthe studies. The average dailyfeed consumption
bydosedmicewassimilartothatofcontrols.Theaverage
amount ofnitrofurazone consumed per day was approx-
imately 14-16 or 29-33 mg/kg for low or high dose male
and female mice. The survival ofthe high dose group of
malemicewas lowerthanthat ofthe controls afterweek
205NTP/NIEHS
88 (final survival-male: 39/50; 31150; 27/50; female:
39/50; 40/50; 35/50).
In mice of each sex, nitrofurazone administration
induced stimulus-sensitive convulsive seizuresbeginning
atweek4or5forhighdosemiceandweek24forlowdose
female mice. These seizures were observed primarily in
the first year ofthe study.
Nonneoplastic and Neoplastic Effects in theTwo-Year
Studies: Degenerative changes involving the vertebral
and femoro-tibial (knee) joints were observed at
increased incidences in dosed rats. The degenerative
changes primarily affected the articular cartilage and
were similartothose seeninthe13-weekstudies. Degen-
eration of the sternal synchondroses was increased in
high dose female rats. The osteoporosis seen in the 13-
week studies was not observed in the 2-year studies.
Testicular degeneration, characterized byatrophy ofthe
germinal epithelium and aspermatogenesis, was
observed at increased incidences in dosed male rats
(control, 12/50; low dose, 49/50; high dose, 47/50).
Adenomas of the sebaceous glands and tri-
choepitheliomas or sebaceous adenomas (combined) of
theskinwereobservedinhighdosemalerats (0/50;0/50;
5/50). Carcinomas ofthe preputial gland were increased
in dosed male rats (1150; 8/50; 5/50). The incidences of
preputial gland adenomas or carcinomas (combined) in
dosedmaleratswerenotstatisticallygreaterthanthatin
the controls (9/50; 16/50; 7/50). However, in the low dose
group, theincidenceis greaterthanthehighestincidence
observed inhistoricaluntreated control groups (9/50). In
addition,hyperplasiaofthepreputialglandwasobserved
in six low dose male rats in which neither adenomas nor
carcinomas occurred. The incidence ofmesotheliomas of
the tunica vaginalis in low dose male rats was greater
than that in the controls (0/50; 7/50; 2/50).
Fibroadenomas of the mammary gland occurred at
markedly increased incidences in dosed female rats
(8/49; 36/50; 36/50). Three adenocarcinomas were also
observed (1149; 0/50; 2/50).
Ovarian atrophy (7/47; 44/50; 38/50) and tubular cell
hyperplasia of the ovary (1/47; 23/50; 21/50) were
observed at markedly increased incidences in dosed
female mice. The incidences of benign mixed tumors
(0/47; 17/50; 20/50), granulosa cell tumors (1147; 4/50;
9/50), and granulosa cell tumors or luteomas (combined)
(3/47; 6/50; 9/50) ofthe ovarywere increased in exposed
female mice.
Mononuclear cell leukemiainrats occurred with nega-
tive trends (male: 21150; 23/50; 6/50; female: 15/49; 2/50;
2/50). In female mice, the incidences of adenomas or
carcinomas (combined) of the anterior pituitary gland
occurred with a negative trend (10/50; 7/50; 2/49). The
incidences of testicular interstitial cell tumors were
decreased in dosed male rats (45/50; 30/50; 28/50).
GeneticToxicity: Nitrofurazone wasmutagenic inSal-
nonella typhimurium strains TA98 and TA100 both
with and without exogenous metabolic activation. The
responses in strains TA1535 and TA1537 were more
varied: nitrofurazone was mutagenic in strain TA1535
only in the presence of S9 and produced no consistent
increase in gene reversions in strain TA1537 with or
without S9. In the absence ofmetabolic activation, nitro-
furazone induced forward mutations at the TK+/- locus
ofmouse L5178Y lymphoma cells; the chemical was not
tested with S9. Treatment of cultured Chinese hamster
ovary cells with nitrofurazone in the absence of S9
produced a dose-related increase in sister chromatid
exchanges and chromosomal aberrations; with S9, sister
chromatid exchangeswereincreased, but noinduction of
chromosomal aberrations was observed.
Audit: The data, documents, and pathology materials
from the 2-year studies of nitrofurazone were audited at
the NTP Archives. The audit findings show that the con-
duct ofthe studies is documented adequately and support
the data and results given in this Technical Report.
Conclusions: Undertheconditions ofthese2-yearfeed
studies, there was equivocal evidence ofcarcinogenic
activity ofnitrofurazone formale F344/N rats as shown
by the occurrence of sebaceous gland adenomas and
trichoepitheliomas of the skin, mesotheliomas of the
tunica vaginalis, and preputial gland tumors. There was
clear evidence of carcinogenic activity of nitro-
furazoneforfemale F344/N rats as shownbyamarkedly
increased incidence of fibroadenomas of the mammary
gland. There was no evidence ofcarcinogenic activity
formaleB6C3F1 micefed diets containingnitrofurazone
at concentrations of 150 or 310 ppm. There was clear
evidence ofcarcinogenic activity of nitrofurazone for
femaleB6C3F1 mice as shownbyincreasedincidences of
benign mixed tumors and granulosa cell tumors of the
ovary.
Administration of nitrofurazone was associated with
decreased incidences of mononuclear cell leukemia in
male andfemalerats, testicularinterstitial celltumorsin
male rats, andpituitarygland neoplasms in female mice.
Convulsive seizures in mice ofeach sex, ovarian atrophy
in female mice, testicular degeneration in rats, and
degenerationofarticularcartilageinratswereallassoci-
ated with the administration ofnitrofurazone.
Synonyms: 5-nitro-2-furaldehyde semicarbazone; 2-[(5-
nitro-2-furanyl)methylene]hydrazine carboximide
Trade Names:Aldomycin;Amifur; Chemfuran; Coxistat;
Furacin; Furacinetten; Furaplast; Furazol W; Furesol;
Furracoccid; Mammex; Nefco; Nifuzon; Nitrofural;
Vabrocid
Report Date: June 1988
TR-338 Toxicology and Carcinogenesis
Studies ofErythromycin Stearate (CAS




stearate (USP grade, greater than 96% pure) were con-
ducted by administering the antibiotic in feed to groups
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ofF344/N rats and B6C3F1 mice ofeach sexfor 14 days,
13weeks, or2years. Erythromycin stearatewas studied
because of its widespread use in humans as a broad-
spectrum macrolide antibiotic and because ofthe lack of
adequate long-term studies for carcinogenicity.
Fourteen-Day and Thirteen-Week Studies: In the 14-
daystudies, noneoftherats(atdietaryconcentrations up
to 50,000 ppm) and 2/5 female mice that received 50,000
ppm died before the end ofthe studies. Final mean body
weights of male rats that received 12,500, 25,000, or
50,000 ppm were 10%, 30%, or 36% lower, respectively,
than that ofcontrols; final mean bodyweights offemale
rats were 10%, 12%, or 32% lower. None of the dosed
mousegroupsgainedweight.Thefinalmeanbodyweight
of male mice that received 50,000 ppm was 10% lower
than that ofcontrols.
In the 13-week studies, none of the rats or mice (at
dietary concentrations up to20,000 ppm) died before the
end of the studies. Final mean body weights of the
20,000-ppm groups of rats were more than 12% lower
than that of the controls for males and 7% lower for
females. Final mean body weights ofmice that received
10,000 or20,000 ppmwere 15% or19% lowerthan thatof
controls for males and 5% or 14% lower for females.
Multinucleated syncytial hepatocytes were observed
in 10/10 male rats that received 20,000 ppm but in 0/10
maleratsthatreceived10,000ppm. Nocompound-related
gross or microscopic pathologic effects were observed in
mice.
Based ontheseresults,2-yearstudies oferythromycin
stearate were conducted by feeding diets containing 0,
5,000, or 10,000 ppm erythromycin stearate to groups of
50 rats of each sex for 103 weeks. Diets containing 0,
2,500, or5,000ppmwerefed to groups of50mice ofeach
sex for 103 weeks.
Body Weight and Survival in the Two-Year Studies:
Mean bodyweights ofhigh dosemale ratswere compar-
able to those of controls throughout the studies. Mean
body weights of high dose female rats were 5%-10%
lowerthanthoseofcontrols. Meanbodyweightsofdosed
and control mice were comparable. The average daily
feed consumption was similarfordosed and controlmale
andfemale rats. Formice, estimated dailyfeed consump-
tionbylowandhigh dosemaleswas similartothatofthe
controls and bylow and high dose females was 92% that
of the controls. The average amount of erythromycin
stearate consumedperdaywasapproximately180 or370
mg/kgformaleratsand210 or435mg/kgforfemalerats;
formice, the average amountswere 270 or545mg/kgfor
males and 250 or 500 mg/kg for females.
No significant differences in survival were observed
between any groups of rats or mice of either sex (final
survival-male rats: control,28/50; lowdose, 23/50; high
dose, 27/50; female rats: 29/50; 30/50; 38/50; male mice:
34/50; 33/50; 40/50; female mice: 38/50; 34/50; 40/50).
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Granulomas of the liver were observed at
increased incidences in high dose rats (male: 1150; 2/50;
10/50;female: 18/50;27/50;43/50).Granulomatousinflam-
mation or granulomas of the spleen were observed in
dosed female rats (0/48; 1/49; 3/50). Reticulum cell hyper-
plasia in the bone marrow occurred at increased inci-
dences in high dose female rats (10/50; 14/50; 25/50).
Squamous cell papillomas of the oral mucosa were
observedin1/50control,2/50lowdose,and3/50highdose
female rats. These tumors were considered to be margi-
nal and not related to exposure. Hyperplasia ofthe oral
mucosa was not observed.
Pheochromocytomas of the adrenal gland in female
rats occurredwith apositive trend (1/50; 4/49; 5/50). The
incidences inthe dosed groups are similarto the average
historical incidence (9%) ofthis tumor in untreated con-
trol female F344/N rats at the study laboratory. This
marginal tumor increase is not considered to be biolog-
icallyimportant. Noincreasesinincidencesofneoplasms
were observed at any site in dosed male rats.
Inflammation in the glandular stomach was observed
at increased incidences in dosed male mice (1/49; 4/50;
6/50). Lymphoid hyperplasia in the urinary bladder was
observed at increased incidences in dosed female mice
(1/50; 9/47; 7/48).
Noincreasesinincidences ofneoplasmswereobserved
at any site in dosed male or female mice.
Genetic Toxicology: Erythromycin stearate was not
mutagenic in Salmoella typhimurium strains TA98,
TA100, TA1535, or TA1537 when tested both with or
without exogenous metabolic activation. Erythromycin
stearate demonstrated equivocal mutagenicity in the
mouse L5178Y lymphoma cell assay in the absence of
exogenous metabolic activation (S9); erythromycin stea-
rate was notmutagenic in the presence ofS9. Treatment
of cultured Chinese hamster ovary cells with
erythromycin stearatedid notproduce anincreaseinthe
frequencyofsisterchromatidexchanges orchromosomal
aberrations in either the presence or absence of meta-
bolic activation.
Audit: The data, documents, and pathology materials
from the 2-year studies of erythromycin stearate have
beenaudited.Theauditfindings showthattheconductof
the studies is documented adequately and support the
data and results given in this Technical Report.
Conclusions: Under the conditions of these 2-year
studies, therewasno evidence ofcarcinogenic activity
oferythromycin stearateformale orfemale F344/N rats
administered erythromycin stearate in the diet at 5,000
or 10,000 ppm. There was no evidence ofcarcinogenic
activity of erythromycin stearate for male or female
B6C3F1 mice administered erythromycin stearateinthe
diet at 2,500 or 5,000 ppm. Dose-related increases in the
incidences of granulomas of the liver were observed in
male and female rats. The absence of any biologically
important chemical-associated effects in mice suggests
that higher doses could have been given to male and
female mice.
Synonyms: erythrocin stearate; erythromycin
octadecanoate
Trade Names: Abbotcine; Bristamycin; Dowmycin E;
Eratrex; Erypar; Ethril; Gallimycin; HSDB 4178; OE 7;
Pantomicina; Pfizer-E; SK-Erythromycin; Wyamycin S
207NTP/NIEHS
Report Date: December 1988
TR-339 Toxicology and Carcinogenesis
Studies of2-Amino-4-Nitrophenol (CAS
No. 99-57-0) in F344/N Rats and B6C3F
Mice (Gavage Studies)
2-Amino-4-nitrophenolisusedtocolorsemipermanent
hair dyes and in the manufacture of mordant dyes for
leather, nylon, silk,wool, and fur. 2-Amino-4-nitrophenol
was nominated by the National Cancer Institute for
toxicology and carcinogenesis studies because of wide-
spread human exposure associatedwith itsmanufacture
and use. Toxicology and carcinogenesis studies were
conducted byadministering 2-amino-4-nitrophenol (98%
pure) in corn oilbygavage, 5 daysperweek, to groups of
F344/N rats and B6C3F1 mice ofeach sex in 15-day, 13-
week, and 2-year studies.
Fifteen-Day and Thirteen-Week Studies: During the
15-daystudies,ratsandmicereceiveddosesof0,313,625,
1,250, 2,500, or 5,000 mg/kg. All rats that received 2,500
or5,000mg/kgandallfemaleratsthatreceived1,250mg/
kg died before the end of the studies. Final mean body
weights ofchemically exposed rats surviving to the end
of the studies were comparable to those ofvehicle con-
trols. Diarrhea was observed in all groups of exposed
rats except those receiving 313 mg/kg. All mice that
received 2,500 or 5,000 mg/kg, 2/5 males and all females
that received 1,250 mg/kg, and 1/5 females that received
313 mg/kg diedbefore the end ofthe studies. Final mean
bodyweights ofexposed mice surviving until the end of
the studies were comparable to those of vehicle
controls.
In 13-week studies, F344/N rats and B6C3F1 mice of
each sex received 2-amino-4-nitrophenol at doses of 0,
62.5,125, 250, 500, or 1,000 mg/kg. All rats that received
1,000mg/kgand2/10malesand2/10femalesthatreceived
500 mg/kg died before the end of the studies. The final
mean bodyweight ofmale rats that received 500 mg/kg
was reduced 10% compared with that ofvehicle controls;
final mean body weights of all other surviving exposed
rat groups were comparable to those ofvehicle controls.
Diarrhea and lethargy were observed for rats that
received 500 or 1,000 mg/kg. All male mice and most
females that received 1,000 mg/kg and 4/10 females that
received 500 mg/kg died before the end of the studies.
Final mean body weights of chemically exposed mice
were comparable to those of vehicle controls. No
compound-related clinical signs were observed in mice
during the studies.
Mineralization ofthe renal cortex and degeneration of
the renal tubular epithelium were observed in male and
female rats that received 1,000 mg/kg and in males that
received 500 mg/kg. Degeneration and necrosis of the
renal tubular epithelium was observed in 5/10 male and
3/10 female mice thatreceived 1,000 mg/kg.
BodyWeightand Survival intheTwo-YearStudies: In
the 2-year studies, rats and mice received 2-amino-4-
nitrophenol at doses of0, 125, or 250 mg/kg. Mean body
weights of male rats that received 250 mg/kg were
8%-10% lower than those ofvehicle controls throughout
most of the 2-year study. Mean body weights offemale
rats were comparable to those of vehicle controls. Soft




week 89 (final survival: vehicle control, 32/50; 125mg/kg
group,24/50; 250mg/kggroup, 10/50). Survival offemale
rats was comparable among all groups (final survival:
25/50; 27/50; 31/50).
Mean body weights of male and female mice that
received 250 mg/kg were comparable to those ofvehicle
controls; the mean body weights of female mice that
received 125 mg/kg were as much as 17% greater than
thatofvehicle controls. Survival ofallmouse groupswas
comparable during the 2-year studies (final survival:
male-28/50; 29/50; 23/50; female-28/50; 31/50; 30/50).
Nonneoplastic and Neoplastic Effects inthe Two-Year
Studies: Pigmentation ofthe small and large intestines
was present in exposed rats but not in vehicle controls.
Ulcers and erosive lesions of the digestive tract were
observed in male rats that received 250 mg/kg and to a
lesser extent in male rats that received 125 mg/kg. A
carcinoma of the colon occurred in one male rat that
received 250 mg/kg; no other neoplasms were observed
in the gastrointestinal tract of rats. No pigmentation,
ulcers, orerosivelesionswerefoundinthedigestivetract
ofmice.
The severity ofnephropathywas markedly greater in
exposed male rats than in vehicle controls. Associated
with the nephropathywere nonneoplastic lesions indica-
tive of reduced renal function and secondary hyper-
parathyroidism, including parathyroid hyperplasia,
mineralization of various organs, and fibrous
osteodystrophy.
Renal tubular cell hyperplasia (1/50; 4/48; 5/50) and
renal cortical (tubular cell) adenomas (0/50; 1/48; 3/50)
occurredinmalerats. Renalcortical adenomas areinfre-
quently observed in male F344/N rats (historical inci-
dence, 0.5%).
More preputial gland adenomas or carcinomas (com-
bined) were observed in low dose male rats than in
vehiclecontrols(3/50;10/48;3/50),whereastheincidences
of clitoral gland neoplasms were decreased in dosed
female rats (9/50; 6/50; 1/49).
Hemangiomas or hemangiosarcomas (combined)
occurred in male mice that received 2-amino-4-
nitrophenol(0/50;1/50;5/50);eachtumorwaspresentata
different site. The historical control incidence is 11% at
the study laboratory and 6% in 2-year NTP studies.
Genetic Toxicology: 2-Amino-4-nitrophenol was muta-
genic in Salmonella typhimurium strains TA98 and
TA100 with metabolic activation. 2-Amino-4-nitrophenol
was not mutagenic in strains TA1535 or TA1537.
2-Amino-4-nitrophenol wasmutagenic inthemouselym-
phoma L5178Y/TK+/- assay without metabolic activa-
tion. It was not tested with activation. 2-Amino-4-
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nitrophenol induced sister chromatid exchanges (SCEs)
and chromosomal aberrations in Chinese hamster ovary
cells inthe presence and absence ofmetabolic activation.
Audit: The data, documents, and pathology materials
from the 2-year studies of 2-amino-4-nitrophenol were
audited at the NTP Archives. The audit findings show
thattheconductofthe studiesis documented adequately
and support the data and results given in this Technical
Report.
Conclusions: Under the conditions of these 2-year
gavage studies, there was some evidence of car-
cinogenic activity of 2-amino-4-nitrophenol for male
F344/N rats, as shown by increased incidences ofrenal
cortical (tubular cell) adenomas. The incidences ofrenal
tubular cell hyperplasia were also increased in male rats
exposed to 2-amino-4-nitrophenol. The survival ofmale
rats that received 2-amino-4-nitrophenol was reduced
compared with survival of vehicle control male rats.
There was no evidence of carcinogenic activity of
2-amino-4-nitrophenol forfemaleF344/Nratsorformale
or female B6C3F1 mice that received 125 or 250 mg/kg
per day.
Report Date: June 1988
TR-340 Toxicology and Carcinogenesis
Studies of lodinated Glycerol (Organidin®)
(CAS No. 5634-39-9) in F344/N Rats and
B6C3F1 Mice (Gavage Studies)
Toxicology and carcinogenesis studies of iodinated
glycerol (Organidin®, acomplexmixturepreparedbythe
reaction ofiodinewith glycerol andfound tocontain33%
3-iodo-1,2-propanediol as the major component) were
conducted because of human exposure to iodinated
glycerol asanexpectorantanditspossiblerelationshipto
the formation of alkyl iodides, e.g., methyl iodide, a
suspected animal carcinogen. These studies were con-
ductedbygivingiodinated glycerolinwaterbygavage (5
days per week) to groups of F344/N rats and B6C3F1
mice for 16 days, 13weeks, or 2 years. Genetic toxicology
studieswereconductedwithiodinatedglycerolinSalmo-
nella typhimurium, mouse L5178Y lymphoma cells,
Chinese hamster ovary (CHO) cells, and B6C3F1 mice
(invivobonemarrowmicronucleus test).Also,3-iodo-1,2-
propanediol was tested inS. typhimurium and B6C3F1
mice (in vivo micronucleus assay).
Sixteen-Day and Thirteen-Week Studies: Sixteen-day
studies were conducted by giving iodinated glycerol at
doses up to 1,000 mg/kg to rats and up to 500 mg/kg to
mice. All female rats and 4/5 male mice in the highest
dose group diedbefore the end ofthe studies; therewere
nodose-related effects onbodyweights ofmale orfemale
rats or male mice at the end of the studies. The fore-
stomach of2/5 female mice thatreceived 500 mg/kgwas
thickened and granular.
Thirteen-week studies were conducted by administer-
ing iodinated glycerol at doses up to 500 mg/kg to rats
and mice. Duringthese studies, 3/10 female rats and1110
female mice that received 500 mg/kg died. Final mean
body weights of rats and mice that received 500 mg/kg
were 4% lower than those ofvehicle controls for males
and 6%-7% lower for females.
Kidneytubularcell lesions, including cortical necrosis,
regeneration, and calcification, were observed at
increased incidences in the highest dose group of
female rats. Lymphoid hyperplasia of the stomach was
observed in dosed male and female rats. Kidney tubular
cellregenerationwasalsoobservedindosedfemalemice.
Inflammation or abscesses ofmild-to-moderate severity
and hyperplasia, acanthosis, and/or hyperkeratosis of
mild-to-moderate severity were observed in the
forestomach of the highest dosed group of female
mice.
Body Weight and Survival in the Two-Year Studies:
Two-year studies were conducted by administering 0,
125,or250mg/kgiodinatedglycerolindeionizedwaterby
gavage, 5 days per week for 103 weeks, to groups of 50
male F344/N rats and 50 male B6C3F1 mice. Groups of
50female F344/N rats and 50 female B6C3F1 micewere
administered iodinated glycerol on the same schedule at
lower doses of 0, 62, or 125 mg/kg because of the
increased severity of kidney and stomach lesions in the
13-week studies. Mean body weights of high dose male
rats were 5%-10% lower than those of vehicle controls
from week 43 to week 68 and 10%-13% lower from week
72 to the end ofthe studies. Mean body weights of low
dose male rats and high dose female rats were 4%-9%
lower than those ofvehicle controls fromweek 88 to the
endofthe studies. The survival ofthehigh dose group of
male ratswas considerablylowerthanthatofthevehicle
controlsafterweek86. Noothersignificantdifferencesin
survival were observed between any groups of rats of
either sex (male: vehicle control, 28/50; low dose, 20/50,
high dose, 2/50; female: 31150; 30/50; 27/50). Mean body
weights of dosed and vehicle control male mice were
similar. Mean body weights of high dose female mice
were 6%-8% lower than those of vehicle controls from
week 40 to week 64 and were 9%-13% lower thereafter.
No significant differences in survival were observed
between any groups of mice of either sex (male: 36/50;
40/50; 32/50; female: 40/50; 33/50; 38/50).
Nonneoplastic and Neoplastic Effects in theTwo-Year
Studies: Theincidenceofmononuclearcellleukemiawere
increased in dosed male rats (vehicle control, 14/50; low
dose, 29/50; high dose, 24/50).
Follicular cell carcinomas ofthe thyroid gland in male
rats occurred at an increased incidence in low dose male
rats (0/49; 5/49; 1V49). Reduced survivalofhighdosemale
rats mayhave been responsible for the decreased tumor
incidence in this group relative to that in the low dose
group. Follicular cell carcinomas were observed in one
low dose and one high dose female rat. Follicular cell
carcinomas of the thyroid gland have been observed in
3/293watergavagevehicle controlmale F344/N rats and
in 10/1,904 untreated control male F344/N rats.
Adenomas of the nasal cavity were observed in two
high dose male rats. Adenomas ofthe nasal cavity have
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not been observed in 300 water gavage vehicle control
male F344/N rats or in 1,936 untreated control male
F344/N rats.
Squamous metaplasia andfocalatrophyofthe salivary
glands were observed at increased incidences in dosed
rats (squamous metaplasia-male: 0/48; 47/50; 48/49;
female: 1/49; 48/50; 49/50; focal atrophy-male: 1148;
10/50; 30/49; female: 0/49; 4/50; 11/50).
In dosed female mice, adenomas ofthe anterior pitui-
tary gland were increased (10/47; 15/45; 24/46). The
incidences ofadenomas ofthe harderian gland in dosed
female mice were increased (6/50; 8/40; 13/50). A car-
cinoma of the harderian gland was observed in another
high dose female mouse.
Dilatationofthethyroidglandfollicle andfollicularcell
hyperplasia were observed at increased incidences in
dosed mice (dilatation-male: 0/48; 28/50; 32/50; female:
4/48; 11/48; 10/48; hyperplasia-male: 3/48; 46/50; 34/50;
female: 2/48;25/48;35/48).Theincidencesoffollicularcell
adenomas were 3/48, 6/50, and 0/50 for males and 2/48,
3/48, and 4/48 for females.
Hyperkeratosis and acanthosis of the forestomach
were observed atincreased incidences in high dose male
mice (hyperkeratosis: 0/49; 0/49; 5/50; acanthosis: 0/49;
1/49; 5/50). Squamous cell papillomas were observed in
female mice (1/49; 2/50; 5/49). The historical incidence of
forestomach squamous cell neoplasms is 4/339 (1.2%) in
water gavage vehicle control female B6C3F1 mice and is
18/1,994(0.9%) inuntreated controlfemaleB6C3F1 mice.
Squamous cell neoplasms were not observed in male
mice.
GeneticToxicology: Treatmentofthebase-substitution
mutantS. typhimurium strains TA100andTA1535with
iodinated glycerol in apreincubational protocolwith and
without S9 resulted in a dose-related increase in the
number of revertant colonies; no increase in revertants
was observed with the frame-shift mutant strains TA98
or TA1537. 3-Iodo-1,2-propanediol was also mutagenic in
TA100 with orwithout S9; itwas not mutagenic in TA98.
Iodinated glycerol increased the number of
trifluorothymidine-resistant cells in mouse lymphoma
L5178Y/TK+/- assay in the absence ofexogenous meta-
bolic activation; it was not tested with activation. Iodi-
nated glycerol induced sister chromatid exchanges
(SCEs) and chromosomal aberrationsin CHOcellswith-
out S9; with S9, the frequency of SCEs was increased
more than without S9 but no chromosomal aberrations
were induced. No increase in micronucleated poly-
chromatic erythrocytes was observed in the bone mar-
rowofB6C3F1 mice afterinjectionwith eitheriodinated
glycerol or 3-iodo-1,2-propanediol.
Conclusions: Under the conditions of these 2-year
gavage studies, there was some evidence of car-
cinogenic activity for male F344/N rats administered
iodinated glycerol, as indicated by increased incidences
of mononuclear cell leukemia and follicular cell car-
cinomas of the thyroid gland. Adenomas of the nasal
cavity in two high dose male rats may have been related
tothe administration ofiodinatedglycerol. Therewasno
evidence of carcinogenic activity for female F344/N
rats administered 62 or 125 mg/kg iodinated glycerol by
gavage for 103 weeks. There was no evidence of car-
cinogenic activity for male B6C3F1 mice administered
125 or 250 mg/kg iodinated glycerol by gavage for 103
weeks. There was some evidence of carcinogenic
activity forfemale B6C3F1 miceadministered iodinated
glycerol, as indicated by increased incidences of ade-
nomas ofthe anterior pituitary gland and neoplasms of
the harderian gland. Squamous cell papillomas of the
forestomachmayhavebeenrelatedtotheadministration
ofiodinated glycerol.
Significant nonneoplastic lesions considered related to
exposure of iodinated glycerol were squamous meta-
plasiaandfocal atrophyofthe salivaryglandinmale and
female rats. Dilatation of the thyroid gland follicle and




Report Date: March 1990
TR-341 Toxicology and Carcinogenesis
Studies ofNitrofurantoin (CAS No.
67-20-9) in F344/N Rats and B6C3F1 Mice
(FeedStudies)
Nitrofurantoin was studied and evaluated because of
its widespread use as a drug for treating urinary tract
infectionsinhumans,itsstructuralrelationshiptoknown
carcinogenic 5-nitrofuran compounds, and the lack of
adequate studiestoassessitscarcinogenicity. Toxicology
and carcinogenesis studies of nitrofurantoin were con-
ducted by administering nitrofurantoin (greater than
99% pure) in feed to groups ofF344/N rats andB6C3Fj
mice ofeach sex for 14 days, 13 weeks, or 2 years.
Fourteen-Day and Thirteen-Week Studies: None of
therats (atdietaryconcentrationsupto20,000ppm)died
before the end ofthe 14-day studies. Rats that received
5,000,10,000, or20,000ppmlostweight. Fouroffivemale
and 4/5 female mice that received 10,000 ppm and 1/5
females that received 5,000 ppm nitrofurantoin died
before the end of the studies. Mice that received 5,000
ppm andmale micethatreceived 10,000 ppmlostweight.
Inthe13-weekstudies, finalmeanbodyweightsofrats
that received 2,500, 5,000, or 10,000 ppmwere 10%, 34%,
or47% lowerthanthatofthecontrolsformales and15%,
31%, or 41% lower for females. Feed consumption by
dosed and control rats was generally similar. Degenera-
tion of the germinal epithelium of the seminiferous
tubules of the testis was observed in male rats that
received 2,500 to 10,000 ppm nitrofurantoin. Necrosis of
the ovarianfollicleswas observed in8/10femalerats that
received 10,000 ppm, in 3/10 females that received 5,000
ppm, and in 1/10 that received 2,500 ppm.
For mice, final mean body weights of the 5,000-ppm
groupswere13%lowerthanthatofthecontrolsformales
and 15% lower for females. Two of 10 male mice that
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received 5,000 ppm and 1/10males that received 300ppm
died before the end of the 13-week studies. Estimated
feed consumption was similar for dosed and control
groups. Degeneration of the germinal epithelium ofthe
testis was observed in males that received 1,300 to 5,000
ppm; necrosis of the ovarian follicles was observed in
females thatreceived 5,000ppmbutnotinthelowerdose
groups. Necrosis of the renal tubular epithelium was
observed in 2/9 males that received 5,000 ppm.
Based on these results, 2-year studies of nitrofuran-
toin were conducted byfeeding diets containing 0,1,300,
or2,500ppmnitrofurantointo groups of50male F344/N
rats and to groups of 50 male and female B6C3F1 mice
for 103weeks. Groups of50 female F344/N rats were fed
diets containing 0, 600, or 1,300 ppm nitrofurantoin on
the same schedule.
Body Weight and Survival in the Two-Year Studies:
Meanbodyweightandaveragedailyfeedconsumptionof
dosed male and female rats were similar to those ofthe
controls throughout the studies. The average amount of
nitrofurantoin consumed per daywas estimated tobe 60
and110mg/kgforlowandhighdosemaleratsand30and
60 mg/kg for low and high dose female rats. No signifi-
cant differences in the number of rats surviving to the
end ofthe studies were observed between any groups of
rats of either sex (male: control, 24/50; low dose, 27/50;
high dose, 26/50; female: 25/50; 26/50; 31/50).
Meanbodyweights ofhigh dosemale andfemalemice
wereupto 12% lowerthanthose ofthe controls through-
outmost ofthe studies. The average dailyfeed consump-
tion by dosed mice ranged from 93% to 100% that by
controls. The average amount of nitrofurantoin con-
sumed per day was estimated to be 280-300 mg/kg and
570-580 mg/kg for low and high dose mice. The survival
ofthecontrolgroupoffemalemicewaslowerthanthatof
the dosed groups (control, 19/50; low dose, 37/50; high
dose, 37/50). The decrease in survival was most likely
related to the increase in microbial infection in the
reproductive tract observed in the controls. Groups of
male mice had similar survival (28/50; 29/50; 34/50).
Nonneoplastic and Neoplastic Effects in theTwo-Year
Studies: Organs showing toxicity from nitrofurantoin
exposure identified in the short-term studies were the
testis inmale rats andmice, the ovaryinfemale rats and
mice, and the kidney in male mice. Lesions observed in
the 2- year studies were in the testis in male rats and
mice, ovary in female mice, and kidney in male rats.
Chronic nephropathy was observed in nearly all rats,
buttheseverityofthelesionswasjudged tobegreaterin
dosed male rats. Hyperplasia of the transitional cell
epithelium (control, 0/50; lowdose, 5/50; high dose, 2/50)
and hydronephrosis ofthe renal pelvis (0/50; 5/50; 2/50)
were also observed in dosed male rats. In the standard
single sections oftheleftandrightkidneyfrom each rat,
tubular cell adenomaswere observedin onelowdose and
two high dose males; a tubular cell carcinoma was
observedin anotherhighdosemale. Becausethenumber
of renal tubular cell neoplasms identified by standard
procedures in the dosed male rats was low, additional
step-sections of the kidney were evaluated. The inci-
dences oftubular cell adenomas derived from the step-
sections and original sections (combined) were signifi-
cantly increased in dosed male rats (adenomas: 3/50;
11/50; 19/50); tubular cell carcinomas occurred in two
high dose males only.
Lesions considered to be associated with the
nephropathyandnitrofurantoin exposurewereobserved
in male rats and included hyperplasia ofthe parathyroid
glands (3/49; 18/47; 23/49), fibrous osteodystrophy ofthe
bone (0/50; 5/50; 5/50), and mineralization ofthe glandu-
lar stomach (1/49; 8/50; 14/50).
Atypical cells ofthe epididymis (0/50; 0/50; 12/50) and
degeneration of the testis (0/50; 0/50; 36/50) were
observed in high dose male rats. Fibrinoid necrosis of
arterioles (1/50; 8/50; 15/50) and perivascular infiltration
of mononuclear cells (3/50; 9/50; 19/50) were also
observed in the testis ofmale rats. Interstitial cell ade-
nomasofthetestisoccurredwithanegativetrend (47/50;
45/50; 21/50), and no adenomas or carcinomas of the
preputial gland were seen in high dose male rats (12/48;
11/50; 0/47). The incidence of clitoral gland neoplasms
was increased in low dose female rats (5/44; 10/38; 4/42).
Osteosarcomas were observed in the bone of one low
dose and two high dose male rats. The historical inci-
denceofosteosarcomasinuntreatedmaleF344/Nratsis
8/1,937 (0.4%). The incidences of subcutaneous tissue
neoplasms in dosed male rats were greater than that in
the controls (1/50; 7/50; 5/50).
Noneoplasticlesionsindosedfemalerats ormalemice
were considered to be compound related at the doses of
nitrofurantoin administered.
For female mice, ovarian atrophy was observed in
48/50 low dose and 49/50 high dose mice but not in
controls. Tibular cell adenomas ofthe ovary (0/50; 0/50;
5/50), benign mixed tumors (tubular and stromal) (0/50;
0/50; 4/50), and granulosa cell tumors (0/50; 3/50; 2/50))
were observed in dosed female mice. One granulosa cell
tumor in the high dose group was malignant. Ovarian
abscesses (18/50) and suppurative inflammation of the
uterus (11/50) were observed in control female mice but
notin dosedfemale mice and arebelieved toberelated to
indigenous microbial infections and most likelywere the
cause ofearly deaths in this group. Adenocarcinomas of
theuteruswere seenin onelowdoseandin onehighdose
mouse.
Testicular aspermatogenesis (1/49; 1/49; 16/50), degen-
erationofthegerminalepithelium (0/49;3/49;23/50), and
atypical cells (0/50; 0/49; 26/50) and depletion (1/50; 1/49;
15/50) of the epididymis were observed at increased
incidences in high dose male mice.
Spindle cell hyperplasia of the adrenal cortex was
observed in dosed female mice (3/50; 41/50; 45/50). A
spindle cell adenoma (adrenal capsule adenoma) was
seen in one low dose female mouse, and a spindle cell
carcinoma (adrenal capsule carcinoma) was seen in one
low dose male mouse.
Mineralization of the renal medulla (male: 0/50; 0/50;
17/50; female: 0/50; 0/50; 7/50) and dilatation ofthe renal
tubules (male: 0/50; 0/50; 14/50) were observed in high
dose mice.
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Hepatocellular neoplasms (adenomas or carcinomas,
combined) were observed at an increased incidence in
high dosefemalemice (2/50; 2/50; 8/50).An Ito celltumor
of the liver was observed in one low dose and one high
dose female mouse. Malignant lymphomas occurred in
female mice (12/50; 19/50; 24/50).
Genetic Toxicology: Nitrofurantoin was mutagenic in
Salmonella typhimurium strains TA98 and TA100,
with andwithoutmetabolic activation, butwas notmuta-
genic for strains TA1535 or TA1537. Nitrofurantoin
induced forward mutations atthe TK+/- locus ofL5178Y
mouselymphoma cellsinthe absenceofmetabolic activa-
tion (it was not tested with activation). Nitrofurantoin
induced increased numbers of sister chromatid
exchangesandchromosomal aberrationsincultured Chi-
nese hamster ovary cells with and without metabolic
activation. Results of the sex-linked recessive lethal
assay in Drosophila were negative after administration
ofnitrofurantoin by feeding or by injection.
Conclusions: Undertheconditions ofthese2-yearfeed
studies, there was some evidence of carcinogenic
activity ofnitrofurantoinformaleF344/Nratsasshown
byincreased incidences ofuncommonkidneytubularcell
neoplasms. Uncommon osteosarcomas of the bone and
neoplasms of the subcutaneous tissue were observed in
dosed male rats. Incidences ofinterstitial cell adenomas
ofthe testis and neoplasms of the preputial gland were
decreased in the 2,500-ppm group of male rats. There
wasno evidenceofcarcinogenic activity ofnitrofuran-
toinforfemale F344/N ratsfed diets containing600ppm
or1,300 ppmfor2years. Female rats mayhave been able
to tolerate higher doses. There was no evidence of
carcinogenic activity of nitrofurantoin for male
B6C3F1 micefeddietscontaining1,300ppmor2,500ppm
for 2 years. There was clear evidence ofcarcinogenic
activity of nitrofurantoin for female B6C3F1 mice as
shown by increased incidences of tubular adenomas,
benign mixed tumors, and granulosa cell tumors of the
ovary.
Nonneoplastic lesions considered related to nitro-
furantoin exposure were chronic nephropathy and asso-
ciated lesions (hyperplasia of the parathyroid gland,
fibrousosteodystrophyofthebone, andmineralization of
theglandularstomach)inmaleratsandtesticulardegen-
eration in male rats and mice. Ovarian atrophy and
hyperplasia of the adrenal cortex spindle cells were





Trade Names: Benkfuran; Benkfurin; Chemiofuran;
Cyantin; Dantafur; Furadantin; Furadantine; Furadan-
toin; Furadonin; Furadonine; Furantoin; Furatoin;
Furobactina; Ituran; Macrodantin; Nifurantin; NSC
2107; N-Toin; Orafuran; Parafuran; Urizept; USAF
EA-2; Welfurin; Zoofurin
Report Date: September 1989
TR-342 Toxicology and Carcinogenesis
Studies ofDichlorvos (CAS No. 62-73-7) in
F344/N Rats and B6C3F1 Mice (Gavage
Studies)
Toxicology and carcinogenesis studies of dichlorvos
(99% pure), a contact and stomach poison for control of
insects and parasites, were conducted by administering
dichlorvos in corn oilbygavage to groups ofF344/N rats
and B6C3F1 mice of each sex for 13 weeks or 2 years.
Previous feed studies were done by the National Cancer
Institute using Osborne-Mendel rats and B6C3F1 mice.
Thirteen-Week Studies: Thirteen-week studies with
groupsof10ratsofeach sexwereconducted atdosesof0,
2, 4, 8,16, 32, or 64 mg/kg dichlorvos in corn oil. All rats
that received 32 or 64 mg/kgdichlorvos and 4/10 females
thatreceived 16mg/kgdiedbefore the end ofthe studies.
Final mean body weights of dosed and vehicle control
rats were similar. Thirteen-week studies with groups of
10mice ofeach sexwereconducted atdosesof0,5,10,20,
40, 80, or 160 mg/kg. All 10 male mice and 9/10 female
mice that received 160 mg/kg and 5/10 male mice that
received 80 mg/kg dichlorvos died before the end ofthe
studies. Final mean body weights of dosed and vehicle
control mice were similar. No compound-related gross or
microscopic pathologic effects were observed in rats or
mice.
Two-year studies of dichlorvos were conducted by
administering 0, 4, or 8 mg/kg dichlorvos, 5 days per
week for 103 weeks, to groups of50 F344/N rats ofeach
sex. Groups of50 male B6C3F1 mice were administered
0, 10, or 20 mg/kg dichlorvos on the same schedule, and
groups of50 B6C3F1 female mice were administered 0,
20, or 40 mg/kg dichlorvos.
Body Weight and Survival in the Two-Year Studies:
Meanbodyweights ofdosed andvehicle control rats and
mice were similar. No significant differences in survival
were observed between any groups of rats or mice of
either sex (rats-male: vehicle control, 31150; low dose,
25/50; high dose, 24/50; female: 31/50; 26/50; 26/50;
mice-male: 35/50; 27/50; 29/50; female: 26/50; 29/50;
34/50).
NeoplasticEffects intheTwo-YearStudies:Adenomas
ofthe exocrine pancreas occurred at greater incidences
in dosed rats than in vehicle controls (male: vehicle
control, 25/50; low dose, 30/49; high dose, 33/50; female:
2/50; 3/47; 6/50). Mononuclearcellleukemiainboth dosed
groups of male rats occurred more frequently than in
vehicle controls (11150; 20/50; 21150). Mammary gland
fibroadenomas and fibroadenomas or adenomas (com-
bined) in dosed female rats occurred at increased inci-
dences relative to thevehicle controls (9/50; 19/50; 17/50).
Multiple fibroadenomas occurred in dosed female rats
but not in vehicle controls (0/50; 6/50; 3/50); carcinomas
occurred in two vehicle control and two low dose female
rats.
In mice, incidences ofsquamous cell papillomas ofthe
forestomach were increased in the high dose groups
compared with those in the vehicle controls (male: 1150;
212ABSTRACTS FROMLONG-TERM CANCER STUDIES, 1976-1992
1150;5/50; female: 5/49; 6/49;18/50). Twohigh dose female
mice developed forestomach squamous cell carcinomas.
Genetic Toxicology: Dichlorvos was mutagenic in Sal-
mrnella typhimurium strain TA100 with and without
metabolic activation but was not mutagenic in strain
TA98. Dichlorvos wasmutagenicinthe mouse lymphoma
L5178Y/TK+/- assay without metabolic activation.
Dichlorvos induced sister chromatid exchanges and
chromosomal aberrations in Chinesehamster ovarycells
in the absence and presence ofmetabolic activation.
Conclusions: Under the conditions of these 2-year
gavage studies, there was some evidence of car-
cinogenic activity of dichlorvos for male F344/N rats,
as shown by increased incidences of adenomas of the
exocrine pancreas and mononuclear cell leukemia. There
was equivocal evidence of carcinogenic activity of
dichlorvosforfemaleF344/Nrats, asshownbyincreased
incidences of adenomas of the exocrine pancreas and
mammary gland fibroadenomas. There was some evi-
dence of carcinogenic activity of dichlorvos for male
B6C3F1 mice, as shown by increased incidences offore-
stomach squamous cell papillomas. There was clear evi-
dence ofcarcinogenic activity ofdichlorvos for female
B6C3F1 mice, as shown by increased incidences of for-
estomach squamous cell papillomas.
Synonyms: 2,2-dichloroethenyl dimethyl phosphate; 2,2-
dichlorovinyl dimethyl phosphate; O,O-dimethyl-O-(2,2-
dichlorovinyl)phosphate; DDVP
Trade Names: BAY-19149; DDVF; ENT-20738; OMS-14;
SD1750; Canogard®; Crossman's Fly-Cake®; Dedevap®;
De-Pester Insect Strip®; Estrosol®; Herkol®; Kill-fly
Resin Strip®; Lethalaire®; Mafu®; Misect®; Nogos®;
Nuvan®; No-Pest Strip®; Oko®; Phoracide®; Phosvit®;
Vapona®; Vaponicide®; Vaporette Bar®
Anthelmintics: Atgard®; Dichlorman®; Equigard®;
Taskg
Report Date: September 1989
Note: Dichlorvos (technical grade) waspreviouslytested
in Osborne-Mendel rats and B6C3F1 mice administered
in feed (See TR-10, reported 1979).
TR-343 Toxicology and Carcinogenesis
Studies ofBenzyl Alcohol (CAS No.
100-51-6) in F344/N Rats and B6C3F1 Mice
(GavageStudies)
Toxicology and carcinogenesis studies of technical-
grade benzyl alcohol (99% pure), a textile dye additive,
solvent, and food flavoring agent, were conducted by
administering the chemical by gavage in corn oil vehicle
to groups of F344/N rats and B6C3F1 mice of each sex
for 16 days, 13 weeks, or 2 years.
Short-Term Studies: In 16-day studies, all five male
and five female rats and mice dosed with 2,000 mg/kg
benzyl alcohol died. Two offive male and 3/5 female rats
and1/5 male and 2/5 female mice dosed with 1,000 mg/kg
died. Rats and mice ofeach sex in the two highest dose
groups were lethargic after dosing. Other toxic
responsestobenzylalcoholinthesedosegroupsincluded
blood around the mouth and nose, subcutaneous hemor-
rhages, and blood in the urinary and gastrointestinal
tracts of rats and blood in the urinary bladder of mice.
Animals administeredlower doses ofbenzyl alcohol (125,
250, or 500 mg/kg) had no compound-related histologic
lesions.
Doses selected for the 13-week studies were 0, 50, 100,
200, 400, and 800 mg/kg for rats and mice. Eight of 10
male rats dosedwith800mg/kgdied duringweeks 7and
8; fourofthese deathswere described as gavage related.
Rats dosedwith800mg/kgexhibited clinical signsindic-
ative of neurotoxicity including staggering, respiratory
difficulty, and lethargy. Hemorrhages occurred around
the mouth and nose, and there were histologic lesions in
the brain, thymus, skeletal muscle, and kidney. In mice,
deaths were scattered among all dose levels, but none
occurred in vehicle controls. Four male and six female
mice died after being dosed; all deaths but one were
described as gavage related. Staggering after dosing
also occurred during the first 2 weeks ofthe studies in
mice dosed with 800 mg/kg. Some of the deaths in the
rats and mice may have been caused by a combination of
the gavage procedure and chemical toxicity, since there
was evidence that benzyl alcohol induced neurotoxic
effects. There were reductions in relative weight gain in
male rats dosedwith 800mg/kgbenzyl alcohol, infemale
rats dosed with 200 mg/kg or more, in male mice dosed
with400or800mg/kg, andinfemalemicedosedwith200
mg/kg or more. No notable changes in bodyweight gain
or compound-related histopathologic lesions were
observed in rats or mice from the lower dose groups.
Based on mortality, reduction in relative body weight
gain, and the histopathologic lesions, doses selected for
2-year studies in ratswere 0, 200, and 400 mg/kg. Doses
selected for 2-year studies in mice were 0, 100, and 200
mg/kg, based on mortality and depression in relative
bodyweight gain.
Body Weight and Survival in the Two-Year Studies:
Fifty animals ofeach species and sexwere administered
benzyl alcohol in corn oil by gavage 5 days per week for
103weeks.Administration ofbenzyl alcoholdid notaffect
survivalinmalerats (final survivalrates:vehiclecontrol,
28/50; low dose, 27/50; high dose, 24/50) but reduced
survival ofdosed female ratsbyhalf(36/50; 18/50; 17/50).
Many ofthe early deaths were considered related to the
gavage procedure. Survival in mice was not affected by
benzyl alcohol administration (male: 34/50; 33/50; 35/50;
female: 26/50;32/50; 36/50). No effectofbenzylalcohol on
body weight gain in rats or mice was observed. In the
third month of the studies, clinical signs of sia-
lodacryoadenitis virus infection were observed in rats. A
positive serologic reaction for rat coronavirus was
observed in sentinel animals at 6 months and again at 18
months.
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: No apparent compound-related nonneoplastic
responses were observed. Dose-related negative trends
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in the incidences of anterior pituitary gland neoplasms
were seeninfemale rats (vehicle control, 29/50; lowdose,
17/47; high dose, 9/49) and ofHarderian gland adenomas
in male mice (8/50; 3/50; 2/50). Adenomas ofthe adrenal
cortex occurred at an increased incidence in high dose
male mice (0/48; 0/44; 3/48), but this slight increase was
not considered to be related to chemical exposure.
Genetic Toxicology: Benzyl alcohol was notmutagenic
when tested bythe preincubational protocol in the pres-
ence or absence of exogenous metabolic activation in
Salmonellatyphimurium strainsTA98,TA100,TA1535,
orTA1537. Inthemouse L5178Y/TK+/-lymphoma assay,
benzyl alcohol induced an increase in trifluorothymidine
(Tft)-resistant cells in the absence, but not in the pres-
ence, of S9; the effect was associated with toxicity. In
cytogenetic assays with Chinese hamster ovary (CHO)
cells, treatmentwithbenzylalcoholproducedanincrease
in sister chromatid exchanges (SCEs) which wasjudged
to be equivocal both with and without S9; a significant
increase inchromosomal aberrationswas observed after
exposure to benzyl alcohol in the presence, but not the
absence, ofS9.
Audit: The data, documents, and pathology materials
from the 2-year studies of benzyl alcohol have been
audited. The audit findings show that the conduct ofthe
studies is documented adequately and support the data
and results given in this Technical Report.
Conclusions: Under the conditions of these 2-year
gavage studies, there was no evidence ofcarcinogenic
activity ofbenzyl alcoholformale orfemale F344/N rats
dosed with 200 or 400 mg/kg. Survival in both dose
groups of female rats was 50% that ofvehicle controls,
primarily due to an increased number ofgavage-related
deaths. Therewasno evidenceofcarcinogenic activity
ofbenzyl alcohol for male or female B6C3F1 mice dosed
with 100 or 200 mg/kg for 2 years.
Synonyms: benzenemethanol; phenylcarbinol; phe-
nylmethanol; a-hydroxytoluene; benzenecarbinol; phe-
nolcarbinol; ao-toluenol
Report Date: June 1989
TR-344 Tbxicology and Carcinogenesis
Studies ofTetracycline Hydrochloride
(CAS No. 64-75-5) in F344/N Rats and
B6C3F1 Mice (Feed Studies)
Tetracyclinehydrochlorideisabroad-spectrumantibi-
otic used for its bactericidal action in human and veteri-
nary medicine. Toxicology and carcinogenesis studies of
tetracycline hydrochloride (USP grade, 91% pure) were
conducted by feeding diets containing tetracycline
hydrochloride to groups of F344/N rats and B6C3F1
mice ofeach sex for 14 days, 13 weeks, or 2 years.
Fourteen-Day and Thirteen-Week Studies: The same
dietary concentrations were used for the 14-day and 13-
week studies (0, 3,125, 6,250, 12,500, 25,000 and 50,000
ppm tetracycline hydrochloride). In the 14-day studies,
noneoftherats ormicedied.Thefinalmeanbodyweight
of male rats that received 50,000 ppm was 24% lower
than that ofthe controls. The final mean bodyweight of
mice that received 50,000 ppm in the dietwas 18% lower
than that of the controls for males and 15% lower for
females. No compound-related effects were observed in
rats or mice at necropsy.
During the 13-week studies, none of the rats or mice
died. The final mean body weight of male rats that
received 50,000 ppm was 18% lower than that of the
controls. Compound-related effects included cytoplasmic
vacuolizationintheliverofmaleratsat25,000and50,000
ppm. Bone tetracycline concentrations in rats and mice
increased with increasing dose of tetracycline hydro-
chloride. The final mean body weight of mice that
received 50,000 ppm was 16% lower than that of the
controls for males and 6% lower for females. Estimated
feed consumption by dosed rat and mouse groups was
similar to that of the controls. No compound-related
gross ormicroscopic pathologic effects were observed in
mice.
Based on these results, 2-year studies oftetracycline
hydrochloride were conducted by feeding diets contain-
ing0,12,500, or25,000ppmtetracyclinehydrochlorideto
groups of50 rats and 50 mice ofeach sex for 103 weeks.
BodyWeight, Survival, and Feed Consumption in the
Two-Year Studies: Mean body weights of dosed and
control male and female rats were similar throughout
mostofthestudies.Thesurvivalofboththelowandhigh
dosefemale groupswasgreaterthanthatofthecontrols.
No significant differences in survival were observed
between any groups of male rats (male: control, 27/50;
low dose, 24/50; high dose, 31150; female: 27/50; 39/50;
38/50). Meanbodyweights ofdosed micewere markedly
(more than 10%) lower than those of the controls
throughout mostofthe studies. The survival rates ofthe
dosed groups ofmale micewere greaterthan that ofthe
controlgroup. No significantdifferences in survivalwere
observed between any groups of female mice (male:
31V50; 43/50; 43/50; female: 37/50; 35/50; 38/50). Feed
consumption was similar by dosed and control rats and
mice ofeither sex throughout the studies.
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Basophilic cytoplasmic change and clear cell
change were positively correlated with tetracycline
hydrochloride administrationinmalerats. Otherwise, no
significant increases in neoplastic or nonneoplastic
lesions in rats or mice of either sex were considered
related to tetracycline hydrochloride administration.
The incidence ofadenomas or carcinomas (combined)
ofthe pancreaticislets in lowdosemale ratswas greater
than that in the controls (control, 0/49; low dose, 5/49;
high dose, 0/49). This marginal effect in the low dose
group was not considered to be chemically related. The
historical control rate ofpancreatic islet cell neoplasms
from previous studies at this laboratory is 6% (9/148).
Decreased incidences and severity of chronic
nephropathy in male rats were associated with
tetracycline hydrochloride administration (48/50; 35/50;
36/50). Female mice administered tetracycline hydro-
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chloride in feed did not develop hepatocellular adenomas
or carcinomas (combined incidence: 10/49; 0/48; 0/50).
The historical control rate for hepatocellular adenomas
or carcinomas (combined) from previous studies at this
laboratory is 18/149 (12%). Other decreases in tumor
incidence involving several tissues were considered to be
ofmarginal biologic significance.
Genetic Toxicology: Tetracycline hydrochloride was
not mutagenic in four strains of Salmonella
typhimurium (TA98, TA100, TA1535, or TA1537) when
tested in a preincubation protocol in the presence or
absence of exogenous metabolic activation. Tetracycline
hydrochloride was negative in the mouse lymphoma
L5178Y/TK+/- assaywith orwithoutinduced ratliver S9
but gave a marginally positive response when tested in
the presence of noninduced S9. In cytogenetic assays
with Chinesehamsterovary(CHO) cells, treatmentwith
tetracyclinehydrochloride, bothwith andwithoutS9, did
not induce chromosomal aberrations or sister chromatid
exchanges (SCEs). Tetracycline hydrochloride did not
induce sex-linked recessive lethal mutations when
administered byfeeding orinjection to adultmale Dros-
ophila.
Conclusions: Undertheconditions ofthese2-yearfeed
studies, therewasno evidence ofcarcinogenic activity
oftetracycline hydrochloride for male or female F344/N
rats and B6C3F1 mice fed diets containing 12,500 or
25,000 ppm. Tetracycline hydrochloride-dosed female
rats and male mice had greater survival rates than the
respective controls duringthese studies. Dosed micehad
lower bodyweight than controls, and dosed female mice
had no hepatocellular adenomas or carcinomas.
Trade Names for Tetracycline or Tetracycline hydro-
chloride: Achromycin; Amycin; Bristacycline; Cyclopar;
Dumocyclin; Neocyclin B; Panmycin; Polycycline;
Robitet; Ro-cycline; Steclin; Sumycin; Topicycline;
Unimycin
Report Date: August 1989
TR-345 Toxicology and Carcinogenesis
Studies of Roxarsone (CAS No. 121-19-7) in
F344/N Rats and B6C3F1 Mice (Feed
Studies)
Roxarsone is a veterinary drug used as a growth
promoterandas ananticoccidial agentandfortreatment
ofswine dysentery. Toxicology and carcinogenesis stud-
ies were conducted by administering roxarsone (greater
than 99.4% pure) in feed to groups of F344/N rats and
B6C3F1 miceofeachsexfor14days, 13weeks, or2years.
Fourteen-Day and Thirteen-Week Studies: In the 14-
day studies, the diets fed to rats contained 0 or100-1,600
ppm roxarsone, and those fed to mice contained 0 or
60-1,000 ppm. Deaths occurred in rats and mice that
received the highest doses. Rats that received 800 or
1,600ppmlostweight. Malemice thatreceived 1,000ppm
and female mice that received 500 ppm lostweight.
In the first 13-week studies, roxarsone was fed to rats
and mice at dietary concentrations of 0 or 50-800 ppm.
Decreases (morethan10%)infinalmeanbodyweights of
dosed ratsrelative tothose ofcontrolswere observedfor
males thatreceived 200, 400, or800 ppm and forfemales
thatreceived 400 or800 ppm. Deaths occurred in groups
that received 800 ppm. Clinical signs of toxicity (trem-
bling, ataxia, and pale skin) were seen primarily in rats
that received 800 ppm. Kidney lesions were observed in




regeneration in the rats that lived to the end of the
studies.
Additional 13-week studies were conducted in rats at
dietary concentrations of 0, 100, or 400 ppm to demon-
strate the absorption of roxarsone from the gastroin-
testinal tract; to determine its distribution in liver,
kidney, and blood; and to study its effects on various
hematologic and clinical chemical values. No deaths
occurred. Renal lesions ofminimal severity observed in
male rats that received 400 ppm were characterized by
tubular epithelial cell degeneration and regeneration,
tubular casts, and mineralization. Arseniclevels inurine,
blood, kidney, and liver of dosed rats increased
(140%-300%) with time on study and were proportional
to the dietary concentrations of roxarsone. No
compound-related hematologic or clinical chemical
effects were observed in rats.
Inthefirst13-weekstudies,finalmeanbodyweightsof
mice that received 800 ppm were 11%-18% lower than
those ofcontrols. Deaths occurred in males and females
receiving 400 and 800 ppm. No compound-related gross
or histopathologic lesions were observed.
In the second 13-week studies in mice, no compound-
related hematologic or clinical chemical effects were
observed. At the end of the studies, arsenic concentra-
tions in dosed micerangedfrom 0.45 to 0.99 ,ug/gofliver
and from 0.85 to 2.98 pLg/g of kidney. No arsenic was
detected in the liver or kidney ofcontrol mice.
Becauseofkidneylesions, lowerbodyweightgain, and
increased mortality in rats and lower body weight gain
and increased mortality in mice in the short-term stud-
ies, dietary concentrations of roxarsone selected for the
2-year studies were 0, 50, or 100 ppm for rats and 0, 100,
or 200 ppm for mice.
Body Weight and Survival in the Two-Year Studies:
Mean bodyweights ofdosed rats were generally within
5% of those of controls. No significant differences in
survival were observed between any groups of rats of
either sex, although survival in males was lower than
usual (final survival-male: control, 24/50; low dose,
18/50; high dose, 18/50; female: 27/50; 35/50; 32/50). The
average feed consumption by high dose rats was 95%
that of controls for males and 88% for females. The
average amount of roxarsone consumed per day was
approximately 2 mg/kgforlowdose rats and 4mg/kgfor
high dose rats. Mean body weights of high dose male
mice were generally 5%-8% higher than those of the
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controls, whereas those of female mice were generally
6%-15% lower thanthose ofthe controls. The survival of
the control groupofmalemicewaslowerthanthatofthe
low dose group after month 22; survival forfemales was
low (final survival-male: 27/50; 40/50; 33/50; female:
14/50;18/50;17/50).Thelowsurvivalinfemaleswasduein
part to utero-ovarian infection, with more than 50% of
the animals in each dose group having suppurative
inflammation at this site. The average daily feed con-
sumption by dosed mice was 105%-110% that by the
controls. The averageamountofroxarsoneconsumedper
day was approximately 21 or 43 mg/kg for low dose or
high dose male mice and 27 or 54 mg/kg for low dose or
high dose female mice.
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Although the incidence of adenomas of the
exocrine pancreas in high dose male rats was not statis-
ticallygreaterthanthatinthe controls (control,1150; low
dose, 1150; high dose, 5/50), itwas greater than that seen
in any historical control group ofmale F344/N rats. The
historicalrateis1/437(0.2%)forthestudylaboratoryand
5/1,871(0.3%)throughouttheProgram.Theincidences of
hyperplasia were 2/50; 0/50; 3/50. No hyperplasia or
adenomas were observed in the exocrine pancreas of
female rats.
Clitoralglandadenomas infemaleratsoccurredwitha
marginally positive trend (1144; 3/47; 6/48; P = 0.049).
One carcinoma was also observed in each ofthe groups.
The incidences of adenomas or of adenomas or car-
cinomas (combined) inthe dosed groupswere notsignifi-
cantlydifferentfromthose inthe controls. Thismarginal
effect was not considered to be related to roxarsone
administration.
No chemical-related increases in neoplastic or non-
neoplastic lesions occurred in male orfemale mice. Lym-
phomas in female mice occurred with a negative trend;
the incidences in the dosed groups were lower than that
in the controls (13/50; 2/50; 3/50; P. 0.01).
Genetic Toxicology: Roxarsone was not mutagenic in
Salmonella typhimurium strainsTA98,TA100,TA1535,
or TA1537 with or without metabolic activation. Rox-
arsone induced trifluorothymidine (Tft) resistance in
mouse lymphoma L5178Y cells in the absence of meta-
bolic activation; it was not tested with activation.
Exposure of adult male Drosophila nelanogaster to
roxarsone by injection or by feeding did not cause an
increase in sex-linked recessive lethal mutations.
Audit: The data, documents, and pathology materials
from the 2-year studies ofroxarsone have been audited.
The auditfindings showthattheconductofthe studiesis
documented adequatelyand supportthe dataandresults
given in this Technical Report.
Conclusions: Undertheconditions ofthese2-yearfeed
studies, there was equivocal evidence ofcarcinogenic
activity ofroxarsone for male F344/N rats, as indicated
by a marginally increased incidence of adenomas ofthe
exocrine pancreas. There was no evidence of car-
cinogenic activity for female F344/N rats fed diets
containing 50 or 100 ppm roxarsone for 2 years. There
was no evidence ofcarcinogenic activity for male or
female B6C3F1 mice fed diets containing100 or 200 ppm
roxarsone for 2 years.
Synonyms: 4-hydroxy-3-nitrophenylarsonic acid;
4-hydroxy-3-nitrobenzenearsonic acid; 2-nitro-1-
hydroxybenzene-4-arsonic acid; nitrophenolarsonic acid;
3-nitro-4-hydroxybenzenearsonic acid; 3-nitro-4-
hydroxyphenylarsonic acid
Trade Names: Ristat; Ren-O-sal; 3-nitro; 3-nitro-10;
3-nitro-20; 3-nitro-50; 3-nitro-80
Report Date: March 1989
TR-346 Toxicology and Carcinogenesis
Studies ofChloroethane (Ethyl Chloride)
(CAS No. 75-00-3) in F344/N Rats and
B6C3F1 Mice (Inhalation Studies)
Toxicologyand carcinogenesis studies ofchloroethane
(99.5% pure), an alkylating agent and chemical inter-
mediate, as well as a topical and inhalation anesthetic,
were conducted by exposing groups of F344/N rats and
B6C3F1 mice ofeach sex to chloroethane bywhole-body
inhalation once for 4 hours or for 6 hours per day, 5 days
per week for 14 days, 13 weeks, or 2 years. Genetic
toxicology studies were conducted in Salmonella
typhimurium.
Single-Exposure, Fourteen-Day, and Thirteen-Week
Studies: In the single-exposure and 14-day inhalation
studies, all rats and mice exposed to 19,000 ppm chlo-
roethane survived. The animals were not exposed at
lower concentrations. No clinical signs of toxicity were
seen. In the 14-day studies, final mean body weights of
exposed male rats and exposed mice were higher than
those of controls. Mean body weights of exposed and
control female rats were similar.
In the 13-week studies, rats and mice were exposed to
0, 2,500, 5,000, 10,000, or 19,000 ppm chloroethane. No
compound-related deaths occurred in rats or mice. The
finalmeanbodyweightofratsexposedto19,000ppmwas
8%lowerthanthatofcontrolsformales and4%lowerfor
females. Final mean bodyweights ofexposed mice were
generally higher than those of controls. No compound-
related clinical signs or gross or microscopic pathologic
effectswereseeninratsormice.Theliverweighttobody
weight ratios for male rats and female mice exposed to
19,000 ppm were greater than those for controls.
Although no chemically related toxic effects were
observed in the short-term studies, concerns about
potential flammability and explosion led to the selection
of 0 and 15,000 ppm as the exposure concentrations for
rats and mice for the 2-year studies.
Body Weight and Survival in the Two-Year Studies:
Mean body weights of exposed male rats were 4%-8%
lower than those of controls after week 33. Mean body
weights of exposed female rats were generally 5%-13%
lower than those of controls throughout the study.
Although survival ofmale rats and exposed female rats
was low at the end of the studies (male: control, 16/50;
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exposed,8/50;female:31150;22/50),nostatisticallysignif-
icant differences in survival were observed between
exposed and control groups of either sex. Survival at
week 90 for male rats was 37/50 (control) and 31/50
(exposed) and for females, 43/50 (control) and 33/50
(exposed). The high incidence ofmononuclear cell leuke-
mia may have contributed to the high mortality.
Mean body weights of exposed male mice were up to
13% higher than those ofcontrols throughout the study.
Mean body weights ofexposed and control female mice
were generally similar throughout the study. The sur-
vival ofthe exposed groups ofboth male (after day 330)
and female (after day 574) mice was significantly lower
than that ofcontrols (final survival-male: 28/50; 11/50;
female: 32/50; 2/50).Themajorityofexposedfemalemice
died as a result of uterine carcinomas. Male mice, and
particularly exposed mice, died early as a result of an
ascending urinary tract infection.
Nonneoplastic and Neoplastic Effects in theTwo-Year
Studies: Malignant astrocytomas ofthe brain were seen
inthree exposed female rats, and gliosis was observed in
a fourth. The historical incidence ofglial cell neoplasms
in untreated control female F344/N rats is 23/1,969. The
highestincidence observedinanuntreatedcontrol group
is 3/50.
Trichoepitheliomas (1/50), sebaceous gland adenomas
(1/50), basal cell carcinomas (3/50), and squamous cell
carcinomas (2/50) of the skin were observed only in
exposed male rats. Keratoacanthomas occurred in four
control and two exposed male rats.
Exposureoffemalemicetochloroethanecausedahigh
incidence of uterine carcinomas of endometrial origin
(control, 0/49; exposed, 43/50). One control female did
have a uterine carcinoma, although it was not of
endometrial origin. The tumors observed in 34 exposed
females were highly malignant, invading the uterine
myometrium and metastasizing to a wide variety of
organs, primarilylung (23), ovary (22), lymph nodes (18),
kidney (8), adrenal gland (8), pancreas (7), mesentery (7),
urinary bladder (7), spleen (5), and heart (4), and to a
lesser extent, colon, stomach, gallbladder, small intes-
tine, ureter, and liver.
Two marginally increased incidences of other neo-
plasms were observed in exposed male and female mice.
The incidence of hepatocellular carcinomas in exposed
femalemicewasgreaterthanthatincontrols (3/49;7/48).
One otherexposedfemale had ahepatocellular adenoma.
The incidence of alveolar/bronchiolar neoplasms of the
lung in exposed male mice was greater than that in
controls (adenomas or carcinomas, combined: 5/50;
10/48).
Genetic Toxicology: Chloroethane, tested within the
closed environment of a desiccator, was mutagenic with
and without exogenous metabolic activation in S.
typhimurium strainTA1535; in strain TA100, apositive
response was observed only with activation. No muta-
genic activity was observed in S. typhimurium strain
TA98 with or without metabolic activation.
Conclusions: Under the conditions of these 2-year
inhalation studies, there was equivocal evidence ofcar-
cinogenic activity of chloroethane for male F344/N
rats, as indicated by benign and malignant epithelial
neoplasmsoftheskin. ForfemaleF344/Nrats,therewas
equivocal evidence of carcinogenic activity, as indi-
catedbythreeuncommonmalignantastrocytomasofthe
brain in the exposed group. The study of male B6C3F1
mice was considered to be an inadequate study of
carcinogenicity because of reduced survival in the
exposed group. However, there was an increased inci-
dence of alveolar/bronchiolar neoplasms of the lung.
There was clear evidence ofcarcinogenic activity for
female B6C3F1 mice, as indicated by carcinomas of the
uterus. Amarginallyincreased incidence ofhepatocellu-
lar neoplasms was observed in the exposed group.
Synonyms: monochloroethane; chloroethyl; etherhydro-
chloric; ether muriatic; aethylis; aethylis chloridum;
ether chloridum; ether chloratus
Trade Names: Kelene; Chelen; Anodynon; Chloryl Anes-
thetic; Narcotile
Report Date: October 1989
TR-347 Toxicology and Carcinogenesis
Studies ofd-Limonene (CAS No. 5989-27-5)
in F344/N Rats and B6C3F1 Mice (Gavage
Studies)
Toxicologyandcarcinogenesis studies ofd-limonene, a
naturally occurring monoterpene found in many volatile
oils, especially in citrus oils, were conducted because of
itswidespread use as aflavor and fragrance additive for




F344/N rats and B6C3F1 mice to identify toxic effects
and affected sites and to help establish doses for the
2-year studies. Genetic toxicology studies were con-
ducted in Salmcnella typhimurium, mouse L5178Y
cells, and Chinese hamster ovary (CHO) cells.
The doses selected for the 16-daystudies ranged from
413 to 6,600 mg/kg for both rats and mice; deaths and
reduction in bodyweight gain occurred at the two high-
est doses. No compound-related clinical signs or histo-
pathologic lesions were observed in any ofthe surviving
dose groups.
In the 13-week studies, doses of d-limonene ranged
from 150 to 2,400 mg/kg for rats and from 125 to 2,000
mg/kg for mice. Deaths occurred in the high dose group
ofeach species and sex. Greater than 10% reductions in
bodyweight gain were observed in the two highest dose
groups of male rats and male mice and the high dose
female rats. Rough hair coats and decreased activity
were observed at the two highest doses in both rats and
mice. There were no chemical-related histopathologic
lesions in female rats or in mice of either sex. A
compound-relatedincreasedseverityofnephropathywas
observed in the kidney of male rats. This lesion was
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characterized by degeneration of epithelial cells in the
convoluted tubules, granular casts in the outer stripe of
the outer medulla, and epithelial regeneration. These
lesions have been described as reasonablycharacteristic
ofthehyalinedropletnephropathythatisassociatedwith
an accumulation of liver-generated a2%R-globulin in the
cytoplasm oftubular epithelial cells.
Two-year studies of d-limonene were conducted by
administering 0, 75, or 150 mg/kg d-limonene in corn oil
by gavage to groups of50 F344/N male rats, 5 days per
week for 103 weeks; groups of 50 female F344/N rats
were administered 0, 300, or 600 mg/kg. These doses
were selected based on compound-related, potentially
life-threatening kidney lesions observed in males at 300
mg/kg and higher and on the large number ofdeaths of
female rats at 2,400 mg/kg. Groups of 50 male B6C3F1
micewereadministered 0,250, or500mg/kgaccordingto
the same schedule; groups of 50 female B6C3F1 mice
were administered 0, 500, or 1,000 mg/kg. These doses
wereselectedbased onthedeathsobservedforbothmale
and female mice at 2,000 mg/kg during the 13-week
studies and the body weight depression in male mice at
1,000 mg/kg and higher.
Mean body weights of rats dosed with d-limonene
were similar to those ofvehicle controls throughout the
studies. Survival ofthe high dose female rats afterweek
39 and ofthe vehicle control male rats afterweek 81was
significantly reduced (survival at week 104-male: vehi-
cle control, 29/50; low dose, 33/50; high dose, 40/50;
female: 42/50; 40/50; 26/50). Meanbodyweights ofdosed
and vehicle control male mice were similar throughout
the studies. Meanbodyweights ofhigh dosefemalemice
were notably lower than those of the vehicle controls
after week 28. Survival of the low dose group of male
micewas significantly lowerthan that ofvehicle controls
attheendofthestudy(33/50;24/50;39/50). Nodifference
in survival was observed between vehicle control and
dosed female mice (43/50; 44/50; 43/50).
Inthe2-year studies, the kidneywas confirmed asthe
primary target organ for chemically related lesions. No
lesions were observed in female rats. For males, the
nonneoplastic lesions included exacerbation of the age-
related nephropathy, linear deposits of mineral in the
renal medulla and papilla, and focal hyperplasia of the
transitional epithelium overlying the renal papilla.
Uncommon tubular cell adenomas and adenocarcinomas
ofthe kidney also occurred in dosed male rats, and this
effect was supported by a dose-related increased inci-
dence of tubular cell hyperplasia, as shown in the table
below (see page 4 ofthe Technical Report).
Insubsequent21-daystudies,maleandfemale F344/N
rats were administered d-limonene at doses ranging
from 75 to 1,200 mg/kg. Microscopic examination ofthe
kidney sections from these rats indicated a compound-
relatedincreaseinintracytoplasmicgranulesintheprox-
imal convoluted tubules of dosed male rats but not of
female rats. The granules were shown to contain Cx2p-
globulin by an immunohistochemical strain. %2pL-
Globulin was shown to be increased in kidney homoge-
nates from dosed male rats by an ELISA test.
In mice, no chemically related increases in neoplasms
were observed. The incidence ofneoplasms ofthe ante-
rior pituitary gland in high dose female mice was lower
than that in vehicle controls (adenomas or carcinomas,
combined: vehicle control, 12/49; high dose, 2/48). Cells
with an abnormal number of nuclei (8/49; 32/50) and
cytomegaly (23/49; 38/50) were observed in the liver of
high dose male mice.
Genetic Toxicology: d-Limonene was notmutagenic in
four strains ofS. typhimurium (TA98, TA100, TA1535,
or TA1537), did not significantly increase the number of
trifluorothymidine (Tft)-resistant cells in the mouse
L5178Y/TK+/- assay, and did not induce chromosomal
aberrations or sister chromatid exchanges (SCEs) in
cultured CHO cells. All assays were conducted in the
presence and absence ofexogenous metabolic activation.
Conclusions: Under the conditions of these 2-year
gavage studies, there was clear evidence of car-
cinogenic activity ofd-limonene for male F344/N rats,
as shown by increased incidences of tubular cell hyper-
plasia, adenomas, and adenocarcinomas of the kidney.
There was no evidence of carcinogenic activity of
d-limonene for female F344/N rats that received 300 or
600 mg/kg. There was no evidence of carcinogenic
activity of d-limonene for male B6C3F1 mice that
received 250 or 500 mg/kg. There was no evidence of
carcinogenic activity ofd-limonene for femaleB6C3Fj
mice that received 500 or 1,000 mg/kg.
An increased severity of spontaneous nephropathy,
increased incidences oflinearmineralization ofthe renal
medulla and papilla, and hyperplasia of the transitional




diene; carvene; cinene; cajeputene
Report Date: January 1990
TR-348 Toxicology and Carcinogenesis
Studies ofalpha-Methyldopa
Sesquihydrate (CAS No. 41372-08-1) in
F344/N Rats and B6C3F1 Mice (Feed
Studies)
x-Methyldopa sesquihydrate is used in the treatment
ofhypertension; over20millionprescriptions arewritten
annually for oa-methyldopa or a-methyldopa sesquihy-
drate in the United States. ox-Methyldopa sesquihydrate
(USP grade, greater than 99% pure) was selected for
study because of widespread human exposure and the
lack ofcarcinogenicity studies on this compound.
Fourteen-day, 13-week, and 2-year studies were con-
ducted in F344/N rats and B6C3F1 mice. The chemical
was administered in feed because human exposure is
primarily by the oral route. Short-term studies were
performed in bacteria and mammalian cells to evaluate
the potential for genetic damage.
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Fourteen-Day and Thirteen-Week Studies: In the 14-
day studies, the chemical was administered at dietary
concentrations of 0 and 6,250-100,000 ppm. All rats
receiving 100,000 ppm and 2/5 female rats receiving
50,000 ppm died. All mice lived until the end of the
studies. Final mean body weights of dosed male rats
were 14%-43% lower than that of controls, and those of
dosedfemaleratswere 9%-24%lower. Feedconsumption
by dosed male and female rats was reduced. Final mean
bodyweights ofdosed miceweregenerallywithin 10% of
those ofcontrols; feed consumption bydosed groupswas
lower than that by controls during the first week ofthe
studies.
Inthe 13-week studies, the chemicalwas administered
at dietary concentrations of 0 and 3,100-50,000 ppm.
Deaths occurred in 4/10 male rats, 7/10 female rats, and
2/10 female mice at 50,000 ppm and in 1110 female rats at
25,000 ppm. Finalmeanbodyweights ofdosed ratswere
6%-46% lower than those ofcontrols. Feed consumption
by dosed rat groups was lower than that by controls.
Final mean body weights of male mice at 25,000 and
50,000 ppm and female mice at 50,000 ppmwere reduced
12%-19%. Feed consumption by dosed and control mice
was comparable.
Rats and mice receiving 25,000 and 50,000 ppm exhib-
ited clinical signs oftoxicityincludinglethargy, hyperex-
citability, oculardischarge, androughhaircoats. Clinical
signs oftoxicity werejudged to be more severe in dosed
male mice than in female mice. Minimal to moderate
kidney tubular cell regeneration was seen in male and
female rats at 12,500, 25,000, and 50,000 ppm. Bone
marrow hypoplasia occurred in male rats at 25,000 and
50,000 ppm and in female rats at 6,300 ppm and higher.
Nuclearenlargement (karyomegaly) oftherenal cortical
tubularepitheliumwasobservedinmale andfemalemice
administered 12,500-50,000 ppm; these kidney lesions
were judged to be more severe and occurred more fre-
quently at concentrations of25,000 ppm and higher.
Becauseofkidneylesions,bonemarrowresponses, and
body weight effects at 12,500 ppm and higher and
increased deaths and clinical signs at 25,000 and 50,000
ppm, dietaryconcentrations selectedformale andfemale
rats in the 2-year studies were 0, 3,100, and 6,300 ppm.
Based on clinical signs, kidney effects, and body weight
decreases at 25,000 and 50,000 ppm, dietary concentra-
tions selected for male and female mice in the 2-year
studies were 0, 6,300, and 12,500 ppm. Diets containing
the chemical at these concentrations were fed to groups
of50 male and 50 female rats and 50 male and 50 female
mice for 103 weeks.
Body Weight and Survival in the Two-Year Studies:
Meanbodyweights ofdosed ratsweregenerally8%-17%
lower than those ofcontrols, and mean body weights of
dosed mice were generally 5%-22% lower than those of
controls throughout the studies. The average amount of
x-methyldopa sesquihydrate consumed per day was
approximately 110-120 or 230-240 mg/kg per day by low
and high dose rats and 830-890 or 1,760-1,800 mg/kg by
lowand high dose mice. Survival was comparable among
dosed and control groups (male rats: control, 28/50; low
dose, 26/50; high dose, 27/50; female rats: 35/50; 34/50;
29/50; male mice: 44/50; 42/50; 39/50; female mice: 42/50;
40/50; 38/50). Clinical signs considered tobe dose-related
included fighting in male rats, irritability in male mice,
and rough hair coats in female mice.
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Several lesions of the forestomach, including
edema, chronic inflammation, epithelial hyperplasia, and
ulcers, were seen at low incidences in high dose rats. No
forestomach neoplasms occurred. No neoplastic lesions
were observed in either male or female rats which were
considered related to ot-methyldopa sesquihydrate
exposure.
Nephropathy (control, 3/50; lowdose, 21150; high dose,
32/50), karyomegaly (nuclearenlargement) ofcells ofthe
tubular epithelium (0/50; 46/50; 44/50, and cysts (2/50;
10/50; 10/50)were observedin the kidneyofdosedfemale
mice. Low incidences of tubular cell hyperplasia (0/50;
1/50; 1/50), tubular cell adenomas (0/50; 2/50; 0/50), and
tubular cell adenocarcinomas (0/50; 0/50; 1/50) were
observed in male mice. Thbular cell adenomas (3/2,029,
0.15%) andtubularcell adenocarcinomas (3/2,029,0.15%)
are uncommon in untreated control male B6C3F1 mice.
No neoplastic lesions in female mice were considered
related to a.-methyldopa sesquihydrate exposure.
Decreased incidences of several site-specific neo-
plasms were observed in dosed rats and mice; these
decreases might have been due in part to decreased
weight gain in dosed groups. The decreases occurred in
theadrenalmedullaofmalerats (pheochromocytomas or
malignant pheochromocytomas, combined: 21/49; 3/49;
10/50),uterus offemalerats(endometrial stromalpolyps:
15/50; 5/49; 1/50), liver of male and female mice
(hepatocellular adenomas or carcinomas, combined-
male: 15/50; 5/50; 6/50; female: 4/50; 1/50; 0/50), and
anterior pituitary gland offemale mice (adenoma: 9/49;
4/40; 2/50). The incidences of malignant tumors (male:
19/50; 9/50; 8/50; female: 21/50; 16/50; 12/50) and benign
or malignant tumors (combined) (male: 32/50; 15/50;
17/50; female: 33/50; 22/50; 21/50) were reduced in dosed
mice.
Reproductive Studies: ao-Methyldopa sesquihydrate
was administered to male F344/N rats in corn oil by
gavage 5 days perweek for 65 days at doses of0, 50,100,
200, or 400 mg/kg. Decreased body weight was seen in
dosedanimals. Maleratswerematedtountreatedfemale
F344/Nratsondays57-61,necropsieswereperformedon
days 65-67, and reproductive toxicity was measured by
sperm count, sperm motility, organ weights, hormone
levels, and histologic evaluation ofthe testis. Decreased
fertilitywas observed in males dosedwith a.-methyldopa
sesquihydrate at 200 and 400 mg/kg. Decreases were
also seen in sperm count, spermmotility, apparent num-
ber oflate spermatids, and plasma testosterone levels in
malesinthe200and400mg/kggroups.This alterationof
reproductive function in male rats was found to be
reversible after a 13-week recovery period (without dos-
ing). The decreased fertility observed after a-methyld-
opa sesquihydrate administration was probably due in
part to the decreases in plasma testosterone levels.
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GeneticToxicity: a-Methyldopa sesquihydratewasnot
mutagenic when tested with orwithout exogenous meta-
bolic activation with a preincubation protocol in four
strains of Salmonella typhimurium (TA97, TA98,
TA100, or TA1535). No increase in chromosomal aberra-
tions or sister chromatid exchanges was observed in
Chinese hamster ovary (CHO) cells exposed to
ac-methyldopa sesquihydrate with orwithout S9.
Audit: The data, documents, and pathology materials
from the 2-year studies ofa-methyldopa sesquihydrate
have been audited. The audit findings show that the
conduct of the studies is documented adequately and
support the data and results given in this Technical
Report.
Conclusions: Undertheconditions ofthese2-yearfeed
studies, therewasno evidence ofcarcinogenic activity
ofox-methyldopa sesquihydrate formale orfemale F344/
Nratsfeddietscontaining3,100or6,300ppm.Therewas
equivocal evidence of carcinogenic activity of
a-methyldopa sesquihydrate for male B6C3F1 mice, as
shownbythreedosedmicehavinguncommontubularcell
tumors of the kidney. There was no evidence of car-
cinogenic activity of a-methyldopa sesquihydrate for
female B6C3F1 mice fed diets containing 6,300 or12,500
ppm. Nonneoplastic lesions of the kidney including
karyomegaly were observed in dosed female mice.
Decreased incidences of several tumor types (in the
adrenal gland in male rats, uterus in female rats, liverin
male and female mice, and anterior pituitary gland in
female mice) were considered related to cx-methyldopa
sesquihydrateexposure.
Synonyms for (x-Methyldopa or a-Methyldopa sesquihy-
drate: 3-hydroxy-a-methyl-L-tyrosine sesquihydrate;
L-(ax-MD); a-methyl-L-3,4-dihydroxyphenylalanine;






Trade Names for ac-Methyldopa or a-Methyldopa ses-
quihydrate: Aldomet; Aldometil; Aldomin; ao-Medopa;
AMD; Bayer 1440 L; Baypresol; Dopamet; Dopatec;
Dopegyt; Hyperpax; Medomet; Medopren; Methoplain;
MK. B51; MK-351; Presinol; Presolisin; Sedometil;
Sembrina
Report Date: March 1989
TR-349 Toxicology and Carcinogenesis
Studies ofTwo Pentachlorophenol
Technical-Grade Mixtures (CAS No.
87-86-5) in B6C3F1 Mice (Feed Studies)
Toxicologystudiesofpentachlorophenol, abiocideused
primarily as a wood preservative, were conducted by
feeding diets containing a technical-grade composite,
Dowicide EC-7 (a technical grade formulation), or pure
pentachlorophenol to groupsofB6C3F1 micefor30days.
These three grades plus another commercial grade of
pentachlorophenol (DP-2) were used in 6-month studies.
These studies were followed by 2-year carcinogenicity
studies of technical-grade pentachlorophenol and of
Dowicide EC-7 in feed. Genetic toxicology studies were
conducted in Salmonella typhimurium and in Chinese
hamster ovary (CHO) cells.
Thirty-Day and Sixteen-Month Studies: Groups of19
malemiceand 5-15femalemicewerefed dietscontaining
0, 20, 100, 500, 2,500, or 12,500 ppm technical-grade
pentachlorophenol, Dowicide EC-7, or pure pen-
tachlorophenol for 30 consecutive days. Necropsies and
histopathologic examinations were performed on all ani-
mals. Selected organswereweighed. Supplemental anal-
yses included hematology, serum chemistry, urinalysis,
immunology, and hepatic enzyme induction. Compound-
related deathswere observed atthehighest dose (12,500
ppm)withallthreematerialsandat2,500ppmwithEC-7
and pure pentachlorophenol (males only). Decreases in
body weight gain were also observed in the groups in
which deaths occurred. Diffuse centrilobular
cytomegaly, karyomegaly, nuclear atypia, degeneration,
or necrosis of the liver were compound-related lesions
observed in all groups that received pure pen-
tachlorophenol, technical-grade pentachlorophenol, or
EC-7 at 500 ppm and above. Serum enzymes associated
with liver injurywere increased.
Inthe6-monthstudies,groupsof10maleand10female
mice were given diets containing the various grades of
pentachlorophenol at the following dietary concentra-
tions: 200, 600, or 1,800 ppm technical-grade pen-
tachlorophenol; 200, 600, or 1,200 ppm DP-2 (not used in
the 30-day studies); 200, 600, or 1,200 ppm EC-7; or200,
500, or 1,500 ppm pure pentachlorophenol for 26-27
weeks. Common control groups of10 male and 10 female
mice were fed control diets. Additional groups of male
micewereexaminedforbehavioral,histopathologic,clini-
cal pathology, biochemical, and immunologic effects.
Allmiceexposedatthehighestdoseoftechnical-grade
pentachlorophenol died, as did2/10male miceexposed at
the highest dose of DP-2. No deaths were observed in
mice exposed to EC-7 or pure pentachlorophenol. Mark-
edly lower final bodyweights were observed in the high
dose groups only (all grades of pentachlorophenol). No
chemical-relatedclinicalsignswereobservedatsublethal
doses. Nomajorbehavioral changeswere observed after
5 weeks' exposure, but increased motor activity and
heightened startle responses were present at the end of
the study in female mice exposed to all four grades of
pentachlorophenol. All grades of pentachlorophenol
caused increases in serum enzymes associated withliver
injury. All grades ofpentachlorophenol alsoresulted in a
dose-related induction ofaryl hydrocarbon hydroxylase
and an increase in cytochrome P450. However, the tech-
nical grade was a more powerful inducer than the other
grades of pentachlorophenol. Pure pentachlorophenol
had no effect on humoral or cell-mediated immunity.
However, DP-2 and particularly technical-grade pen-
tachlorophenol depressed humoral immune function. A
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dose-related increase in liver weight was observed in
mice exposed to all grades ofpentachlorophenol. Adose-
related increase in spleen weight was observed in male
mice exposed to all grades of pentachlorophenol; a
decrease in spleen weight was observed in female mice
exposed to all grades ofpentachlorophenol except pure.
After6months' exposure, histopathologic examination
consistently revealed effects in the liver and urinary
bladder. The liver lesions were present at all doses with
allfour grades ofpentachlorophenol butwereless severe
at comparable doses in the mice exposed to pure pen-
tachlorophenol; they consisted of hepatocellular
karyomegaly, cytomegaly, and degeneration. The
changes in the urinary bladder consisted of a brown
granular pigment in the cells ofthe surface epithelium.
No inflammation or proliferative response was associ-
ated with the pigment.
Based primarily on the liver lesions observed in the
6-month studies, diets chosen for the 2-year studies
contained 0, 100, or 200 ppm technical-grade pen-
tachlorophenol or 0,100, 200, or 600 ppm EC-7, fed to
groups of 50 male and 50 female mice. DP-2 and pure
pentachlorophenol werenotchosenforthe2-yearstudies
because of economic considerations and because the
clinicopathologic syndrome observed in the 6-month
studies was similar to that observed with EC-7.
Body Weights and Survival in the Two-Year Studies:
Mean body weights of mice exposed to technical-grade
pentachlorophenol andEC-7werecomparabletothoseof
controls until weeks 36-82. Thereafter, a 4%-22% dose-
related decrease was observed in the mid and high dose
mice exposed to EC-7 and in high dose mice exposed to
technical-grade pentachlorophenol. Females were more
affected than males. Feed consumption by exposed mice
was similar to that by controls. The average daily doses
of technical-grade pentachlorophenol were approx-
imately 17-18 or 35 mg/kg compared with 17-18, 34-37, or
114-118mg/kgofEC-7. Survival ofmice did notappearto
be affected by exposure to either technical-grade pen-
tachlorophenol or EC-7 at the doses used in these stud-
ies.
Neoplastic and Nonneoplastic Effects in the Two-Year
Studies: The incidences ofhepatocellular adenomas and
carcinomas were increased (dose related) in male and
female mice exposed to either technical-grade pen-
tachlorophenol or EC-7, although the increase was less
marked in females exposed to technical-grade pen-
tachlorophenol (adenomas or carcinomas, combined:
technical-grade: male-control, 7/32, 22%; low dose,
26/47, 55%; high dose, 37/48, 77%; female-3/33, 9%;
9/49,18%; 9/50,18%; EC-7: male-control, 6/35,17%; low
dose, 19/48, 40%; mid dose, 21148, 44%; high dose, 34/49,
69%; female-1/34, 3%; 4/50, 8%; 6/49,12%; 31V48, 65%).
The incidences of pheochromocytomas in male mice
were significantly greaterthanthosein controls forboth
technical-grade pentachlorophenol (0/31; 10/45, 22%;
23/45, 51%) and EC-7 (1V34, 3%; 4/48, 8%; 21148, 44%;
45/49, 92%). These neoplasms were also increased in
female mice exposed to EC-7 at the highest dose (0/35;
2/49, 4%; 2/46, 4%; 38/49, 78%) but not in those exposed
totechnical-gradepentachlorophenol (2/33,6%;2/48,4%;
1149, 2%). Hyperplasia of the adrenal medulla was
observed at increased incidences in mice that received
either technical-grade pentachlorophenol (male: 1/31;
10/45; female: 0/33; 4/48; 2/49) orEC-7 (male: 1134;19/48;
13/48; 1149; female: 2/35; 1149; 5/46; 17/49).
The incidences of hemangiosarcomas in the spleen
and/or liver were significantly greater than those in
controls for high dose female mice that received
technical-grade pentachlorophenol (0/35; 3/50, 6%; 6/50,
12%) or EC-7 (0/35; 1150, 2%; 3/50, 6%; 8/49,16%).
Compound-related nonneoplastic lesions occurred in
the liver, spleen, and nose in mice exposed to either
technical-grade pentachlorophenol or EC-7. The lesions
in the liverincluded dose-related increased incidences of
clearcell foci, chronic activeinflammation, pigmentation,
necrosis, cytomegaly, proliferation ofhematopoietic cells,
and bile duct hyperplasia. Increased amounts of extra-
medullary hematopoiesis of the splenic red pulp were
observed atincreased incidences in dosed male and high
dose female mice that received technical-grade pen-
tachlorophenol (male: 5/30; 15/23; 18/46; female: 2/33;
4/13;11147).Acutefocalinflammation ofthenasalmucosa
and focal metaplasia of the olfactory epithelium were
observed at increased incidences in high dose mice that
received EC-7 (inflammation-male: 4/35; 1113; 3/16;
47/49; female: 0/35; 0/14; 2/5; 46/48; focal metaplasia-
male: 2/35; V13; 2/16; 46/49; female: 1/35; 0/14; 2/5; 45/48)
but not in mice exposed to technical-grade pen-
tachlorophenol.
Genetic Toxicology: Pentachlorophenol (91.6% pure;
equivalent in purity to the technical-grade pen-
tachlorophenol used in the toxicology studies) was not
mutagenic in S. typhimurium strains TA98, TA100,
TA1535, or TA1537 when tested in the presence or
absence of exogenous metabolic activation (S9). In
cytogenetic studies with cultured CHO cells, pen-
tachlorophenol produced an increase in chromosomal
aberrations in the presence but not the absence of S9
metabolic activation; conversely, sister chromatid
exchanges (SCEs) were induced only in the absence of
S9.
Audit: The data, documents, and pathology materials
from the 2-year studies ofpentachlorophenol have been
audited. The audit findings showthat the conduct ofthe
studies is documented adequately and support the data
and results given in this Technical Report.
Conclusions: Underthe conditions ofthese2-yearfeed
studies, there was clear evidence of carcinogenic
activity for male B6C3F1 mice fed diets containing
technical-grade pentachlorophenol, as shown by
increased incidences of adrenal medullary and
hepatocellular neoplasms. There was some evidence of
carcinogenic activity for female B6C3F1 mice exposed
to technical-grade pentachlorophenol, as shown by
increased incidences of hemangiosarcomas and
hepatocellular neoplasms. There was clear evidence of
carcinogenic activity formaleB6C3F1 miceexposed to
pentachlorophenol, EC-7, as shown by increased inci-
dences of adrenal medullary and hepatocellular neo-
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plasms. There was clear evidence of carcinogenic
activity for female B6C3F1 mice exposed to pen-
tachlorophenol, EC-7, as shown by increased incidences
of adrenal medullary and hepatocellular neoplasms and
hemangiosarcomas.
Chemically related increased incidences of non-
neoplastic lesions in mice of each sex included
hepatocellular cytomegaly, necrosis, inflammation, pig-
mentation, and clear cell foci and intrahepatic bile duct
hyperplasia.
Synonyms or Common Names: chlorophen; PCP; pen-
chlorol; penta; pentachlorofenol; pentachlorofenolo; pen-
tachlorphenol; 2,3,4,5,6-pentachlorophenol
Trade Names: Acutox; Chem-Penta; Chem-Tol; Cryp-
togil ol; Dowicide 7; Dowicide EC-7; Dow Pen-
tachlorophenol DP-2 Antimicrobial; Durotox; EP 30;
Fungifen; Fungol; GlazdPenta; GrundierArbezol; Laux-
tol; Lauxtol A; Liroprem; Moosuran; Pentacon; Penta-
Kil; Pentasol; Penwar; Peratox; Permacide; Permagard;
Permasan; Permatox; Priltox; Permite; Santophen; San-
tophen 20; Sinituho; Term-i-Trol; Thompson's Wood Fix;
Weedone; Witophen P
Report Date: March 1989
TR-350 Toxicology and Carcinogenesis
Studies ofnTibromomethane (Bromoform)
(CAS No. 75-25-2) in F344/N Rats and
B6C3F1 Mice (Gavage Studies)
Iribromomethane, a chemical intermediate and sol-
vent,hasbeenidentified asadrinkingwatercontaminant
resulting from water chlorination. Toxicology and car-
cinogenesis studies were conducted by administering
tribromomethane (95%-97% pure) in corn oil by gavage
to groups of F344/N rats and B6C3F1 mice ofeach sex
once or for 14 days, 13 weeks, or 2 years.
Single-Administration, Fourteen-Day, and Thirteen-
Week Studies: All rats thatreceived 2,000 mg/kgand3/5
males and 3/5 females that received 1,000 mg/kg trib-
romomethane died before the end of the single-
administration studies. All mice that received 2,000 mg/
kg, 4/5 males and 2/5 females that received 1,000 mg/kg,
and1/5malesthatreceived500mg/kgdiedbeforetheend
of the studies. Shallow breathing was observed for rats
and male mice that received 1,000 or 2,000 mg/kg trib-
romomethane.
In the 14-day studies, all rats that received 600 or 800
mg/kg and 115 males that received 400 mg/kg trib-
romomethanediedbeforetheendofthestudies.Thefinal
mean bodyweight ofmale rats that received 400 mg/kg
was 14% lower than that ofvehicle controls. One offive
male mice that received 600 mg/kg and 115 female mice
that received 800 mg/kg died before the end of the
studies. Final mean body weights of dosed and vehicle
control mice were comparable.
None of the rats died before the end of the 13-week
studies (doses rangedfrom 12 to200mg/kg). Final mean
body weights were comparable for dosed and vehicle
control rats. Allmale rats thatreceived 100 or200mg/kg
tribromomethane and all female rats that received 200
mg/kg were lethargic. The incidences of cytoplasmic
vacuolization of hepatocytes in dosed male rats were
slightlyincreasedcomparedwiththatinvehiclecontrols.
Theseverityofthislesionwasincreasedinthe200mg/kg
group. One of 10 female mice that received 100 mg/kg
tribromomethane died before the end of the 13-week
studies.Thefinalmeanbodyweightofmicethatreceived
400mg/kgwas 8% lowerthan thatofvehicle controls for
males and was comparable to that ofvehicle controls for
females. Cytoplasmic vacuolization of hepatocytes was
observed in the liver of5/10 male mice that received 200
mg/kg and in 8/10 male mice that received 400 mg/kg
tribromomethane.
Based on these results, 2-year studies of trib-
romomethanewereconducted byadministering0,100, or
200mg/kgtribromomethaneincornoilbygavage,5days
per week for 103 weeks, to groups of 50 F344/N rats of
each sexand 50femaleB6C3F1 mice. Male B6C3F1 mice
were administered 0, 50, or 100mg/kgtribromomethane
on the same schedule.
Body Weights and Survival in the Two-Year Studies:
Mean body weights of high dose male and female rats
were 10%-28% lower than those of vehicle controls
throughoutthesecondyearofthestudies. Survivalofthe
high dosegroupofmaleratswas significantlylowerthan
that ofthe vehicle controls after week 91; no significant
differences in survival were observed between any
groups of female rats (male: vehicle control, 34/50; low
dose, 30/50; high dose, 11150; female: 34/50; 28/50; 28/50).
Reduced survival for male rats given 200 mg/kg trib-
romomethane lowered the sensitivity of this group to
detect a carcinogenic response. Mean body weights of
dosed and vehicle control male mice were comparable
throughout the study. Mean body weights of dosed
female mice were 5%-16% lower than those of vehicle
controls from week 28 to the end of the study. No
significant differences in survival were observed
between any groups of male mice; the survival of both
dosedgroups offemalemicewassignificantlylowerthan
that of the vehicle controls after week 77 (male: 41150;
37/50; 36/50; female: 25/49; 15/50; 20/50). Reduced sur-
vival in all groups of female mice was partly due to a
utero-ovarian infection; nonetheless, survival of all
groups offemale mice was at least 50% byweek 92.
Nonneoplastic and Neoplastic Effects in theTwo-Year
Studies: Uncommon adenomatous polyps or adenocar-
cinomas (combined) ofthe large intestine (colon or rec-
tum) were induced in three male rats (vehicle control,
0/50; low dose, 0/50; high dose, 3/50) and in nine female
rats (0/50; 1150; 8/50); the historical incidence of neo-
plasms ofthe largeintestine is less than 0.2% in approx-
imately 2,000 corn oil vehicle control male F344/N rats,
and none has been observed in approximately2,000 corn
oil vehicle control female F344/N rats. Three of the
neoplasms of the large intestine (one in the high dose
male rats and two in the high dose female rats) were
adenocarcinomas.
222ABSTRACTSFROMLONG-TERMCANCER STUDIES, 1976-1992
Focal ordiffuse fattychangeoftheliverwas observed
atincreased incidences in dosed rats (male: 23/50; 49/50;
50/50; female: 19/50; 39/49; 46/50). Active chronicinflam-
mation was observed at increased incidences in dosed
male and high dose female rats (male: 0/50; 29/50; 23/50;
female: 9/50; 8/49; 27/50).Theincidence ofnecrosisofthe
liver was increased in high dose male rats (7/50; 3/50;
20/50) and decreased indosedfemales (11150; 3/49; 2/50).
Mixed cell focus was observed atincreased incidences
in dosed female rats (8/50; 25/49; 28/50).
Othernonneoplasticlesionsobserved atincreasedinci-
dencesindosedratsincludedchronicactiveinflammation
and squamous metaplasia of the ducts of the salivary
gland (squamous metaplasia-male: 0/50; 15/50; 31V48;
female: 0/49; 10/49; 16/50; chronic active inflammation-
male: 0/50; 16/50; 25/48; female: 0/49; 9/49; 18/50),
squamous metaplasia of the prostate gland (2/49; 6/46;
12/50), ulcers ofthe forestomach (male: 1/49; 5/50; 10/50),
and chronic active inflammation ofthe lung (male: 1/50;
7/50; 15/50). Pigmentation of the spleen was also
observed at an increased incidence in high dose female
rats. The salivary gland and lung lesions were charac-
teristic ofinfection byratcoronavirus, avirus towhich a
positive serologic reaction was observed early in the
studies.
The incidence offollicular cell hyperplasia ofthe thy-
roid glandwas increased in high dose female mice (5/49;
4/49; 19/47), andfattychangeoftheliverwasincreasedin
both dosed groups offemale mice (1149; 9/50; 24/50). No
chemicallyrelated adverse effectswereobservedinmale
mice.
Neoplastic lesions thatoccurred atlowerincidences in
dosed animals compared with those in vehicle controls
included preputial gland neoplasms in male rats (10/41;
5/38; 1/34), uterine stromal polyps in female rats (10/49;
9/50; 2/50), anterior pituitary gland adenomas in male
and female rats (male: 12/50; 12/48; 2/45; female: 29/48;
12/46; 16/48), mammary gland fibroadenomas in female
rats (22/50; 17/50; 6/50), and alveolar/bronchiolar neo-
plasms in male mice (11/50; 7/50; 2/49). Other than con-
comitantdecreases inbodyweights, nootherreasons are
obvious to correlate these decreases with chemical
administration.
GeneticToxicology: Tribromomethane exhibitedequiv-
ocal mutagenicity in Salmcmella typhimurium strain
TA100 in the absence of exogenous metabolic activation
andinstrainsTA97andTA98whenexposureoccurredin
the presence ofhamster S9; tribromomethane produced
no increases in revertant colonies in TA1535 or TA1537
with or without exogenous metabolic activation. Trib-
romomethane induced trifluorothymidine (Tft)
resistance inmouse L5178Ycellswith andwithoutmeta-
bolic activation. When tested in cultured Chinese ham-
ster ovary (CHO) cells for cytogenetic effects,
tribromomethane produced an increase in both sister
chromatid exchanges (SCEs) and chromosomal aberra-
tionsintheabsence,butnotinthepresence,ofexogenous
metabolic activation. Tribromomethane caused sex-
linked recessive lethal mutations in Drosophila when
administered to adult males by feeding; no induction of
mutations was observed when tribromomethane was
administered byabdominal injection. Results oftests for
reciprocal translocations in adult male Drosophila
exposed to tribromomethane by feeding were negative.
Invivo tests forcytogenetic effects inbone marrowcells
ofmale B6C3F1 mice demonstrated thatintraperitoneal
injection of tribromomethane induced an increase in
SCEsbutnoincreaseinchromosomalaberrations. Intra-
peritoneal injection oftribromomethane also induced an
increase in the incidence ofmicronucleated polychroma-
tic erythrocytes in the bone marrow ofB6C3F1 mice.
Audit: The data, documents, and pathology materials
from the 2-year studies of tribromomethane have been
audited. The audit findings show that the conduct ofthe
studies is documented adequately and support the data
and results given in this Technical Report.
Conclusions: Under the conditions of these 2-year
gavage studies, there was some evidence of car-
cinogenic activity oftribromomethaneformaleF344/N
rats and clear evidence of carcinogenic activity for
female F344/N rats, based on increased incidences of
uncommon neoplasms of the large intestine. Reduced
survivalformaleratsgiven200mg/kgtribromomethane
lowered the sensitivity of this group to detect a car-
cinogenic response. Chemically related nonneoplastic
lesions included fatty change and active chronic inflam-
mation of the liver in male and female rats, minimal
necrosisoftheliverinmalerats,andmixedcellfociofthe
liver in female rats. There was no evidence of car-
cinogenic activityformaleB6C3F1micegiven50 or100
mg/kg tribromomethane or for female B6C3F1 mice
given 100 or 200 mg/kg; male mice might have been able
to tolerate a higher dose. Survival of female mice was
reduced, partlydue to autero-ovarian infection.
Synonym: bromoform
Report Date: May 1989
TR-351 Toxicology and Carcinogenesis
Studies ofpara-Chloroaniline
Hydrochloride (CAS No. 20265-96-7) in
F344/N Rats and B6C3F1 Mice (Gavage
Studies)
p-Chloroaniline has a large production volume and is
used as a dye intermediate. Toxicology and car-
cinogenesis studies ofp-chloroaniline (greaterthan 99%
pure) were conducted by administering p-chloroaniline
hydrochloride in water by gavage to groups of F344/N
ratsandB6C3F1miceofeachsexfor16days,13weeks,or
2 years. Vehicle controls were given deionized water by
gavage. All doses were calculated asp-chloroaniline; the
chemical was administered as the hydrochloride after
dissolution in water containing molar equivalents of
hydrochloric acid. Genetic toxicology studies were con-
ducted in Salmonella typhimurium, mouse L5178Y
lymphomacells, and Chinesehamsterovary(CHO) cells.
Hematologicparametersweremeasuredattheendofthe
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13-week studies and at 6, 12, 18, and 24 months in the
2-year studies. Supplemental studies of-the distribution
anddispositionofp-chloroanilinewereconductedinmale
F344 rats.
Sixteen-Day and Thirteen-Week Studies: In the 16-
day studies, male and female rats and mice received 25,
50,100, or400mg/kgofbodyweight. Thevehiclecontrols
received deionized water. All rats and mice that received
200 or 400 mg/kg died during the first 6 days of the
studies. Some deaths occurred in each ofthe lower dose
groups of mice. Splenic enlargement was observed at
necropsy in rats administered 25, 50, or 100 mg/kg.
Congestion of the spleen and hemosiderin deposition in
therenalcorticaltubularepithelial cellswereobserved at
100 mg/kg in male and female rats. Compound-related
lesions in mice included hemosiderosis of the liver
Kupffer cells and congestion ofthe spleen.
In the 13-week studies, 10rats ofeach sexwere admin-
istered doses of0, 5,10,20,40, or80mg/kg.Allmale rats
lived to the end ofthe 13-week studies. One of10 female
rats that received 80 mg/kg died from unknown causes.
Thefinal meanbodyweights ofratsthatreceived 80mg/
kgwere 16% lowerthanthatofvehicle controls formales
and 4% lowerforfemales. Inthe13-week studies inmice,
10 animals ofeach sexwere administered doses of0, 7.5,
15, 30, 60, or 120 mg/kg. Deaths in mice were not related
to p-chloroaniline hydrochloride administration. The
final mean body weights of dosed and vehicle control
mice were similar. In both rats and mice, no chemically
related effects on organ weights were observed at nec-
ropsy, except for the spleen, which was enlarged as a
function of increasing dose. Methemoglobin was
increased in dosed groups and resulted in a secondary
anemia, the severity of which was dose related.
Compound-related lesions observed histologically,
including pigmentation (hemosiderin) in the kidney,
spleen, and liver and hematopoiesis in the liver and
spleen, reflected the response to the hemolytic anemia
and methemoglobinemia induced by p-chloroaniline
hydrochloride.
Based on these results, groups of 50 rats of each sex
were administered 2, 6, or 18 mg/kg p-chloroaniline
hydrochlorideinwaterbygavage,5daysperweekfor103
weeks. Groups of50 mice ofeach sex were administered
3, 10, or 30 mg/kg on the same schedule.
Metabolism and Disposition Studies in Rats: The
metabolism and disposition studies in F344/N rats
showed that metabolic and excretorypathways were not
saturatedbyp-chloroanilineadministeredorallyatdoses
ranging from 0.3 to 30 mg/kg. p-Chloroaniline was
rapidlymetabolized and excretedprimarilyinurinewith
a half-life ofapproximately 2 hours.
Body Weight and Survival in the Two-Year Studies:
Mean bodyweights ofdosed rats were generally within
5% of those of vehicle controls throughout the studies.
The survival ofthelow and mid dose groups ofmale rats
and ofthe low and high dose groups offemale rats was
significantly greater than that of the vehicle controls
(male: vehicle control, 18/49; low dose, 32/50; mid dose,
32/50; high dose, 21150; female: 27/50; 39/50; 36/50;
37/50). The increased survival was attributed to the
decreasedincidences ofmononuclearcellleukemia. Mean
body weights of high dose male and female mice were
generallywithin 5% ofthose ofvehicle controls through-
out the studies. The survival of the mid dose group of
male mice was lower than that of the vehicle controls
after week 99 (male: 43/50; 36/50; 29/50; 35/50; female:
39/50; 42/50; 44/50; 41150).
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Fibrosis of the spleen was increased in dosed
male and high dose female rats (male: vehicle control,
3/49; low dose, 11150; mid dose, 12/50; high dose, 41150;
female: 1/50; 2/50; 3/50; 42/50). Cellular infiltration of
lipocytes (fattymetaplasia)wasobservedinthespleenat
increased incidences in high dose rats (male: 0/49; 0/50;
0/50; 24/50; fema-le: 0/50; 0/50; 0/50; 11150). The incidence
ofuncommon sarcomas of the spleen in high dose male
rats was significantly greater than that in the vehicle
controls (fibrosarcomas, osteosarcomas, or
hemangiosarcomas, combined: 0/49; 1150; 3/50; 38/50).
Manyofthese tumors metastasized to one ormore sites.
Infemale rats, one fibrosarcoma ofthe spleenwas found
in amid dose animal, and one osteosarcoma ofthe spleen
was found in ahigh dose animal. The historical incidence
ofsplenic connective tissue sarcomas (all types) inwater
gavage vehicle controls is 11298 (0.3%) for male rats and
0/297 for female rats. The historical incidence of
hemangiosarcomas in water gavage controls is 0/300 for
male rats and 11297 (0.3%) for female rats.
Adrenal medullary hyperplasia was observed at an
increased incidence in high dose female rats (4/50; 4/50;
7/50; 24/50). Marginally increased incidences of phe-
ochromocytomas were seen in high dose male (13/49;
14/48;15/48;26/49) andfemale (2/50;3/50;1150;6/50)rats.
The historical incidence ofpheochromocytomas in water
gavage vehicle control male F344/N rats is 1211299 (40%
+ 16%); the historical incidence in water gavage vehicle
control female F344/N rats is 20/295 (7% ± 2%).
The incidences ofmononuclear cell leukemia in dosed
male and female rats were lower than those in vehicle
controls (male: 21149; 3/50; 2/50; 3/50; female: 10/50; 2/50;
1150; 1150). The incidences of malignant lymphomas in
dosed male and female mice were lower than those in
vehicle controls (male: 10/50; 3/49; 9/50; 3/50; female:
19/50; 12/50; 5/50; 10/50).
Hematologic and methemoglobin measurements were
made on blood samples collected from 15 randomly




In rats, compound-related nonneoplastic lesions were
seen histopathologically in the bone marrow, spleen, and
liver. These lesions included bone marrow hyperplasia,
hepatic hemosiderosis, and splenic fibrosis and suggest
compound-related effects on thehematopoietic systemin
general, the erythropoietic system specifically, and mes-
enchymal cells in the spleen.





(combined) in water gavage vehicle control male B6C3Fj
mice is 11/350 (3% + 3%).
The incidences of hepatocellular adenomas or car-
cinomas (combined) were increased in dosed male mice
(11/50; 21/49; 20/50; 21/50), primarily due to increased
incidencesofhepatocellularcarcinomas (3/50; 7/49;11/50;
17/50). Hepatocellular carcinomas metastasized to the
lung in 1/50vehicle control, 1/49 low dose, 2/50 mid dose,
and 9/50 highdose male mice. The historicalincidence of
hepatocellular neoplasms in water gavage vehicle con-
trols is 106/347 (31 + 6%).
Genetic Toxicology:p-Chloroaniline was mutagenic in-
S. typhimurium strains TA98 and TA100 in the pres-
ence of exogenous metabolic activation; no increase in
revertantcolonieswas observedin strains TA97, TA1535,
or TA1537. p-Chloroaniline induced trifluorothymidine
(Tft) resistance in mouse L5178Y lymphoma cells with
and without metabolic activation. In cultured CHO cells,
treatment with p-chloroaniline produced significant
increases in sister chromatid exchanges (SCEs) both
with andwithoutmetabolic activation (S9); chromosomal
aberrations weresignificantlyincreasedonlyinthepres-
ence ofS9.
Audit: The data, documents, and pathology materials
from the 2-year studies of p-chloroaniline have been
audited. The audit findings show that the conduct ofthe
studies is documented adequately and support the data
and results given in this Technical Report.
Conclusions: Under the conditions of these 2-year
water gavage studies, there was clear evidence ofcar-
cinogenic activity ofp-chloroaniline hydrochloride for
male F344/Nrats, asindicatedbyincreasedincidences of
uncommon sarcomas ofthe spleen. Pheochromocytomas
ofthe adrenal gland may also have been associated with
chemical administration. There was equivocal evidence
of carcinogenic activity of p-chloroaniline hydro-
chloride for female F344/N rats, as indicated by the
presence ofuncommon sarcomas ofthe spleen in onemid
and one high dose animal and the increased incidence of
pheochromocytomas of the adrenal gland. There was
some evidence of carcinogenic activity of p-chlo-
roaniline hydrochloride for male B6C3F1 mice, as indi-
cated by increased incidences of hepatocellular
neoplasms and of hemangiosarcomas of the liver or
spleen. Therewasno evidence ofcarcinogenic activity
ofp-chloroaniline hydrochloride forfemale B6C3F1 mice
administered 3, 10, or 30 mg/kg by gavage for 2 years.
The incidences of mononuclear cell leukemia in male
andfemaleratsandofmalignantlymphomasinmaleand
female micewere decreased byadministration ofp-chlo-
roaniline hydrochloride. Compound-related splenic




Report Date: July 1989
TR-352 Toxicology and Carcinogenesis
Studies ofN-Methylolacrylamide (CAS No.
924-42-5) in F344/N Rats andB6C3F1 Mice
N-Methylolacrylamide is a cross-linking agentused in
adhesives, binders for paper, crease-resistant textiles,
resins, latex film, and sizing agents. Toxicology and car-
cinogenesis studies were- conducted by administering
N-methylolacrylamide (98% pure) in water by gavage to
groups ofF344/N rats and B6C3F1 mice ofeach sex for
16-days, 13 weeks, or 2-years. In vitro genetic toxicology
studies were conducted in Salmonella typhimurium
and Chinese hamster ovary (CHO) cells; an in vivo bone
marrow micronucleus test was performed with B6C3F1
mice. Neurobehavioral assays were performed during
the 13-week studies.
Sixteen-Day Studies: The doses of N-meth-
ylolacrylamide used ranged from 25 to 400 mg/kg. All
rats that received 400 mg/kg-died within 4 days, and 3/5
male rats that received 200 mg/kg also died before the
end ofthe studies. Compound-related clinical signs seen
with 200 mg/kg included ataxia, muscle tremors, and
hyperirritability. Ataxia after dosingwas observed from
day 7 to the end ofthe studies for rats that received 100
mg/kg. The final mean body weight of male rats that
received 100 or 200 mg/kg was 10% or 27% lower than
thatofthevehiclecontrols.Thefinalmeanbodyweightof
female rats thatreceived 200mg/kgwas 20% lowerthan
that ofthe vehicle controls. Compound-related lesions in
ratsincludedhyperplasiaofthebronchiolarandtracheal
epithelium, dysplasia of the nasal and tracheal epi-
thelium, centrilobular hepatocellular necrosis, lymphoid
depletion of the spleen, and myelin degeneration of the
lumbar ventral spinal nerve.
All 5male and4/5femalemicethatreceived 400mg/kg
N-methylolacrylamide died on the second day ofthe 16-
day studies. The surviving female mouse in the 400 mg/
kggroup and themale and female mice inthe 200mg/kg
groupswereataxicaftertheyweredosed, startingonday
2.Weightchangeswereinconsistent amongdose groups.
Bronchial epithelial hyperplasia (mild) appeared to be
dose related in males and females. Sinusoidal congestion
of the liver and vacuolar degeneration of myocardial
fibers were seen in males and females given 400 mg/kg.
Thirteen-Week Studies: The doses of N-meth-
ylolacrylamide used ranged from 12.5 to 200 mg/kg. All
ratsthatreceived100 or200mg/kgdiedbeforetheend of
the studies. Rats thatreceived100 or200mg/kghadhind
limb ataxia, which progressed to hind limb paralysis.
Rats that received 50 mg/kg had hind limb ataxiabegin-
ningatweek8,whichprogressed to hind limbparesisby
week11.Thefinalmeanbodyweightofratsthatreceived
25 or 50 mg/kg was 8% or 16% lower than that of the
vehicle controls for males and 6% or 10% lower for
females. In neurobehavioral assessments, decreased
forelimbandhindlimbgripstrengthwas seenatdoses as
lowas25mg/kgforfemaleratsandatdoses aslowas12.5
mg/kg for male rats. A decreased startle response was
seenforfemales atdoses aslowas25mg/kg.Thelanding
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foot spread was significantly increased for male and
female rats that received 50 mg/kg.
Axon filament and myelin sheath degeneration ofthe
brain stem, spinal cord, and/or peripheral nerves was
seen in rats at increased incidences at 25 mg/kg and
higher doses. Inflammation and/or hemorrhage and
edema of the urinary bladder mucosa were seen with
doses of 25 mg/kg or more in a few rats that had
distended bladders at gross examination.
All mice that received 200 mg/kg N-meth-
ylolacrylamide died before the end of the studies. Final
mean body weights of dosed and vehicle control mice
were similar. A decreased relative testis weight was
observed formice that received 12.5 mg/kg or more. The
relative kidneyweights for male mice receiving 50 or 100
mg/kg were greater than that for vehicle controls. Neu-
robehavioral studies indicated decreased forelimb grip
strength in male and female mice at doses as low as 25
mg/kg. An exaggerated startle response was seen for
female mice given 100 mg/kg. A reduction in rotarod
performance was seen for male and female mice receiv-
ing 100 mg/kg and for male mice receiving 25 mg/kg.
Hepatocellular necrosis and thymic lymphocytic
necrosiswerecompound-related effectsinmicegiven200
mg/kg N-methylolacrylamide. Hemorrhage, necrosis,
and mineralization ofthe zona reticularis ofthe adrenal
gland were present in 3/10 female mice given 200 mg/kg,
and cytoplasmic vacuolization ofthe adrenal cortex was
seen with lower doses.
Based on the results of these short-term studies,
2-year studies were conducted by administering 0, 6, or
12 mg/kg N-methylolacrylamide in water by gavage, 5
days perweek for 103weeks, to groups of50 rats ofeach
sex. Groups of50 mice ofeach sex were administered 0,
25, or 50 mg/kg on the same schedule.
Body Weight and Survival in the Two-Year Studies:
Meanbodyweights ofdosedratswerewithin6%ofthose
ofvehicle controls throughout most ofthe studies. Mean
bodyweights ofdosedmicewereasmuch as25%greater
than those ofvehicle controls forfemales and as much as
13% greater for males. The survival offemale rats given
25 mg/kgper daywas lower than that ofvehicle controls
after day550, but survival offemale rats given 50mg/kg
per day was not different from that of vehicle controls
(vehicle control, 35/50; low dose, 22/50; high dose, 33/50).
No differences in survival were observed between any
other groups of rats or mice of either sex (male rats:
28/50; 22/50; 27/50;malemice: 30/50; 20/50; 21150; female
mice: 41V50; 35/50; 33/50).
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: In rats, no biologically important nonneoplastic
orneoplastic lesionswere attributed to administration of
N-methylolacrylamide. Higher doses might have
increased the sensitivity ofthe studies to determine the
presence or absence of a carcinogenic response.
In mice, the incidences ofadenomas ofthe Harderian
gland were increased in males given either dose of
N-methylolacrylamide and in females given the top dose
(male: vehicle control, 1148; low dose, 14/49; high dose,
29/50; female: 5/47; 8/45; 20/48). The incidences of car-
cinomas of the Harderian gland were not significantly
increased by N-methylolacrylamide administration
(male: 1148; 0/49; 2/50; female: 0/47; 3/45; 2/48).
The incidences of hepatocellular adenomas were
increased in male and female mice given 50 mg/kg
N-methylolacrylamide (male: 8/50; 4/50; 19/50; female:
3/50; 4/50; 17/49). The incidences of hepatocellular car-
cinomas were also marginally increased in dosed male
mice (male: 6/50; 13/50; 12/50; female: 3/50; 3/50; 2/49).
Hepatocellular adenomas and carcinomas (combined)
occurredwithpositivetrends, and theincidences inmale
and female mice receiving 50 mg/kg were increased
compared with those in thevehicle controls (male: 12/50;
17/50; 26/50; female: 6/50; 7/50; 17/49).
Chronic inflammation and alveolar epithelial hyper-
plasia ofthe lungwere observed at increased incidences
in mice givenN-methylolacrylamide. Sentinel mice were
seropositiveforSendaivirusat18months.Theincidences
of alveolar/bronchiolar adenomas (3/49; 6/50; 11150) and
carcinomas (2/49; 4/50; 10/50) were increased in male
mice given 50 mg/kg. Alveolar/bronchiolar adenomas or
carcinomas (combined) occurred with apositive trend in
male mice (5/49; 10/50; 18/50). The incidence of alveolar/
bronchiolar adenomas or carcinomas (combined) was
increased in female mice given the top dose of50 mg/kg
(6/50; 8/50; 13/49).
Ovarian atrophywas observed atincreasedincidences
in female mice receiving N-methylolacrylamide (3/50;
39/45; 38/47). The incidences of benign granulosa cell
tumors were also increased in the dosed groups (0/50;
5/45; 5/47).
The incidence ofadenomas ofthe pars distalis in high
dose female mice was significantly lower than that in
vehicle controls (13/49; 5/14; 4/43).
Genetic Toxicology: N-Methylolacrylamide was not
mutagenic in S. typhimurium strains TA97, TA98,
TA100, orTA1535whentestedwith orwithoutexogenous
metabolic activation.N-Methylolacrylamide inducedboth
sister chromatid exchanges (SCEs) and chromosomal
aberrations in CHO cells with and without metabolic
activation. No increase in micronucleated polychromatic
erythrocytes (PCEs) was observed in the bone marrow
of B6C3F1 mice after intraperitoneal injection of
N-methylolacrylamide.
Conclusions: Under the conditions of these 2-year
studies, therewasno evidence ofcarcinogenic activity
ofN-methylolacrylamide formale orfemale F344/N rats
receiving doses of 6 or 12 mg/kg per day by aqueous
gavage. There was clear evidence of carcinogenic
activity ofN-methylolacrylamide formaleB6C3F1 mice,
based onincreased incidences ofneoplasms ofthe Hard-
eriangland, liver, andlung. There was clearevidence of
carcinogenic activity of N-methylolacrylamide for
female B6C3F1 mice, based on increased incidences of
neoplasms of the Harderian gland, liver, lung, and
ovary.
In rats, because no biologicallyimportant toxic effects
wereattributedtoN-methylolacrylamide administration,
somewhathigher doses could have beenused to increase
the sensitivityofthese studies for determiningthe pres-
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ence or absence of a carcinogenic response. In female




Report Date: September 1989
TR-353 Toxicology and Carcinogenesis
Studies of2,4-Dichlorophenol (CAS No.
120-83-2) in F344/N Rats and B6C3F1 Mice
(FeedStudies)
2,4-Dichlorophenol is a chemical intermediate used
principally in the manufacture of the herbicide 2,4-
dichlorophenoxyacetic acid. Toxicology and car-
cinogenesis studies were conducted by feeding diets
containing 2,4-dichlorophenol (greater than 99% pure)
for 14 days, 13weeks, or2years to groups ofF344/N rats
and B6C3F1 mice of each sex. Genetic toxicology tests
were conducted in Salmonella typhimurium, mouse
L5178Y lymphoma cells, and Chinese hamster ovary
(CHO) cells.
Fourteen-Day and Thirteen-Week Studies: In the 14-
day studies, male and female rats and mice were given
diets containing 2,4-dichlorophenol at concentrations up
to40,000ppm. Onehigh dosemale mouse diedbefore the
endofthestudies; nodeathsoccurredinanyothergroup,
and no compound-related lesions were seen at necropsy
in rats or mice. In the 13-week studies, groups of10 rats
and10mice ofeach sexwerefeddietscontaining0,2,500,
5,000, 10,000, 20,000, or 40,000 ppm 2,4-dichlorophenol.
All rats lived to the end ofthe studies, whereas all mice
thatreceived 40,000 ppm died duringthe first3weeks of
the studies. Final mean body weights of rats that
received 20,000 or 40,000 ppm and of male mice that
received 20,000 ppm were at least 10% lower than those
of controls. Bone marrow atrophy in rats and necrosis
and syncytial alteration (multinucleated hepatocytes) in
the liver of male mice were compound-related effects.
Two-year studies were conducted by feeding diets con-
taining 0, 5,000, or 10,000 ppm 2,4-dichlorophenol to
groupsof50malerats and50maleand50femalemicefor
103 weeks. Groups of 50 female rats received diets con-
taining 0, 2,500, or 5,000 ppm.
Body Weight and Survival in the Two-Year Studies:
Mean body weights of high dose male and female rats,
high dose male mice, and both dosed groups of female
mice were generally lower than those of controls. No
significant differences in survival were observed
between any groups of rats or mice of either sex (male
rats: control, 33/50; low dose, 25/50; high dose, 32/50;
female rats: 34/50; 43/50; 40/50; male mice: 33/50; 32/50;
31150;femalemice:45/50;40/50;43/50).Theaveragedaily
feed consumption by rats in the low dose and high dose
groupswas 94%-97% thatbythe controls. The estimated
dailymean consumption of2,4-dichlorophenol was210 or
440mg/kgforlowdose orhigh dosemale rats and 120 or
250 mg/kg for low dose or high dose female rats. The
average daily feed consumption by mice in the low dose
and high dose groups was 97% and 78% of that by the
controls for males and 94% and 85% for females. The
estimated daily mean consumption of2,4-dichlorophenol
was 800 or 1,300 mg/kg for low dose or high dose male
mice and 430 or 820 mg/kg for low dose or high dose
female mice.
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Therewere no compound-related increased inci-
dences ofneoplastic lesionsinrats ormice. Theincidence
of mononuclear cell leukemia was decreased in dosed
male rats relative to that in controls (control, 31150; low
dose, 17/50; high dose, 17/50); the incidence ofmalignant
lymphomas was decreased in high dose female mice
(4/50) relative to thatin controls (12/50). Syncytial altera-
tion ofhepatocyteswas observed atincreased incidences
in dosed male mice (11150; 33/49; 42/48).
Genetic Toxicology: The mutagenic effect of 2,4-
dichlorophenol in S. typhimurium strain TA1535 was
considered to be equivocal only in the presence of ham-
ster S9; 2,4-dichlorophenol produced no increases in
revertantcoloniesinstrainsTA98,TA100, orTA1537with
or without exogenous metabolic activation. 2,4-
Dichlorophenol increased trifluorothymidine (Tft)
resistance in the mouse L5178Y assaywithout metabolic
activation; it was not tested with activation. In cultured
CHO cells, 2,4-dichlorophenol did not induce chromoso-
mal aberrations but did significantly increase the fre-
quencyofsisterchromatid exchanges (SCEs) bothinthe
presence and absence of S9.
Audit: The data, documents, and pathology materials
from the 2-year studies of2,4-dichlorophenol have been
audited. The audit findings show that the conduct ofthe
studies is documented adequately and support the data
and results given in this Technical Report.
Conclusions: Underthe conditions ofthese2-yearfeed
studies, therewasno evidence ofcarcinogenic activity
formale F344/N rats fed diets containing 5,000 or 10,000
ppm 2,4-dichlorophenol or for female F344/N rats fed
diets containing 2,500 or 5,000 ppm 2,4-dichlorophenol.




Report Date: June 1989
TR-354 Toxicology and Carcinogenesis
Studies ofDimethoxane (CAS No. 828-00-2)
(Commercial Grade) in F344/N Rats and
B6C3F1 Mice (GavageStudies)
Dimethoxane is used as an antimicrobial agent in
water-based paints, dyestuffs, fabric softeners, sizings,
and spinning emulsions. In the past, it was used in
lipsticksandothercosmeticpreparations.Toxicologyand
carcinogenesis studieswere conducted byadministering
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commercial-grade dimethoxane (80% pure, none ofthese
impurities exceeded 3%) in corn oil gavage to groups of
F344/N rats and B6C3F1 mice ofeach sex one time or 5
daysperweekfor16days,13weeks,15months, or2years.
Clinicalpathologyanalyseswereperformedat15months
in the 2-year studies. Commercial-grade dimethoxane
was studied because that is the grade to which humans
aregenerallyexposed. Thesamelotofcommercial-grade
dimethoxane was used in genetic toxicology tests for
mutagenicity in Salmonella typhimurium, for sister
chromatid exchanges (SCEs) and chromosomal aberra-
tions in Chinese hamster ovary (CHO) cells, and for sex-
linked recessive lethal mutations and translocation in
Drosophila.
Sixteen-Day Studies: In the 16-day studies, rats and
mice received 0, 125, 250, 500, 1,000, or 2,000 mg/kg
dimethoxane in corn oil per day. Deaths occurred in rats
and in male mice that received 2,000 mg/kg. Body
weights ofrats and mice were similar to those ofvehicle
controls. Compound-related clinical signs were not seen
in surviving rats. Hemorrhage and necrosis ofthe stom-
achwereobservedinratsinthe2,000mg/kggroupwhich
died before the end of the studies. Lesions of the fore-
stomach, including inflammation, hyperplasia, hyper-
keratosis, and ulceration, occurred in rats that received
250-2,000 mg/kg. Mice that received 500-2,000 mg/kg
dimethoxane had lesions of the forestomach including
erosion, ulceration, hyperplasia, and hyperkeratosis.
Forestomach lesions were not seen at 125 or 250 mg/kg.
Thirteen-Week Studies: No compound-related deaths
occurred in rats. Doses used were 0, 31, 62, 125, 250, or
500 mg/kg dimethoxane in corn oil by gavage. The final
meanbodyweights ofrats thatreceived 500mg/kgwere
17% lowerthan that ofvehicle controls formales and 5%
lower for females. Ulceration, inflammation, and
acanthosis with hyperkeratosis of the stratified
squamous epithelium of the forestomach were seen in
rats that received 500 mg/kg. Forestomach lesions were
not seen in males that received 31 mg/kg or in females
that received 31, 62, or 125 mg/kg.
All mice lived to the end of the studies (doses used
were0,31,62,125,250, or500mg/kgdimethoxanein corn
oil by gavage). Final mean body weights of dosed and
vehicle control mice were similar. Minimal-to-mild
acanthosis and hyperkeratosis of the squamous epi-
thelium of the forestomach were seen in 4/10 high dose
male and 1110 high dose female mice.
Because of the forestomach lesions observed in rats
and mice and reduced body weight observed for male
rats, doses selected forthe2-yearstudieswere0,62.5, or
125 mg/kg dimethoxane in corn oil, given by gavage 5
daysperweektogroupsof60malerats;0,125, or250mg/
kgtogroupsof60femalerats; and0,250, or500mg/kgto
groups of58 or 60 mice ofeach sex. Ten animals per sex
and species from each dose group were killed 15 months
after initiation ofthe studies to determine toxicity, pre-
neoplastic lesions, and early induced neoplasia.
Fifteen-Month Studies: Minimal diffuse acanthosis
and hyperplasia of the forestomach were seen in 7/10
femalerats at250mg/kg,7/10males at125mg/kg, and1/9
male and 1/9 female vehicle controls. Acanthosis of the
forestomachwas seenin7/10maleand6/10femalemiceat
500 mg/kg. Harderian gland adenomas were seen in one
high dose male and one high dose female mouse. A
harderian gland adenocarcinoma was seen in a second
high dose female mouse. No compound-related effects
were observedforclinical chemical orhematologicvalues
or for organ weights for rats or mice.
Body Weight and Survival in the Two-Year Studies:
Meanbodyweights ofdosed andvehicle control rats and
mice of each sex were generally similar. No significant
differences in survival were observed between any
groups of rats (male: vehicle control, 23/50; low dose,
28/50; high dose, 21/50; female: 30/50; 31/50; 24/50) or
mice (male: 33/50; 27/48; 29/50; female: 36/50; 35/50;
34/50).
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: At no site was a significantly increased inci-
dence of neoplastic lesions observed in dosed male or
female rats or in dosed female mice. Acanthosis and
hyperkeratosis were increased in the forestomach of
high dose rats; acanthosis, hyperkeratosis, focal hyper-
plasia, and chronic activeinflammationwereincreasedin
the forestomach of dosed mice. The incidence of
squamous cell papillomas of the forestomach was
increased in high dose male mice (vehicle control, 2/47;
low dose, 3/47; high dose, 7/50). A squamous cell car-
cinoma of the forestomach was present in another high
dose male mouse. Although the incidence of squamous
cell papillomas in the high dose group was not signifi-
cantly different from that in the vehicle controls, the
incidence exceeded the highest observed in historical
corn oil gavage vehicle controls (3/49). Other than a
single squamous cellpapilloma in the esophagus ofa low
dose male mouse, no hyperplastic or neoplastic lesions
were seen outsidethe stomach ofdosedmicewhich could
be related to the administration ofdimethoxane. Despite
the observation of three harderian gland neoplasms in
mice killed at 15 months, no increase in the incidences of
harderian glandneoplasmswas seenin dosedmiceinthe
2-year studies (male: 2/48; 2/48; 2/48; female: 2/48; 0/49;
2/50).
Genetic Toxicity: Dimethoxane was mutagenic in
strain TA100 ofS. typhimurium in the presence but not
the absence ofexogenous metabolic activation; itwas not
mutagenic in strains TA98, TA1535, or TA1537 with or
withoutactivation. DimethoxaneinducedSCEsandchro-
mosomal aberrations in CHO cells both with or without
exogenous metabolic activation. Dimethoxane induced
sex-linked recessivelethal mutations in Drosophilawhen
administered by abdominal injection to adult males; no
induction of reciprocal translocations was observed in
adult males after injection of dimethoxane.Conclusions:
Under the conditions of these 2-year corn oil gavage
studies, therewasno evidence ofcarcinogenic activity
of dimethoxane for male F344/N rats receiving 62.5 or
125mg/kg orforfemale F344/N ratsreceiving125 or250
mg/kg per day. There was equivocal evidence of car-
cinogenic activity of dimethoxane for male B6C3F1
mice, as indicated by an increased incidence of fore-
228ABSTRACTS FROMLONG-TERM CANCER STUDIES, 1976-1992
stomach neoplasms. There was no evidence of car-
cinogenic activity for female B6C3F1 mice receiving
250or500mg/kgperday.Acanthosis andhyperkeratosis
occurred at increased incidences in the forestomach of
high dose rats. Inflammation, acanthosis with hyper-
keratosis, and focal hyperplasia occurred at increased
incidences in the forestomach ofdosed mice.
Synonyms: acetomethoxan; acetomethoxane; 6-ace-
toxy-2,4-dimethyl-m-dioxane; 2,6-dimethyl-m-dioxan-4-
yl acetate; 2,6-dimethyl-m-dioxan-4-ol acetate; 2,6-
dimethyl-1,3-dioxan-4-ol acetate
Report Date: September 1989
TR-355 Toxicology and Carcinogenesis
Studies ofDiphenhydramine
Hydrochloride (CAS No. 147-24-0) in F344/
N Rats andB6C3F1 Mice (Feed Studies)
Diphenhydramine hydrochloride is awidelyused anti-
histaminic drug in human and veterinary medicine. Tox-
icology and carcinogenesis studies were conducted by
feeding diets containing USP-grade diphenhydramine
hydrochloride (greater than 99% pure) to groups of
F344/N rats and B6C3F1 mice ofeach sexfor14 days, 13
weeks, or 2 years. Genetic toxicology studies were con-
ducted in Salmonella typhimurium, mouse L5178Y
cells, and Chinese hamster ovary (CHO) cells.
Fourteen-Day and Thirteen-Week Studies: In the 14-
day studies, dietary concentrations ranged from 620 to
10,000 ppm for rats and from 310 to 5,000 ppm for mice.
All rats that received diets containing 10,000 ppm and
9/10 rats that received diets containing 5,000 ppm died
before the end of the studies. The final mean body
weights of rats receiving 1,250 or 2,500 ppm were
12%-13% or 30%-34% lower than those ofcontrols. Feed
consumption by rats at the three highest concentrations
was more than 30% less than that by controls. All mice
receiving 5,000 ppm, 4/5 males and 4/5females receiving
2,500ppm, and4/5malesreceiving1,250ppmdiedbefore
the end of the studies. The final mean body weights of
micethatreceived1,250or2,500ppmwerelowerthanthe
initialweights. All dosed rats and micewere hyperactive
and sensitive to sound and/or touch.
In the 13-week studies, dietary concentrations of
diphenhydramine hydrochloride ranged from 156 to
2,500 ppmforrats and from 78 to 1,250ppmformice. All
rats lived to the end ofthe studies. The final mean body
weights ofrats receiving 1,250 or 2,500 ppm were about
15% or35% lower than those ofcontrols. The final mean
body weight of female rats receiving 625 ppm was 9%
lower than that of controls. Increased activity was
observed for allmale and female ratsreceiving1,250 and
2,500ppm. Cytoplasmicvacuolization oftheliver, charac-
teristic of fat accumulation, was observed in male and
female rats receiving313-2,500 ppm. The severityofthis
change increased with increased dose. For mice, 1/10
males receiving 313 ppm, 2/10 males receiving 625 ppm,
and8/10malesreceiving1,250ppm diedbefore the end of
the studies. The final mean body weights of mice that
received 625 or 1,250 ppm were about 9% or 16% lower
than those of controls. No compound-related histo-
pathological effects were observed in mice.
Based on the mortality and body weight effects of
diphenhydramine hydrochloride in the short-term stud-
ies, dietaryconcentrations selectedforthe2-yearstudies
were 0, 313, and 635 ppm diphenhydramine hydro-
chloride formale rats and 0, 156, and 313 ppm forfemale
rats and male and female mice.
Body Weight and Survival in the Two-Year Studies:
Mean body weights of dosed and control rats were
similarthroughoutthestudies,andmeanbodyweightsof
dosed mice were 3%-13% lower than those of controls
throughout most of the studies. No significant dif-
ferences in survival were observed between any groups
ofrats ormice ofeithersex(malerats: control, 29/50; low
dose, 32/50; high dose, 24/50; female rats: 35/50; 32/50;
36/50; male mice: 29/50; 30/50; 24/48; female mice: 37/50;
39/50; 32/50). Theestimated averagedailyfeed consump-
tion by dosed rats and dosed mice was similar to thatby
controls. The average amount of diphenhydramine
hydrochloride consumed per day was approximately 13
or 27 mg/kg for low dose or high dose male rats, 7 or 15
mg/kg for low dose or high dose female rats, and 21 or
46-47 mg/kg for low dose or high dose male and female
mice.
Nonneoplastic and Neoplastic Effects in theTwo-Year
Studies: For three high dose male rats, astrocytomas
were found in brain sections taken by routine sampling
procedures. Gliomas, containing neoplastic astrocytes
and oligodendrocytes, were found in one control and one
additional high dose male rat. The incidence ofglial cell
tumorsinhighdosemalerats(4/50)exceededthehighest
incidenceinhistoricalcontrolsintheProgram(2/50).The
historical incidence ofglial cell tumors is less than 0.7%
in approximately 2,000 untreated control male F344/N
rats. Three additional sections of brain were prepared
from the residual fLxed tissues of each male and female
rat. One additional astrocytoma in a high dose male rat
and one astrocytoma in a high dose female rat were
observed in these sections.
Adenomas of the anterior pituitary gland in female
rats occurred with a significant positive trend; the inci-
dences in low dose male and high dose female rats were
marginallygreater than those in controls (male: control,
11/49; low dose, 21/50; high dose, 14/49; female: 23/50;
26/50; 35/50).
The incidence ofalveolar/bronchiolar adenomas in low
dose male rats was slightly greater than that in controls
(0/49; 5/50; 3/50). The incidences of alveolar/bronchiolar
adenomas or carcinomas (combined) in dosed male rats
were not significantly different from that in controls
(1/49; 6/50; 5/50) but exceeded the highest incidence in
historical controls (4/49). The historical incidence of
alveolar/bronchiolarneoplasmsinuntreatedcontrolmale
F344/N rats is approximately2.2%.Adenomatous hyper-
plasiaofthelungwas notincreased inincidence in dosed
male rats compared with controls.
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The incidences of granulomas of the liver were
increased in dosed rats (male: 0/49; 3/50; 4/50; female:
8/50; 15/49; 18/50).
At no site were the incidences of neoplastic lesions in
dosed mice considered to be compound related.
Cytoplasmic vacuolization (fatty metamorphosis) of the
liverwas observed atanincreased incidenceinhigh dose
female mice (0/49; 1/49; 8/49).
Genetic Toxicology: Diphenhydramine hydrochloride
was not mutagenic in S. typhimurium strains TA98,
TA100, TA1535, or TA1537 when tested in either the pres-
ence or absence of exogenous metabolic activation.
Exposure to this chemical did not induce tri-
fluorothymidine (Tft) resistance in mouse L5178Y lym-
phoma cells with or without metabolic activation. In
cytogenetic tests with cultured CHO cells,
diphenhydramine hydrochloride induced chromosomal
aberrations in the absence, but not the presence, of
exogenous metabolic activation (S9); no induction ofsister
chromatid exchanges (SCEs) was observed in these cells
with orwithout S9.
Conclusions: Underthe conditions ofthese2-yearfeed
studies, there was equivocal evidence ofcarcinogenic
activity of diphenhydramine hydrochloride for male
F344/Nrats,basedonmarginallyincreasedincidencesof
uncommon brain neoplasms (astrocytomas or gliomas)
and ofalveolar/bronchiolar neoplasms. Therewas equiv-
ocalevidence ofcarcinogenic activity forfemale F344/
N rats, based on a marginal increase in the incidence of
pituitary gland adenomas. There was no evidence of
carcinogenic activity for male or female B6C3F1 mice





benzhydryl ether hydrochloride; benzhydramine hydro-
chloride
Trade Names: Alleran; Benadryl
Report Date: September 1989
TR-356 Toxicology and Carcinogenesis
Studies ofFurosemide (CAS No. 54-31-9) in
F344/N Rats and B6C3F1 Mice (Feed
Studies)
Furosemideis adiureticusedinhumanandveterinary
medicine. Toxicology and carcinogenesis studies were
conducted by feeding diets containing furosemide (99%
pure, USP grade) to groups ofF344/N rats and B6C3F1
mice ofeach sexfor14 days, 13weeks, or2years. Genetic
toxicology studies were conducted in Salmonella
typhimurium, mouse L5178Ylymphoma cells, and Chi-
nese hamster ovary (CHO) cells.
Fourteen-Day and Thirteen-Week Studies: Dietary
concentrations offurosemide used in the 14-day studies
for rats and mice ranged up to 46,000 ppm. Two of five
male and 3/5 female rats that received 46,000 ppm
furosemide died before the end ofthe studies. Rats that
received15,300 or46,000ppmlostweightoverthe course
ofthe studies. The final mean bodyweights ofrats that
received 1,700 or 5,100 ppmwere 12% or 23% lower than
that of controls for males and 8% or 16% lower for
females. Nephrosiswas doserelatedin rats. Allfivemale
and1/5femalemicethatreceived 46,000 ppmfurosemide
died before the end ofthe 14-day studies. Male mice that
received15,300ppmandfemalemicethatreceived46,000
ppm lost weight. The final mean body weights of male
mice that received 1,700 or 5,100 ppm were 16% or 14%
lower than that ofcontrols. The final mean bodyweight
offemales that received 15,300 ppm was 13% lower than
that of controls. Slight dilatation of the renal cortical
tubules and/or nephrosis were dose related in mice.
Dietary concentrations of furosemide used in the 13-
week studies were 0 and 625-10,000 ppm for male rats
and 0 and 938-15,000 ppm forfemale rats and male mice.
Concentrations for female mice were 0 and 1,250-20,000
ppm. None ofthe rats died before the end ofthe studies.
The final mean body weights of male rats that received
2,500,5,000, or10,000 ppmfurosemidewere 11%, 22%, or
44% lower than that of controls. The final mean body
weights of female rats that received 3,750, 7,500, or
15,000 ppm were 18%, 26%, or 35% lower than that of
controls. Minimal-to-mild nephrosis occurred in the two
highest dose groups ofmale and female rats. Mineraliza-
tionofminimaltomild severitywas observed attherenal
corticomedullary junction in dosed male rats receiving
625 ppm or more; the severity and incidence of the
mineralization increased with increased dose. No
compound-related deaths occurred in mice. The final
mean body weights of male mice that received 3,750,
7,500, or15,000were 12%, 22%, or17% lowerthanthat of
controls. Final mean body weights of dosed and control
female mice were comparable. Compound-related lesions
in mice induced minimal-to-mild nephrosis.
Because of the lower body weights and the kidney
lesions in the 13-week studies, doses selected for the
2-year studies were 0, 350, or 700 ppmfurosemide in the
diet for groups of50 F344/N rats ofeach sex. Groups of
50 B6C3F1 mice ofeach sex were fed diets containing 0,
700, or 1,400 ppm furosemide for 104 weeks.
Body Weight and Survival in the Two-Year Studies:
Mean body weights of dosed and control rats were
comparable throughout the studies. No significant dif-
ferences in survival were observed between any groups
ofrats ofeither sex (final survival-male: control, 17/50;
low dose, 17/50; high dose, 20/50; female: 35/50; 31/50;
34/50). The final survival of all groups of male rats was
low, reflecting the large number of moribund animals
killed afterweek91. Survival atweek90was35/50,28/50,
and 34/50. Mean body weights of high dose male mice
were up to 17% lower than those of controls, and mean
bodyweights oflow dose male mice were about 5%-10%
lower than those of controls after week 31. Mean body
weights ofhigh dose female mice were up to 22% lower
than those of controls. Mean body weights of low dose
female mice were 5%-13% lower than those of controls
230ABSTRACTS FROMLONG-TERM CANCER STUDIES, 1976-1992
after week 82. The survival of the high dose group of
female micewas significantlylowerthan that ofcontrols
after week 99 (final survival-male: 31/50; 24/50; 26/50;
female: 36/50; 29/50; 18/50). Feed consumption by dosed
rats was similar to that by controls. The estimated
average amount of furosemide consumed per day was
approximately 14-16 or 29-31 mg/kg for low dose or high
dose rats. Feed consumption by dosed mice was approx-
imately 5%-7% greater than that by controls. The aver-
age amount of furosemide consumed per day was
approximately91-99 or191-214mg/kgforlowdoseorhigh
dose mice.
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Nephropathy occurred at similar incidences in
all groups ofrats, but the severity was greater in dosed
male rats. Thbular cell hyperplasia was observed in 4/50
control, 2/50 low dose, and 4/50 high dose male rats.
Thbular cell adenomas of the kidney occurred in 1/50
control, 3/50 low dose, and 1/50 high dose male rats.
Thbular cell adenocarcinomas were seen in a fourth low
dose male rat and in a second high dose male rat (ade-
nomas or adenocarcinomas, combined: control, 1/50; low
dose, 4/50; high dose, 2/50). The historical incidence of
renal tubular cell adenomas or adenocarcinomas (com-
bined) in untreated male F344/N rats is 9/1,928 (0.5%),
and the highest incidence observed in controls is 3/50.
Malignant meningiomas ofthe brain occurred in 3/50
low dose male rats; none was observed in other groups.
The historical incidence of meningiomas in untreated
male F344/N rats is 2/1,928 (0.1%).
C-Cell adenomas of the thyroid gland in female rats
occurred with a positive trend; the incidence in the high
dose group was not statistically greater than that in the
controls (4/50; 6/50; 11/50). A C-cell carcinoma occurred
in another low dose female rat. The incidence of ade-
nomas of the anterior pituitary gland in low dose male
rats was marginally greater than that in controls (4/50;
11/50; 8/50). Neither of these marginal increases was
considered to be chemically related.
Malignant mixed tumors (adenocarcinoma, type C) of
the mammary gland occurred in dosed female mice (0/50;
1/50; 5/48). One mammary gland acinar cell carcinoma
occurred in asecond lowdose female mouse. Thehistorical
incidence of all malignant mammary gland neoplasms in
untreated female B6C3F1 mice is 40/2,040 (2%).
Compound-related nonneoplastic lesions ofthe kidney
in mice included nephropathy and dilatation ofthe renal
pelvis for males and females and tubular cysts, suppura-
tive inflammation, and epithelial hyperplasia ofthe renal
pelvis for males. Kidney lesions may have contributed to
the low survival ofhigh dose female mice.
Mucosal epithelial hyperplasia and submucosal
chronic focal inflammation of the urinary bladder were
observed at increased incidences in dosed male mice.
Suppurative inflammation of the prostate was observed
at an increased incidence in high dose male mice. Fight-
ing may have contributed to urogenital lesions in male
mice. Suppurative inflammation of the ovary or uterus
was observed at an increased incidence in high dose
female mice. Hematopoiesis was observed at increased
incidences in the spleen and liver ofdosed male and high
dose female mice and in the adrenal cortex ofhigh dose
female mice.
Genetic Toxicology: Furosemide was not mutagenic in
S. typhimurium strains TA98, TA100, TA1535, or
TA1537whentestedwith orwithoutexogenousmetabolic
activation. In the mouse lymphoma assay for tri-
fluorothymidine (Tft) resistance, furosemide produced
an equivocal response in the absence ofmetabolic activa-
tion and apositiveresponse in thepresence ofactivation.
Furosemide induced sister chromatid exchanges and
chromosomal aberrations in CHO cells in both the pres-
ence and absence ofexogenous metabolic activation.
Audit: The data, documents, and pathology materials
fromthe 2-yearstudies offurosemide havebeen audited.
The auditfindings showthatthe conduct ofthe studies is
documented adequatelyand supportthe dataand results
given in this Technical Report.
Conclusion: Under the conditions ofthese 2-year feed
studies, there was equivocal evidence ofcarcinogenic
activity offurosemideformaleF344/Nrats, as shownby
marginal increases in uncommon tubular cell neoplasms
ofthe kidney and meningiomas ofthe brain. There was
no evidence ofcarcinogenic activity offurosemide for
female F344/N rats fed diets containing 350 or 700 ppm
furosemide for 2 years. There was no evidence ofcar-
cinogenic activity for male B6C3F1 mice fed diets
containing 700 or 1,400 ppm furosemide for 2 years.
There was same evidence ofcarcinogenic activity of
furosemide for female mice, as shown by an increase in
malignant tumors ofthe mammary gland.
Nephropathy was more severe in the kidney of male
rats and of male and female mice fed diets containing
furosemide than in controls.
Synonyms: 5-(aminosulfonyl)-4-chloro-2-[(2-furanyl-
methyl)amino]benzoic acid; frusemide; fursemide
Trade Names: Aisemide; Aluzine; Beronald; Desdemin;
Diural; Dryptal; Errolon; Frusemin; Fulsix;
Fuluvamide; Furosemide "Mita"; Katlex; Lasilix; Lasix;
Lowpstron; Rosemide; Transit; Urosemide
Report Date: May 1989
TR-357 Toxicology and Carcinogenesis
Studies ofHydrochlorothiazide (CAS No.
58-93-5) in F344/N Rats and B6C3F1 Mice
(FeedStudies)
Hydrochlorothiazide is a diuretic active at the distal
convoluted tubule and collecting duct. Toxicology and
carcinogenesis studies were conducted by feeding diets
containing hydrochlorothiazide (USP grade, greater
than 98% pure) to groups of F344/N rats and B6C3Fj
mice ofeach sex for 15 days, 13 weeks, 1 year, or 2 years.
Additional studies were performed to evaluate
teratologic effects in CD® rats and CD®-1 mice. Genetic
toxicology studies were performed with Salmonella, Chi-
nese hamster ovary (CHO) cells, mouse lymphoma cells,
and Drosophila.
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Fifteen-Day and Thirteen-Week Studies: All rats and
mice lived to the end of the 15-day studies (dietary
concentrations of 0 and 3,125-50,000 ppm). The final
mean bodyweights ofall dosed rat groups were 5%-11%
lower than those of controls. The final mean body
weights of the groups of male mice that received
6,250-50,000 ppm were 10%-14% lower than that ofcon-
trols. The final mean body weights ofdosed and control
female mice were similar. Calculi were seen in the uri-
nary bladder of 2/5 male and 2/5 female mice at 50,000
ppm and in 115 male and 1/5 female mice at 25,000 ppm.
All rats lived to the end of the first 13-week studies
(dietaryconcentrations of0 and 3,125-50,000ppm). Final
body weights of dosed rats were 7%-16% lower than
those of controls. Mineralization in the kidney was
observed in all dosed rats and because ofthis, additional
13-week studies in rats were conducted at lower dietary
concentrations. All rats lived to the end ofthe second 13-
week studies (dietary concentrations of0 and 250-4,000
ppm). The final mean body weights of all dosed rat
groups were 5%-10% lower than those ofcontrols. Renal
mineralizationwasdoserelated andjudgedtobeminimal
to mild at the lowest dose.
In the 13-week studies in mice, 7/10 males and 1110
females that received 50,000 ppm hydrochlorothiazide
died. The final mean bodyweights ofmice that received
50,000 ppm were 11% lower than those of controls for
males and females. Calculi were seen in the urinary
bladder of mice that received hydrochlorothiazide at
12,500 ppm and above. Nephrosis occurred with dose-
related incidences in mice receiving 12,500 ppm and
above.
Based on these results, 2-year studies were conducted
by feeding diets containing 0, 250, 500, or 2,000 ppm
hydrochlorothiazide to groups of 50 male and 50 female
rats for105-106weeks. Diets containing0,2,500, or5,000
ppm hydrochlorothiazide were fed to groups of 50 male
and 50femalemicefor103-104weeks. Tenadditional rats
per sexand dose groupwereplaced onstudyandkilled at
1 year for blood-clotting studies and histopathologic
examination.
Effects in the One-Year Studies: One of10female rats
in the 1-year study group that received 2,000 ppm died
with internal hemorrhage. In addition, evidence ofhem-
orrhage was found in 11 ofthe 16 dosed female rats that
died during the first year of the 2-year study. Hema-
tologic analyses revealed no compound-related effects;
however, activated partial thromboplastin times
(APTTs) were highly variable and were lengthened in
somedosedmalerats. Noeffects onAPTTswere seenfor
females, and no effects on prothrombin times or on the
fibrinogen content of plasma were observed for dosed
male orfemale rats. Nephropathy occurred in dosed and
control rats, and the severitywasjudged tobe greaterin
dosed male and high dose female rats. Increased inci-
dences of mild focal renal mineralization were also
seen in mid and high dose male rats and dosed female
rats.
Body Weight and Survival in the Two-Year Studies:
Mean body weights of dosed rats were 8%-25% lower
than those ofcontrols. Mean bodyweights ofdosed and
control mice were similar throughout the studies. No
significant differences in survival were observed
between rats or mice of either sex (rats-male: control,
18/50; low dose, 16/50; mid dose, 9/50; high dose, 11150;
female: 31150; 26/50; 30/50; 27/50; mice-male: control,
43/50; low dose, 42/50; high dose, 43/50; female: 38/50;
40/50; 35/50). Survival ofall groups ofmale rats was low
because a large number of animals were killed in a
moribund condition late in the study. The average daily
feed consumption by dosed rats was 89%-94% that by
controls. The average amount of hydrochlorothiazide
consumed per daywas approximately11,23, or 89mg/kg
for low, mid, or high dose rats. The average daily feed
consumption by dosed mice was 100%-105% that by
controls. The average amount of hydrochlorothiazide
consumed per day was approximately 280 or 575 mg/kg
for low dose or high dose mice.
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Nephropathy occurred in nearly all male and
femalerats,buttheseverityofthisdiseasewasgreaterin
dosed rats, as evidenced by increases in renal cysts and
epithelial hyperplasia of the renal pelvis in dosed rats
shown in the followingtable (see page 4 ofthe Technical
Report). Mineralization was observed at increased inci-
dences in dosed male and dosed female rats.
Changes associated with or secondary to renal injury
were increased in dosed rats. These lesions included
parathyroidhyperplasia,fibrousosteodystrophy ofbone,
and mineralization ofmultiple organs.
Adenomas or carcinomas (combined) of the Zymbal
gland inmale rats occurred in1150 control,1149lowdose,
2/50mid dose, and4/50high dose animals. The historical
incidence ofZymbal gland neoplasms inuntreated F344/
Nratsis19/1,936(1.0%),andthehighestobservedcontrol
group incidence is 4/50. This marginal increase was not
considered to be chemically related.
The incidences of fibroadenomas of the mammary
gland were decreased in dosed female rats (30/50; 12/50;
11149; 5/50).
The incidence of hepatocellular neoplasms was
increased in high dose male mice (adenomas or car-
cinomas, combined: control, 7/48; low dose, 10/49; high
dose, 21150). The historical incidence of hepatocellular
adenomasorcarcinomas(combined)is609/2,032(30%)in
untreated controls.
Teratology: Hydrochlorothiazide produced no
teratologic effects in the offspring ofCD® rats or CD®-1
miceaftergavage administration topregnantfemales on
day 6 through day 15 ofgestation.
GeneticToxicology: Inthe absence ofexogenous meta-
bolicactivation,hydrochlorothiazideproduced anequivo-
cal increase in revertant colonies in Salmonella
typhimurium strainTA98; no increase was observed in
strains TA100, TA1535, orTA1537with orwithout activa-
tion. Hydrochlorothiazide induced an increase in tri-
fluorothymidine (Tft)-resistant cells in a mouse
lymphoma L5178Y/TK+/- assaywithout exogenous met-
abolic activation; this assay was not performed with
activation. In cultured CHO cells, hydrochlorothiazide
induced sister chromatid exchanges (SCEs) in the pres-
ence and absence of exogenous metabolic activation but
did not induce chromosomal aberrations. Hydro-
chlorothiazide did not increase the frequency of sex-
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linked recessive lethal mutations when administered by
feeding or injection to adult male Drosophila
melanogaster.
Audit: The data, documents, and pathology materials
fromthe2-yearstudies ofhydrochlorothiazide havebeen
audited. The audit findings show that the conduct ofthe
studies is documented adequately and support the data
and results given in this Technical Report.
Conclusions: Undertheconditions ofthese2-yearfeed
studies, therewasno evidence ofcarcinogenic activity
of hydrochlorothiazide for male or female F344/N rats
given feed containing 250, 500, or 2,000 ppm hydro-
chlorothiazide. There was equivocal evidence of car-
cinogenic activity of hydrochlorothiazide for male
B6C3F1 mice, based on increased incidences of
hepatocellular neoplasms. There was no evidence of
carcinogenic activity for female B6C3F1 mice given
diets containing 2,500 or 5,000 ppm hydrochlorothiazide.
Chronic renal disease was more severe in rats admin-
istered hydrochlorothiazide, and increased incidences of
secondary lesions (parathyroid hyperplasia, fibrous
osteodystrophy, and mineralization in multiple organs)
occurred in dosed rats.
Synonym: 6-chloro-3,4-dihydro-2H-1,2,4-benzothia-
diazine-7-sulfonamide 1,1-dioxide
Trade Names: Aquarius; Bremil; Chlorzide; Cidrex;
Dichlorosal; Dichlotride; Diclotride; Direma; Disalunil;
Esidrix; Fluvin; Hidroronol; Hydril; Hydro-Aquil;
Hydro-Diuril; Hydrosaluric; Hydrothide; Hypothiazide;
Ivaugan;Jen-Diril; Maschitt; Nefrix; Neo-Codema; Neo-
flumen; Oretic; Panurin; Ro-Hydrazide; Thiaretic;
Thiuretic; Urodiazin; Vetidrex
Report Date: July 1989
TR-358 Toxicology and Carcinogenesis
Studies ofOchratoxin A (CAS No. 303-47-9)
in F344/N Rats (Gavage Studies)
OchratoxinAis anaturallyoccurringfungaltoxinthat
is acontaminant in corn, peanuts, storage grains, cotton-
seed, meats, dried fish, and nuts. Toxicology and car-
cinogenesis studies were conducted by administering
ochratoxin A (98% pure) in corn oil by gavage to groups
ofF344/Nrats ofeachsexfor16days,13weeks, 9months,
15 months, or 2 years. Only rats were studied because
ochratoxin Ahas been shown to be carcinogenic in mice.
Genetic toxicology tests were performed with bacterial
andmammalian cells. Urinalysis, hematologic and serum
chemical analyses, and bone marrowcellularity determi-
nations were conducted at 9, 15, and 24 months in the
2-year studies.
Sixteen-Day and Thirteen-Week Studies: Rats were
administered 0, 1, 4, or 16 mg/kg ochratoxin Ain corn oil
by gavage 5 days perweek for a total of12 doses over 16
days. All rats that received 16 mg/kg ochratoxin A died
within 6 days. Rats that received 4 mg/kg lost weight.
Compound-related lesions in rats included bone marrow
hyperplasia, thymic atrophy, necrosis and hyperplasia of
the forestomach epithelium, renal tubular cell degenera-
tive and regenerative changes (nephropathy), and adre-
nalglandhemorrhage. Renaltubularchangesweremost
severe in animals that received 4 mg/kg. Rats that
received 16 mg/kg had less severe renal lesions than
those at4mg/kg, perhaps because the acute toxicityand
early death did not allow sufficient time for full develop-
ment oflesions.
No compound-related deaths occurred in the 13-week
studies (doses were 0 and 0.0625 to 1 mg/kg). The final
meanbodyweightofrats thatreceived 0.25, 0.5, or 1mg/
kgwas7%,11%, or19%lowerthanthatofvehiclecontrols
for males and 3%, 4%, or 9% lower for females.
Compound-related lesions in the kidney were charac-
terized as degeneration and regeneration of the epi-
thelium of the proximal convoluted tubules with
individual cell necrosis ofmoderate severity (see page 3
ofthe Technical Report).
Karyomegaly of tubular epithelial cells was wide-
spreadbutmostpronouncedinthestraightportionofthe
tubules just above the corticomedullary junction.
Karyomegaly was present in all dosed groups, and the
severityincreased as the doseincreased.Atlowerdoses,
atrophy of the straight portions of the tubules at the
corticomedullary junction and in the medulla was
observed.
Basedonmortalityandonthepresenceandseverityof
renal lesions, groups of 80 rats per sex and dose group
were administered 0, 21, 70, or210 ,ug/kgochratoxinAin
corn oil by gavage 5 days per week for up to 2 years.
Groups of15ratspersexanddosewerekilled at9 orat15
months and the remaining animals at 2 years.
Nine-Month and Fifteen-Month Studies: Administra-
tion ofochratoxinAbygavage for 9months or15months
to F344/N ratswas associated with increasedincidences
ofrenaltubularcell neoplasms inmales and hyperplasia,
degeneration, and karyomegaly of renal tubular epi-
thelial cells in both males and females (see page 4 ofthe
Technical Report).
Body Weight and Survival in the Two-Year Studies:
Mean body weights of high dose rats were generally
4%-7% lower than those of vehicle controls. No signifi-
cant differences in survival were observed between any
groups of female rats (vehicle control, 32/50; low dose,
23/51; mid dose, 35/50; high dose, 34/50). Survival was
decreasedafter77weeksinhighdosemaleratsandafter
96 weeks in low and mid dose male rats (39/50; 26/51;
26/51; 23/50).
Clinical Pathology: Minor differences were observed
forhematologicvaluesbetween dosed andvehicle control
animals, but these were not considered to be ofbiologic
significance. Results of serum chemistry analysis were
not clearly compound related. Ochratoxin A-dosed ani-
mals had slightincreases comparedwithvehicle controls
inurinevolume and decreases in urine specific gravityin
concentration tests, suggestingthatexposureresultedin
mild to moderate decreases in the ability to concentrate
urine.
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Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: A spectrum of degenerative and proliferative
changes occurred in the kidney ofmale and female rats
given ochratoxinAfor2 years. Degeneration oftherenal
tubular epithelium with formation oftubular cysts, pro-
liferation ofthe tubular epithelium, and karyomegaly of
thenucleioftubularepithelial cells occurredatincreased
incidences in dosed rats (see page 5 of the Technical
Report). Hyperplasia oftherenal tubularepithelium and
renal tubularadenomas and carcinomas also occurred at
increased incidences in the dosed rats; the tumors were
frequently multiple within a single kidney or were bilat-
eral, and many metastasized to other organs.
Theincidenceoffibroadenomas ofthe mammarygland
in high dose female rats was significantly greater than
that in vehicle controls (vehicle control, 17/50; low dose,
23/51; mid dose, 22/50; high dose, 28/50). Multiple fibro-
adenomas of the mammary gland were observed at an
increased incidence in high dose female rats (4/50; 4/51;
5/50; 14/50). One mammary gland adenoma was seen in a
mid dose female, and two mammary gland adenocar-
cinomas were seen in each dosed group; one adenocar-
cinoma was seen in the vehicle control group.
An adenoma of the pars intermedia of the pituitary
gland was observed in one mid dose female rat, and a
carcinoma was observed in a second mid dose female rat.
Squamous cell papillomas ofthe tongue were seen in two
low dose and two mid dose male rats. Neither the pitui-
tary neoplasms nor the papillomas of the tongue were
considered related to ochratoxin A exposure.
GeneticToxicology: OchratoxinAwas notmutagenicin
four strains ofSalmonella typhimurium (TA97, TA98,
TA100, or TA1535) when tested both with and without
exogenous metabolic activation. In cultured Chinese
hamster ovary (CHO) cells, ochratoxin A induced sister
chromatid exchanges (SCEs) inthe presence, butnotthe
absence, of metabolic activation; it did not significantly
increase the number of chromosomal aberrations in
these cells.
Audit: The data, documents, and pathology materials
from the 2-year studies of ochratoxin A have been
audited. The audit findings show that the conduct ofthe
studies is documented adequately and support the data
and results given in this Technical Report.
Conclusions: Under the conditions of these 2-year
gavage studies, there was clear evidence of car-
cinogenic activity ofochratoxinAformale F344/N rats
asshownbysubstantiallyincreasedincidences ofuncom-
montubularcelladenomas andoftubularcellcarcinomas
ofthe kidney. There wasclearevidence ofcarcinogenic
activity for female F344/N rats shown by increased
incidences of uncommon tubular cell adenomas and of
tubular cell carcinomas of the kidney and by increased
incidences andmultiplicityoffibroadenomas ofthe mam-
mary gland.
Ochratoxin A administration also caused nonneoplas-
tic renal changes including tubular cell hyperplasia,
tubular cell proliferation, cytoplasmic alteration,





Report Date: May 1989
TR-359 Toxicology and Carcinogenesis
Studies of8-Methoxypsoralen (CAS No.
298-81-7) in F344/N Rats (Gavage Studies)
Oral administration of8-methoxypsoralen followed by
exposure to longwave ultraviolet light (primarily ultra-
violetA, 320-400 nm) is used in the treatment ofvitiligo
and psoriasis. 8-Methoxypsoralen also occurs naturally
in avariety ofvegetables. Toxicology and carcinogenesis
studies of8-methoxypsoralen withoutultraviolet Awere
conducted by administering USP-grade 8-methox-
ypsoralen (99% pure) in corn oil by gavage to groups of
F344/N rats once or for 16 days, 13 weeks, or 2 years. In
vitro genetic toxicology tests were performed with bac-
teria and mammalian cells.
Single-Administration, Sixteen-Day, andThirteen-Week
Studies: In the single-administration studies, the chemical
wasadministeredatdosesof0and63-1,000mg/kg. Fourof
fivemaleratsand5/5femaleratsthatreceived1,000mg/kg
8-methoxypsoralen died within 2 days.
In the 16-day studies, the chemical was administered
atdosesof0and50-800mg/kg.Allratsreceiving800mg/
kgdiedwithin5days,andonemaleand onefemale at400
mg/kg and one female at 200 mg/kg also died before the
end of the studies. The final mean body weights of
animals at200 or400mg/kgwere14% or30% lowerthan
those of vehicle controls. No compound-related effects
were observed at necropsy.
Inthe13-week studies, the chemicalwas administered
at doses of 0 and 25-400 mg/kg. Six of 10 male rats and
8/10 female rats that received 400 mg/kg died before the
end ofthe studies. The final mean body weight ofmale
rats that received 100, 200, or 400 mg/kg was 12%, 22%,
or45%lowerthanthatofvehiclecontrols.Thefinalmean
bodyweight offemale rats that received 200 or 400 mg/
kg was 15% or 35% lower than that ofvehicle controls.
The liver weight to body weight ratios for all dosed
groups ofrats exceptthelowest(25mg/kg)were greater
thanthoseforvehiclecontrols. Compound-related effects
included fatty change in the liver in males and females
and atrophy ofthe testis, seminalvesicles, and prostate.
Based on these results, 2-year studies were conducted
by administering 0, 37.5 or 75mg/kg8-methoxypsoralen
in corn oil by gavage, 5 days per week for 103 weeks, to
groups of50 F344/N rats ofeach sex.
Body Weight and Survival in the Two-Year Studies:
The mean body weights ofdosed male rats were gener-
ally3%-14% lowerthanthose ofvehicle controls, and the
mean body weights of high dose female rats were
5%-17% lower. The survival ofboth the low and the high
dose groups of male rats was lower than that of the
vehicle controls (male: vehicle control, 30/50; low dose,
16/50; high dose, 16/50;female: 39/50; 33/50; 36/50),likely
because ofkidney toxicity and neoplasia.
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Nonneoplastic and Neoplastic Effects intheTwo-Year
Studies: Mineralization oftherenalpapillawas observed
in high dose male rats (vehicle control, 0/50; low dose,
0/50; high dose, 31/49). The severity ofnephropathywas
increased in dosed male rats. Focal hyperplasia ofrenal
tubularcellswas observedin dosedmalerats (0/50; 8/50;
8/49).Theincidencesoftubularcelladenomas(1/50;11/50;
8/49), adenocarcinomas (0/50; 1/50; 3/49), and adenomas
or adenocarcinomas (combined) (1/50; 12/50; 11/49) were
increased in dosed male rats. Hyperplasia of the para-
thyroid glands (2/49; 22/47; 18/48) and fibrous
osteodystrophy (2/50; 10/50; 12/49) in male rats were
secondary to chronic nephropathy.
The incidences of carcinomas or squamous cell car-
cinomas (combined) ofthe Zymbal glandwere increased
in dosed male rats (1/50; 7/50; 4/49). The mean historical
incidence for carcinomas or squamous cell carcinomas
(combined)in corn oilvehicle controlmale F344/N ratsis
0.8% (16/1,949); the highest incidence in any one group is
4% (2/49).
Fibromas of the subcutaneous tissue in male rats
occurred with a positive trend (1/50; 5/50; 7/49). An
additional high dose male had a sarcoma. The mean
historical incidence of fibromas or fibrosarcomas (com-
bined) of subcutaneous tissue in corn oil vehicle control
male F344/N rats is 9% (171/1,949).
Alveolar/bronchiolar adenomas occurred with a posi-
tive trend in male rats (4/50; 9/50; 9/49).
The mean historical incidence of alveolar/bronchiolar
neoplasms in corn oilvehicle control male F344/N rats is
3% (68/1,944); the highest incidence is 10% (5/50).
Chronic inflammation, ulcers, and epithelial hyper-
plasia of the forestomach were observed at increased
incidencesindosedmalerats (chronicinflammation: 1/50;
6/50; 5/49; ulcers: 5/50; 13/50; 11/49; epithelial hyper-
plasia: 4/50; 19/50; 20/49). Squamous cellpapillomaswere
observed in two low dose male rats.
Squamous cell papillomas were observed in the palate
or tongue of one low dose and three high dose female
rats; none were observed in vehicle controls. These
papillomas were not considered to be related to chemical
administration.
Diffuse hypertrophy of the thyroid gland was
observed at increased incidences in dosed male rats
(2/50; 31/50; 39/49).
Genetic Toxicology: 8-Methoxypsoralen was muta-
genic in Salmonella typhimurium strain TA104 in the
presence and absence of activation and in strains TA98,
TA100, and TA102 when tests were conducted with
exogenous metabolic activation; 8-methoxypsoralen was
not mutagenic with or without activation in strain
TA1535. Treatment with 8-methoxypsoralen induced
both sister chromatid exchanges (SCEs) and chromoso-
mal aberrationsin Chinesehamsterovary(CHO) cellsin
the absence of exogenous metabolic activation; in the
presence of activation, in the presence of activation,
induction ofSCEs occurred, but no significant increases
in chromosomal aberrations was observed.
Audit: The data, documents, and pathology materials
from the 2-year studies of8-methoxypsoralen have been
audited at the NTP Archives. The audit findings show
thatthe conductofthe studiesis documented adequately
and support the data and results given in this Technical
Report.
Conclusions: Under the conditions of these 2-year
gavage studies, therewas clearevidence ofcarcinogenic
activity of 8-methoxypsoralen (without ultraviolet radia-
tion) for male F344/N rats, as shown by increased inci-
dences of tubular cell hyperplasia, adenomas, and
adenocarcinomas of the kidney and carcinomas of the
Zymbal gland. Subcutaneous tissue fibromas and alveolar/
bronchiolaradenomasofthelunginmaleF344/Nratsmay
havebeenrelatedtochemical administration. Dose-related
nonneoplastic lesions in male F344/N rats included
increasedseverityofnephropathyandmineralizationofthe
kidneyand forestomach lesions. Therewasno evidence of





lactone; 8-MP; 8-MOP; 8-methoxy-(furano-3',2':6,7-
coumarin); 8-methoxy-4',5':6,7-furocoumarin; 9-methox-
ypsoralen; 8-methoxypsoralene; methoxsalen; oxy-
psoralen
Trade Names: Ammoidin; Meladinin (VAN); Meladinine;
Meladoxen; Meloxine; Methoxa-Dome; Mopsoralen;
Oxsoralen; Soloxsalen; Trioxun; Xanthotoxin;
Xanthotoxine
Report Date: July 1989
TR-360 lbxicology and Carcinogenesis
Studies ofN,N-Dimethylaniline (CAS No.
121-69-7) in F344/N Rats and B6C3F1 Mice
(GavageStudies)
N,N-Dimethylaniline is used as a chemical intermedi-
ate inthe synthesis ofdyestuffs. Toxicologyand carcino-
genesis studies were conducted by administering
N,N-dimethylaniline (greater than 98% pure) in corn oil
by gavage to groups ofF344/N rats and B6C3F1 mice of
each sex for 2 weeks, 13 weeks, or 2 years. Genetic
toxicology studies were conducted in Salmonella
typhimurium, mouse lymphoma cells, and Chinese
hamster ovary (CHO) cells.




or 750 mg/kg were 15% or 47% lower than that ofvehicle
controls; final mean bodyweights of other groups ofrats
and mice were similar to those of vehicle controls.
Compound-related clinical signs observed included
cyanosisinratsandlethargyandtremorsinratsandmice.
Splenomegaly occurred in nearly all dosed groups ofrats
and mice, and the incidences were dose related.
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In the 13-week studies, doses were 32-500 mg/kg; no
compound-related deaths occurred.The finalmean body
weights ofmaleratsthatreceived250or5(0 mg/kgwere
15% or27% lowerthanthatofvehiclecontrols. Thefinal
meanbodyweightsofallgroupsofdosedfemaleratsand
male andfemalemicewerewithin12%ofthoseofvehicle
controls. Compound-related clinical signs included leth-
argyinrats andmiceandcyanosisinrats. Splenomegaly
was observed in all dosed groups of rats and mice; the
severity was dose related. Compound-related extra-
medullary hematopoiesis and hemosiderosis occurred in
the kidney or testis ofdosed rats and liver and spleen of
dosed rats and mice.
Two-year studies were conducted by administering 0,
3, or30mg/kgN,N-dimethylaniline incornoilbygavage,
5daysperweekfor103weeks,togroupsof50ratsofeach
sex. The lower dose was selected to be one-tenth the
higherdosetoincreasethelikelihoodthatonedosewould
cause only a minimal nonneoplastic response. Groups of
50 mice ofeach sexwere administered 0, 15, or30 mg/kg
on the same schedule.
Body Weight and Survival in the Two-Year Studies:
Meanbodyweights ofvehicle control and dosed rats and
mice were similar throughout the studies. Survival rates
ofallrespective groupswere similarafter2years, except
for the lowered survival of vehicle control female rats
(vehicle control, 21150; low dose 32/50; high dose, 36/50).
This may reflect the large number (24/50) of vehicle
control female rats killed when observed to be in a
moribund state. Final survival for other groups was as
follows: male rats-29/50; 32/50; 28/50; male mice-
34/50; 30/50; 34/50; female mice-35/50; 39/50;
33/50.
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: In these 2-year studies, the spleen was the
expected site of chemical-related effects. Fatty meta-
morphosis and fibrosis in the spleen of high dose male
rats were increased (fatty metamorphosis: vehicle con-
trol, 0/49; low dose, 1/49; high dose, 10/50; fibrosis: 5/49;
2/49; 22/50). Splenic hemosiderosis and hematopoiesis
were present at an incidence greater than 85% in all
groups of rats; however, the severity of the lesions was
greater in dosed groups than in vehicle controls. Sar-
comasofthespleenwere seenin3/50highdosemalerats,
and an osteosarcomawas seeninanotherhighdosemale
rat. One additional high dose male rat had a sarcoma of
the thymus. Splenic sarcomas are uncommon in corn oil
vehicle control male F344/N rats (NTP historical inci-
dence 3/2,081, 0.1%), and thus, these neoplasms in high
dose male rats (4/50, 8%) were considered to be chem-
ically related.
Lower incidences ofmononuclear cell leukemia (which
apparently originates in the spleen) were seen in dosed
maleandfemaleratsthaninvehiclecontrols (male:13/50;
4/50; 3/50; female: 11/50; 7/50; 0/50).
The incidence ofsquamous cell papillomas ofthe fore-
stomachinhighdosefemalemicewasmarginallygreater
than that in vehicle controls (2/50; 2/50; 8/50). No malig-
nant forestomach neoplasms were observed.
Genetic Toxicology: N,N-Dimethylaniline was not
mutagenic in S. typhimurium strains TA98, TA100,
TAM535, or TA1537 in the presence or absence of
exogenous metabolic activation. In the mouse lymphoma
assay,N,N-dimethylaniline produced apositive response
with and without metabolic activation. In CHO cells,
N,N-dimethylaniline induced both sister chromatid
exchanges (SCEs) and chromosomal aberrations in the
presence of exogenous metabolic activation. Without
activation, an increase in chromosomal aberrations was
observed, but no increase in SCEs occurred.
Conclusions: Under the conditions of these 2-year
gavage studies, there was some evidence of carcino-
genic activity ofN,N-dimethylaniline for male F344/N
rats,asindicatedbytheincreasedincidencesofsarcomas
orosteosarcomas(combined)ofthespleen.Therewasno
evidence ofcarcinogenic activity ofN,N-dimethylani-
line for female F344/N rats given 3 or 30 mg/kg body
weight by gavage for 2 years. There was no evidence of
carcinogenic activity ofN,N-dimethylaniline for male
B6C3F1 mice given 15 or 30 mg/kg body weight by
gavage for 2 years. There was equivocal evidence of
carcinogenic activity ofN,N-dimethylaniline forfemale
B6C3F1 mice, as indicated by an increased incidence of
squamous cell papillomas ofthe forestomach. Both rats
and mice could have tolerated doses higher than those
used in these studies.
There were decreased incidences of mononuclear cell
leukemia in dosed male and high dose female rats.
Compound-related splenic fibrosis, hemosiderosis, and




Report Date: October 1989
TR-361 Toxicology and Carcinogenesis
Studies ofHexachloroethane (CAS No.
67-72-1) in F344/N Rats (Gavage Studies)
Hexachloroethane is used in organic synthesis as a
retardingagentinfermentation, as acamphorsubstitute
in nitrocellulose, in pyrotechnics and smoke devices, in
explosives, and as a solvent. In previous long-term
gavage studieswithB6C3F1 mice and Osbourne-Mendel
rats (78 weeks of exposure followed by 12-34 weeks of
observation), hexachloroethane caused increased inci-
dences of hepatocellular carcinomas in mice. However,
survival oflowandhigh dose ratswasreduced compared
with that ofvehicle controls, and the effects on rats were
inconclusive. Therefore, additional toxicology and car-
cinogenesis studies were conducted in F344/N rats by
administering hexachloroethane (approximately 99%
pure) in corn oil by gavage to groups of males and
females for 16 days, 13 weeks, or 2 years. Genetic toxi-
cology studies were conducted in Salmonella
typhimurium and in Chinese hamster ovary (CHO)
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cells. Urinalysis was performed in conjunction with the
13-week studies.
Sixteen-Day Studies: In the 16-day studies (dose
range, 187-3,000 mg/kg), all rats that received 1,500 or
3,000mg/kg and 115males and2/5females that received
750mg/kgdied beforetheend ofthe studies. Finalmean
body weights ofrats that received 750mg/kgwere 25%
lower than that of vehicle controls for males and 37%
lower for females. Compound-related clinical signs seen
at 750mg/kg ormoreincluded dyspnea, ataxia, prostra-
tion, and excessive lacrimation. Other compound-related
effects included hyaline droplet formation in the tubular
epithelial cells in all dosed males and tubular cell
regeneration and granular casts in the tubules at the
corticomedullary junction in the kidney in males receiv-
ing 187 and 375 mg/kg.
Thirteen-Week Studies: In the 13-week studies (dose
range, 47-750mg/kg), 5/10malerats and2/10femalerats
that received 750 mg/kg died before the end of the
studies. The final mean body weight of male rats that
received 750 mg/kg was 19% lower than that ofvehicle
controls. Compound-related clinical signs for both sexes
includedhyperactivityatdosesof94mg/kgorhigherand
convulsions at doses of 375 or 750 mg/kg. The relative
weights of liver, heart, and kidney were increased for
exposed males and females. Kidney lesions were seen in
all dosed male groups, and the severity increased with
dose. Papillary necrosis and tubular cell necrosis and
degeneration in the kidney and hemorrhagic necrosis in
the urinary bladder were observed in the five male rats
that received 750 mg/kg and died before the end ofthe
studies; at all lower doses, hyaline droplets, tubular
regeneration, and granular casts were present in the
kidney. No chemical-related kidney lesions were
observedinfemales. Fociofhepatocellular necrosiswere
observed in several male and female rats at doses of188
mg/kg or higher.
Dose selection for the 2-year studies was based pri-
marily on the lesions of the kidney in males and of the
liver in females. Studies were conducted by administer-
ing hexachloroethane in corn oil by gavage at 0, 10, or 20
mg/kgbodyweight, 5daysperweek,togroupsof50male
rats. Groups of50female ratswereadministered 0,80, or
160 mg/kg on the same schedule.
Body Weight and Survival in the Two-Year Studies:
Mean body weights of high dose rats were slightly
(5%-9%) lower than those ofvehicle controls toward the
end ofthe studies. No significant differences in survival
were observed between anygroups ofrats (male: vehicle
control, 31150; 10 mg/kg, 29/50; 20 mg/kg, 26/50; female:
vehicle control, 32/50; 80 mg/kg, 27/50; 160 mg/kg,
32/50).
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Incidences ofkidneymineralization (vehicle con-
trol, 2/50; low dose, 15/50; high dose, 32/50) and hyper-
plasia of the pelvic transitional epithelium (0/50; 7/50;
7/50) were increased in dosed male rats. Renal tubule
hyperplasia was observed at an increased incidence in
high dosemale rats (2/50; 4/50;11150). Theselesions have
been described as characteristic of the hyaline droplet
nephropathy that is associated with an accumulation of
liver-generated a2p,-globulininthe cytoplasm oftubular
epithelial cells. The severity of nephropathy was
increasedinhighdosemalerats(moderatevs.mild), and
the incidences and severity of nephropathy were
increased in dosed females (22/50; 42/50; 45/50). The
incidences of adenomas (1150; 2/50; 4/50), carcinomas
(0/50; 0/50; 3/50), and adenomas or carcinomas (com-
bined) (1150; 2/50; 7/50) of the renal tubule were also
increased in the high dose male group. One of the car-
cinomasinthehighdosegroupmetastasizedtothelung.
No compound-related neoplasms were observed in
females.
The incidence of pheochromocytomas of the adrenal
gland in low dose male rats was significantly greater
than thatinvehiclecontrols (15/50; 28/50; 21/49), and the
incidences for both dosed groups were greater than the
mean historical control incidence (28% ± 11%).
Genetic Toxicology: Hexachloroethane was not muta-
genic in S. typhimurium strains TA98, TA100, TA1535,
or TA1537 when tested with and without exogenous
metabolic activation. In CHO cells, hexachloroethane did
not induce chromosomal aberrations with or with out
metabolic activation but did produce sister chromatid
exchanges in the presence of exogenous metabolic
activation.
Audit: The data, documents, and pathology materials
from the 2-year studies of hexachloroethane have been
audited. The audit findings show that the conduct ofthe
studies is documented adequately and support the data
and results given in this Technical Report.
Conclusions: Under the conditions of these 2-year
gavage studies, there was clear evidence of carcino-
genic activity of hexachloroethane for male F344/N
rats, based on the increased incidences of renal neo-
plasms. The marginally increased incidences of phe-
ochromocytomas of the adrenal gland may have been
related to hexachloroethane administration to male rats.
There was no evidence of carcinogenic activity of
hexachloroethane for female F344/N rats administered
80 or 160 mg/kg by gavage for 103 weeks.
The severity of nephropathy and incidences of linear
mineralization of the renal papillae and hyperplasia of
the transitional epithelium of the renal pelvis were
increasedindosedmalerats.Theincidencesandseverity
ofnephropathy were increased in dosed female rats.
Synonyms: carbon hexachloride; ethane hexachloride;
hexachlorethane; hexachloroethylene; 1,1,1,2,2,2-hexa-
chloroethane; perchloroethane
Trade Names: Avlothane; Distokal; Distopan; Distopin;
Egitol; Falkitol; Fasciolin; Mottenhexe; Phenohep
Report Date: August 1989
Note: Hexachloroethane was previously tested in
Osborne-Mendel rats and B6C3F1 mice by gavage (See
TR-68, reported 1978).
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TR-362 Tbxicology and Carcinogenesis
Studies of4-Vinyl-l-cyclohexene Diepoxide
(CAS No. 106-87-6) in F344/N Rats and
B6C3F1 Mice (DermalStudies)
4-Vinyl-1-cyclohexene diepoxide is used a chemical
intermediate and as areactive diluentfordiepoxides and
epoxyresins.Toxicologyandcarcinogenesis studieswere
conducted by administering 4-vinyl-1-cyclohexene
diepoxide (97% pure) in acetone bydermal application to
individuallyhoused F344/N rats andB6C3F1 micefor14
days,13weeks,15months, and2years.Additionalstudies
included evaluation of immune function after a 5-day
dermal exposure and evaluation of the oral toxicity of
4-vinyl-1-cyclohexene diepoxide in 16-day and 13-week
corn oil gavage studies. Genetic toxicology studies were
conducted in Salmonella typhimurium, mouse L5178Y
lymphomacells, andChinesehamsterovary(CHO) cells.
Fourteen-Day Dermal Studies: In the 14-day studies,
all rats thatreceived 924 mg/kg orhigher (equivalent to
139 mg/rat or higher for males and 112 mg/rat ofhigher
for females) died before the end of the studies. Final
mean body weights were lower than those of vehicle
controls in males receiving 68 mg/rat and in females
receiving 57 mg/rat. Excoriations on the skin at the
application sitewere observed inthegroups receiving57
mg/rat or more. Males receiving 139mg/rat and females
receiving112mg/rathad congestion and/orhypoplasia of
thebonemarrow;mosthadacutenephrosis. Skinlesions,
including epidermal necrosis and ulceration, epidermal
hyperplasia, and hyperkeratosis, were found in the 139
and 112 mg/rat group; similar lesions of lesser severity
were seen in the two lowest dose groups ofeach sex.
All mice that received 1,787 mg/kg (equivalent to 43/
mouse for males and 37 mg/mouse for females) and 3/5
male mice and 5/5 female mice that received 889 mg/kg
(equivalentto19-21mg/mouse) diedbefore theend ofthe
14-day dermal studies. Final mean body weights of
exposed and vehicle control mice were generally similar.
Lesions ofthe skin atthe site ofapplication were seenin
4/5 males and 4/5 females receiving 5 mg/mouse and all
mice receiving 10 and 21 (males) or 19 (females) mg/
mouse and included epidermal and sebaceous gland
hyperplasia, hyperkeratosis, and ulceration.
Thirteen-Week Studies: In the 13-week dermal stud-
ies, allrats survivedtotheend ofthestudies (dosesupto
60mg/rat). Thefinalmeanbodyweights ofthe 60mg/rat
groups were 9%-14% lower than those of the vehicle
controls. Compound-related clinical signs in the 60 mg/
ratgroups observedduringthesecondhalfofthestudies
included redness, scabs, and ulceration atthe application
site and burrowing behavior after dermal application.
Hyperplasia of the sebaceous glands and acanthosis
(hyperplasia) and hyperkeratosis of the squamous epi-
thelium were seen at the site ofapplication.
In mice, no compound-related deaths occurred after
applications of up to 10 mg/mouse in 13-week dermal
studies, and final mean body weights of exposed and
vehicle control mice were similar. Relative liver and
kidney weights increased with dose. Compound-related
lesions ofthe skin included sebaceous gland hyperplasia
and acanthosis (hyperplasia) and hyperkeratosis of the
stratified squamous epithelium at the site ofapplication;
ovarian atrophy was also considered to be compound
related.
In the 13-week oral studies, the major target organ of
toxicity in rats and mice was the forestomach, as indi-
catedbyhyperkeratosis andhyperplasiaofthe stratified
squamous epithelium. In female mice, ovarian atrophy
was seen in 4-vinyl-1-cyclohexene diepoxide-dosed
groups.
Two-year studies were conducted by administering
4-vinyl-1-cyclohexene diepoxide in acetone by dermal
application, 5daysperweekfor105weekstogroups of60
rats ofeach sex at 0, 15, or 30 mg/animal. Groups of 60
mice of each sex were administered 0, 2.5, 5, or 10 mg/
animal on the same schedule for 103 weeks. None ofthe
dosesselectedhadproducedulcerationofskinin13-week
studies. Ten animals from each group were killed and
examined during month 15 for toxicologic evaluation.
Immune FunctionStudies: Theimmunotoxiceffects of
4-vinyl-1-cyclohexene diepoxide were studied in male
B6C3F1 mice after a 5-day dermal exposure at doses
ranging from 2.5 to 10 mg/mouse per day. 4-Vinyl-i-
cyclohexene diepoxidewasimmunosuppressive at10 mg/
mouseand,toalesserextent,at5mg/mouse,asindicated





Fifteen-Month Evaluation: Two of 10 male rats that
received30mghadasquamouscellcarcinomaoftheskin
at or adjacent to the site of application. Acanthosis was
seen in exposed rats (mild severity at 30 mg/rat and
minimal severity at 15 mg/rat); hyperkeratosis was
observed for rats in the 30 mg/rat groups.
Compound-related nonneoplastic skin lesions in mice
included acanthosis, hyperkeratosis, and sebaceous
gland hyperplasia/hypertrophy. Squamous cell
papillomas and carcinomas were seen in mice that
received 5 or 10 mg/mouse; none was seen in vehicle
control orlowdose groups (papillomas-male: mid dose,
/10; high dose, 2/10; female: 1O; 11O; carcinomas-
male: 2/10; 8/10; female: 2/10; 5/10). One vehicle control
and all exposed female mice had atrophy of the ovary.
Hyperplasia ofthe ovarian surface epithelium was seen
in 8/10 females receiving 5 mg/mouse and 9/9 females
receiving 10 mg/mouse. Two ofnine females receiving 10
mg/mousehadgranulosacelltumorsoftheovary,and1/9
females receiving 10 mg/mouse had an ovarianpapillary
cystadenoma.
Body Weights and Survival in the Two-Year Studies:
In general, the bodyweights and survival were lower in
mid and high dose groups than in vehicle controls. The
survival was lowerin exposed groups, primarilybecause
of neoplasms (survival at week 105-male rats: vehicle
control, 7/50; lowdose,8/50; high dose,4/50; female rats:
27/50; 23/50; 15/50; male mice: vehicle control, 38/50; low
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dose, 35/50; mid dose, 4/50; high dose, 0/50; female mice:
30/50; 31/50; 15/50; 0/50). All high dose male mice diedby
week 83; the 10 surviving high dose female mice were
killed during week 85.
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Acanthosis and sebaceous gland hypertrophy of
skin from the scapula orbackwere observed at substan-
tially increased incidences in exposed male and female
rats. Squamous cell papillomas in male rats and
squamous cell carcinomas in male and female rats were
observed only in exposed rats (squamous cell
carcinomas -male: vehicle control, 0/50; low dose, 33/50;
high dose, 36/50; female: 0/50; 16/50; 34/50). The inci-
dences ofbasal cell adenomas or carcinomas (combined)
were increased (male: 0/50; 1/50; 6/50; female: 0/50; 3/50;
4/50).
Forexposedmice,acanthosis,hyperkeratosis, andnec-
rotizing inflammation ofthe skinwere observed overthe
scapula or back. Squamous cell carcinomas were found
only in exposed mice (male: vehicle control, 0/50; low
dose, 14/50; mid dose, 39/50; high dose, 42/50; female:
0/50; 6/50; 37/50; 41/50).
Follicular atrophy and tubular hyperplasia of the
ovary in female mice were increased (atrophy: 12/50;
43/49; 47/50; tubular hyperplasia: 5/50; 35/49; 38/49;
34/50). Mid and high dose females had benign or malig-
nant granulosa cell tumors (0/50; 0/49; 7/49; 12/50) and
benign mixed tumors (0/50; 0/49; 11/49; 6/50). The com-
bined incidences of luteomas, granulosa cell tumors,
benignmixedtumors, ormalignantgranulosacelltumors
in mid and high dose female mice were increased (1/50;
0/49; 17/49; 18/50).
The incidences of alveolar/bronchiolar adenomas or
carcinomas (combined) in exposed female mice were
marginally increased (4/50; 9/50; 11/50; 7/50).
Genetic Toxicology: 4-Vinyl-1-cyclohexene diepoxide
was mutagenic inS. typhimurium strains TA98, TA100,
and TA1535 with and without exogenous metabolic
activation; the compound was equivocally mutagenic in
strain TA1537without S9but gave apositive response in
the presence ofactivation. 4-Vinyl-1-cyclohexene diepox-
ide induced resistance to trifluorothymidine in mouse
L5178Y/TK cellswithoutexogenous metabolic activation;
it was not tested with activation. 4-Vinyl-1-cyclohexene
diepoxide induced sister chromatid exchanges and chro-
mosomal aberrations in CHO cells in the presence and
absence ofexogenous metabolic activation.
Conclusions: Under the conditions of these 2-year
dermal studies, there was clear evidence of carcino-
genic activity of 4-vinyl-1-cyclohexene diepoxide for
male andfemale F344/N rats, as shownbysquamous cell
and basal cell neoplasms of the skin. There was clear
evidence of carcinogenic activity of 4-vinyl-i-
cyclohexene diepoxide formale andfemaleB6C3F1 mice,
as shown by squamous cell carcinomas of the skin in
males and squamous cell carcinomas of the skin and
ovarian neoplasms in females; increased incidences of
lungneoplasms in females may also have been related to
chemical application.
Synonyms: 4-vinylcyclohexene diepoxide; 4-vinyl-1,2-
cyclohexene diepoxide; 1-vinyl-3-cyclohexene diepoxide;
4-vinylcyclohexene dioxide; 1,2-epoxy-4-(epoxyethyl)
cyclohexane; 1-epoxyethyl-3,4-epoxycyclohexane
Report Date: November 1989
TR-363 Toxicology and Carcinogenesis
Studies ofBromoethane (Ethyl Bromide)
(CAS No. 74-96-4) in F344/N Rats and
B6C3F1 Mice (Inhalation Studies)
Bromoethane is an alkylating agentused primarily as
a chemical intermediate in various organic syntheses. In
toxicology and carcinogenesis studies, groups ofF3441N
rats and B6C3F1 mice of each sex received whole-body
exposure to bromoethane (greater than 98% pure) once
for4 hours orfor 6 hours per day, 5 days perweek, for 14
days, 14 weeks, or 2 years. Genetic toxicology studies
were conducted in Salmonella typhimurium and Chi-
nese hamster ovary (CHO) cells.
Single-Exposure, Fourteen-Day, and Fourteen-Week
Studies: Single-exposure inhalation studies were con-
ducted in rats and mice at target concentrations of 625,
1,250, 2,500, 5,000, or 10,000 ppm bromoethane. All rats
exposed to 10,000 ppm bromoethane and 3/5 female rats
exposed to 5,000 ppm died before the end ofthe single-
exposure studies.Allmiceexposedto5,000 or10,000ppm
bromoethane and 2/5 female mice exposed to 1,250 ppm
died before the end ofthe studies.
Fourteen-day inhalation studies were conducted in
rats and mice at target concentrations of 0, 250, 500,
1,000,2,000, or4,000ppmbromoethane.Allratsandmice
exposed to 2,000 or 4,000 ppm died before the end ofthe
14-day studies. Final mean bodyweights ofexposed and
control rats were similar.
Fourteen-week inhalation studies were conducted in
rats and mice attarget concentrations of0,100,200,400,
800, or 1,600 ppm bromoethane. Four of10 male and 2/10
female rats exposed to 1,600 ppm died before the end of
the 14-week studies. The final meanbodyweights ofrats
exposed to 1,600 ppm were lower than the initial mean
bodyweights. Compound-relatedlesions observedinrats
at 1,600 ppm, but not at lower concentrations, included
minimal atrophy of the thigh muscle, minimal-to-
moderate multifocal mineralization in the cerebellum of
thebrain,minimal-to-severe hemosiderosisofthespleen,
marked atrophy ofthe testis, and minimal-to-mild atro-
phyofthe uterus. The effects in the testis and uterus are
probably due to chemical-related loss in body weight
during the studies.
In mice, compound-related deaths included 3/10 male
and 1/10 female mice exposed to 1,600 ppm, 1/9 males
exposed to 800 ppm, and 1/10 males exposed to 400 ppm.
The final mean body weights of male and female mice
exposed to1,600ppmwere about15% lowerthan those of
controls. Compound-related effects included atrophy of
theuterus andinvolution ofthe ovaryinfemalesexposed
to 1,600 ppm bromoethane.
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Based on these results, 2-year studies were conducted
byexposinggroups of49 or50 rats ormice ofeach sexto
bromoethane at0,100,200, or400ppm, 6hoursperday, 5
days per week.
Body Weight and Survival in the Two-Year Studies:
Mean body weights of exposed and control rats were
generally similar throughout the studies. No significant
differences in survival were observed between any
groups ofmale rats (control, 17/49; 100 ppm, 26/50; 200
ppm, 27/50; 400 ppm, 21150); survival of the 100-ppm
group of female rats was greater than that of controls
(19/50;29/50;24/49;23/50), andthenumberofcontroland
400-ppm male rats and control female rats surviving to
the end ofthe studies was low.
Meanbodyweights ofthe400-ppmgroupofmalemice
were up to 9% lower than those of controls throughout
the study. Mean body weights ofthe 400-ppm group of
female mice were generally 6%-16% lower than those of
controls after week 29. No differences in survival were
observed between any group ofmale mice (35/50; 37/50;
30/50; 34/50). The survival of the 400-ppm group of
female mice was lower than that ofcontrols atthe end of
the study (36/50; 37/50; 37/49; 23/49).
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Theincidences ofpheochromocytomas ormalig-
nant pheochromocytomas (combined) of the adrenal
medulla were increased in exposed male rats (control,
8/40; 100 ppm, 23/45; 200 ppm, 18/46; 400 ppm, 21146).
Granular cell neoplasms of the brain were seen in
exposed male rats but not in controls (0/49; 3/50; 1/50;
1/50).Aglioma, anastrocytoma, or anoligodendroglioma
was seen in 3/50 male rats exposed to 100 ppm. Gliomas
were not observed in control female rats, but they
occurred in exposed female rats with a significant posi-
tive trend (0/50; 1/50; 1/48; 3/50). The historical incidence
of granular cell tumors in male F344/N rat chamber
controls at the study laboratory is 0/297. The incidences
ofgliomas in the exposed female groups were notsignifi-
cantly greater than that in the controls and were within
the historical incidence range forglial cell neoplasms for
untreated controls in NTP studies (mean: 23/1,969, 1%;
range: 0/50-3/50), but they exceeded the historical inci-
dencerangeforchambercontrolsatthestudylaboratory
(mean: 1/297, 0.3%; range: 0/50-1/50).
Alveolar epithelial hyperplasia was increased in rats
exposed to 400 ppmbromoethane (male: 3/48; 7/49; 7/48;
18/48; female: 5/50; 4/48; 5/47; 10/49). Alveolar/
bronchiolar adenomas or carcinomas (combined) were
seen in four male rats exposed to 200 ppm and in one
exposed to 400 ppm. Alveolar/bronchiolar adenomas
were observed in 3/49 female rats at 400 ppm but not at
lower concentrations or in controls. The incidences in
exposed male and female rats were not significantly
greater than those in controls; however, the historical
incidenceinratchambercontrolsforalveolar/bronchiolar
adenomas orcarcinomas (combined) atthe studylabora-
toryis 6/299 (2%) formales and 4/297(1.3%) forfemales.
Theincidences ofepithelial hyperplasia and squamous
metaplasia of the nasal cavity were increased in rats
exposed to400ppm.Theincidenceofsuppurativeinflam-
mation ofthenasal cavitywasincreasedin exposedmale
rats, and the incidences of suppurative inflammation of
the larynx and metaplasia of the olfactory sensory epi-
theliumwere increased in exposed male and female rats.
An adenoma ofthe nose was seen in one 400-ppm male
rat and in one 400-ppm female mouse.
Suppurative inflammation and dilatation of the sali-
vary gland ducts were observed at increased incidences
in the 200- and 400-ppm groups offemale rats. Animals
were found to be positive for rat coronavirus/sialod-
acryoadenitis virus antibodies.
The incidence ofmammary gland neoplasms was sig-
nificantlylowerinfemaleratsat400ppmthanincontrols
(18/50; 15/50; 10/48; 7/50).
Adenomas (0/50; 1/50; 1/47; 6/48), adenocarcinomas
(0/50; 2/50; 3/47; 19/48), and squamous cell carcinomas
(0/50; 1/50; 1/47; 3/48) ofthe uterus occurred in exposed
female mice and not in control mice.
The incidence of alveolar/bronchiolar neoplasms was
greater in male mice at 400 ppm than in controls (ade-
nomas or carcinomas, combined: 7/50; 6/50; 12/50; 15/50).
Acute/chronic inflammation ofthe lungwas observed at
increased incidences in female mice at 200 and 400 ppm.
Genetic Toxicology: Bromoethane, tested in a closed
environment of a desiccator, was mutagenic in S.
typhimurium strainTA100with andwithoutexogenous
metabolicactivation; itwasnotmutagenicinstrainTA98.
In cultured CHO cells,bromoethaneinduced sisterchro-
matid exchanges (SCEs) but not chromosomal aberra-
tions in both the presence and absence of exogenous
metabolic activation.
Conclusions: Under the conditions of these 2-year
inhalation studies, there was some evidence ofcarcino-
genic activity ofbromoethane for male F344/N rats, as
indicatedbyincreasedincidencesofpheochromocytomas
of the adrenal gland; neoplasms of the brain and lung
may also have been related to exposure to bromoethane.
For female F344/N rats, there was equivocal evidence
of carcinogenic activity, as indicated by marginally
increased incidences ofneoplasms ofthe brain and lung.
FormaleB6C3F1 mice, therewasequivocalevidenceof
carcinogenic activity, based on marginally increased
incidences of neoplasms of the lung. There was clear
evidence of carcinogenic activity for female B6C3F
mice, as indicated by neoplasms ofthe uterus.
Synonyms: monobromoethane; bromic ether; hydro-
bromic ether
Report Date: October 1989
TR-364 Tobxicology and Carcinogenesis
Studies ofRhodamine 6G (C.I. Basic Red
1) (CAS No. 989-38-8) in F344/N Rats and
B6C3F1 Mice (FeedStudies)
Toxicology and carcinogenesis studies of rhodamine
6Gwere conductedbecause ofpotential human exposure
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related toits use asadyefornatural and syntheticfibers
and as a research chemical. These studies were con-
ducted by administering rhodamine 6G (greater than
95% pure) in feed to groups ofF344/N rats andB6C3Fj
mice ofeach sexfor14 days, 13weeks, or2years. Genetic
toxicology studies were conducted in Salmonella
typhimurium, mouse L5178Ylymphoma cells, and Chi-
nese hamster ovary (CHO) cells.
Fourteen-Day and Thirteen-Week Studies: In the 14-
daystudies (0,310,620,1,250,2,500, or5,000ppm),allfive
male andfivefemale ratsthatreceived5,000ppmand115
male rats that received 2,500 ppm died before the end of
the studies; all mice lived to the end of the study. The
final mean bodyweights ofrats that received 2,500 ppm




In the 13-week studies, all rats lived to the end ofthe
studies (dietary concentrations of 0 or 120-2,000 ppm).
The final mean body weights of rats that received 500,
1,000or2,000ppmwere12%,13%, or32%lowerthanthat
of controls for males and 4%, 8%, or 20% lower for
females. Feed consumption by rats that received 2,000
ppm was somewhat lower than that by controls. Bone
marrow atrophy was observed at increased incidences
and severity in dosed rats. In the 13-week study (0 or





female mice that received 2,000 or 4,000 ppm were
13%-19% lowerthanthose ofcontrols. Feed consumption
was not related to dose. Minimal-to-moderate
cytoplasmicvacuolization ofhepatocytes was seenin8/10
male mice that received 8,000 ppm.
Basedontheseresults,dietaryconcentrationsselected
forthe2-year studieswere 0,120, or250 ppmrhodamine
6G for rats, 0, 1,000, or 2,000 ppm for male mice, and 0,
500, 1,000 ppm for female mice.
Body Weight and Survival in the Two-Year Studies:
Meanbodyweights ofdosedratswere similartothoseof
controls throughout the studies. The average daily feed
consumption by dosed rats was within 5% that by con-
trols for all dosed groups. The average amount of rho-
damine6Gconsumedperdaywasapproximately 5mg/kg
forlowdoserats and10 or12mg/kgforhigh dosemale or
female rats. Mean body weights of high dose male and
dosed female mice were generally 5%-14% lower than
those ofcontrols. The average dailyfeed consumptionby
dosed mice was within 5% that by controls for all dosed
groups. The average amount ofrhodamine 6G consumed
perdaywas approximately210 or440mg/kgforlowdose
orhighdosemalemiceand125or250mg/kgforlowdose
or high dose female mice. No significant differences in
survival were observed between any groups of rats or
mice(malerats: control,22/50; lowdose,21150; highdose,
27/50; female rats: 29/50; 30/50; 30/50; male mice: 36/50;
32/50; 38/50; female mice: 39/50; 35/50; 36/50).
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: No chemically related nonneoplastic lesions in
male or female rats and no chemically related neoplastic
or nonneoplastic lesions in male or female mice were
observed in these studies.
The incidences of keratoacanthomas of the skin was
increased in high dose male rats (control, 1/50; low dose,
2/50; highdose,8/50).Thehistoricalincidenceofkeratoa-
canthomas in untreated control male F344/N rats is
3V1,936(1.6%;range,0/50-7/49).Bothfurandskinofrats
inthedosedgroupsapparentlywereexposedtofeeddust
containing rhodamine 6G; the intensity of staining was
proportional to the concentration of rhodamine 6G in
feed. Because of the variable background incidence of
keratoacanthomas in F344/N rats, the incidence of ker-
atoacanthomas cannot be conclusively related to expo-
sure to rhodamine 6G.
The incidences of pheochromocytomas (3/50; 3/50;
8/50) ormalignantpheochromocytomas (combined: 3/50;
3/50; 10/50) ofthe adrenal gland were increased in high
dose female rats. The historical incidence of adrenal
medullary neoplasms in untreated control F344/N
femaleratsis99/1,968(5%;range, 0/50-8/50). Thismargi-
nal increase may be related to the administration of
rhodamine 6G.
GeneticToxicology: Rhodamine6Gwasnotmutagenicin
S. typhimurium strains TA98, TA100, TA1535, orTA1537
when testedwith andwithout exogenous metabolic activa-
tion (S9). Rhodamine 6G gave a positive response in the
absenceofS9inthemouselymphomaassayforinductionof
trifluorothymidine (Tft) resistance in L5178Y cells; in the
presenceofS9,rhodamine6Gwasnegative. Rhodarnine6G
induced sisterchromatidexchanges(SCEs)andchromoso-
mal aberrations in cultured CHO cells in the presence, but
not the absence, ofS9.
Conclusions: Undertheconditions ofthese2-yearfeed
studies, there was equivocal evidence ofcarcinogenic
activity for male F344/N rats administered rhodamine
6G, as indicated by a marginally increased incidence of
integumentarykeratoacanthomas. Therewas equivocal
evidence of carcinogenic activity for female F344/N
rats administered rhodamine 6G, as indicated by a mar-
ginal increase in pheochromocytomas ormalignantphe-
ochromocytomas (combined) ofthe adrenal gland. There
was no evidence of carcinogenic activity for male
B6C3F1 mice administered 1,000 or 2,000 ppm rho-
damine6Ginthediet.Therewasnoevidenceofcarcino-
genicactivity forfemaleB6C3F1 miceadministered500
or 1,000 ppm rhodamine 6G in the diet.
There were no significant nonneoplastic lesions
attributed to rhodamine 6G administration to male or
female rats ormale orfemalemice. Male andfemale rats
mighthavebeenabletotolerateahigherconcentrationof
rhodamine 6G in the feed.
Synonym: 2-[6-(ethylamino)-3-(ethylimino)2,7-
dimethyl-3H-xanthen-9-yl] benzoic acid ethyl ester,
monohydrochloride
Common Names: Basic Red 1; Basic RhodamineYellow;
Basic Rhodaminic Yellow; Calcozine Red 6G; Calcozine
241242 NTP/NIEHS
Rhodamine 6GX; C.I. Basic Red 1, Monohydrochloride;
Elcozine Rhodamine 6GDN; Eljon Pink Toner; Fanal
Pink GFK; Fanal Red25532; Flexo Red 482; Heliostable
Brilliant Pink B extra; Mitsui Rhodamine 6GCP; Nyco
Liquid Red GF; Rhodamine 69DN Extra; Rhodamine
F4G; Rhodamine F5G; Rhodamine F5G chloride; Rho-
damine 6GB; Rhodamine 6GBN; Rhodamine 6GCP;
Rhodamine 6GD; Rhodamine 4GD; Rhodamine GDN;
Rhodamine 5GDN; Rhodamine 6 GDN; Rhodamine
GDN Extra; Rhodamine 6GEx ethyl ester; Rhodamine
6GExtra; Rhodamine 6G ExtraBase; Rhodamine 4GH;
Rhodamine 6GH; Rhodamine 5GL; Rhodamine 6G lake;
Rhodamine 6GX; Rhodamine J; Rhodamine 6JH; Rho-
damine 7JH; Rhodamine Lake Red 6G; Rhodamine Y
20-7425; RhodamineZh; Rhodamine6ZH-DN; Silosuper
Pink B; Valley Fast Red 1308
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TR-365 Toxicology and Carcinogenesis
Studies ofPentaerythritol Tetranitrate
(CAS No. 78-11-5) with 80% D-Lactose
Monohydrate (PETN, NF) in F344/N Rats
andB6C3F1 Mice (Feed Studies)
Pentaerythritol tetranitrate (PETN, NF) is a drug
used to preventanginapectoris. PETNwithout alactose
stabilizerisused as anexplosive. Toxicologyandcarcino-
genesisstudieswereconductedbyadministeringPETN,
NF, to groups ofF344/N rats and B6C3F1 mice ofeach
sexoncebygavageorinfeedfor14days,13 or14weeks,or
2 years. The PETN component was greater than 99%
pure. Genetic toxicology studies were conducted with
Salmanella typhimurium and Chinese hamster ovary
(CHO) cells.
Fourteen-Day and Thirteen-Week Studies: All rats
and mice lived to the end of the 14-day studies (dietary
concentrations up to 50,000 ppm). Final mean body
weights ofdosed and control rats were comparable. The
final mean body weight of female mice that received
50,000 ppm was 13% lower than that of controls. No
clinical signs or toxic lesions were attributed to PETN,
NF, administration.
All rats andmicelived totheend ofthe13-week (mice)
and 14-week (rats) studies (dietary concentrations up to
50,000 ppm). Final mean body weights of dosed and
controlrats andmiceweresimilar,althoughweightgains
offemale rats at 25,000 and 50,000 ppm were less than
that of controls. The nitrite level in urine of rats and
methemoglobin levels in whole blood of rats and mice
were not affected by administration of PETN, NF. An
adenoma of the Zymbal gland was seen in a female rat
thatreceived 50,000 ppm. Ahepatocellular adenomawas
seen in a female mouse that received 50,000 ppm.
Based on these results and the NTP convention of
limiting concentrations in 2-year feed studies to 5% of
the diet, the 2-year studies were conducted by admin-
istering 0, 25,000 or 50,000 ppm PETN, NF, in feed for
104weeks to groups of50male rats and for 103weeks to
groups of49 or 50 mice ofeach sex. Groups of50 female
rats were given feed containing 0, 6,200, or 12,500 ppm
PETN, NF, for 104 weeks.
Body Weight and Survival in the Two-Year Studies:
Mean bodyweights ofhigh dose male rats were 2%-9%
lower than those ofcontrols throughout the study; body
weights of all groups of female rats were similar. No
significant differences in survival were observed
between any groups ofrats ofeither sex (male: control,
23/50; low dose, 29/50; high dose, 29/50; female: 33/50;
33/50; 31150). Mean body weights of dosed and control
mice were similar. The survival ofboth groups of dosed
male mice was significantly greater than that of the
controls (26/49; 38/50; 38/50). No significant differences
in survivalwere observed between any groups offemale
mice (38/50; 30/50; 38/50).
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: No nonneoplastic lesions were attributed to
PETN, NF, administration inrats ormice. Neoplasms of
the Zymbal gland occurred in dosed male (control, 0/49;
low dose, 3/45; high dose, 2/41) and dosed female (0/36;
1/37; 3/35) rats. The historical incidence of these neo-
plasmsis 1% ± 2%inuntreatedmales and 0.6% ± 1% in
females.
At no site was a significantly increased incidence of
neoplasms observed in dosed male or female mice.
Genetic Toxicology: PETN, NF, was not mutagenic in
S. typhimurium strains TA98, TA100, TA1535, or
TA1537whentestedwith orwithoutexogenous metabolic
activation (S9). When tested for cytogenetic effects in
culturedCHOcells,PETN,NF,inducedsisterchromatid
exchanges (SCEs) in the presence and absence of
metabolic activation; no induction of chromosomal
aberrations was observed in CHO cells with or without
activation.
Audit: The data, documents, and pathology materials
fromthe2-yearstudies ofPETN, NF,havebeenaudited.
The auditfindings showthatthe conductofthe studiesis
documentedadequatelyand supportthedataandresults
given in this Technical Report.
Conclusions: Underthe conditions ofthese2-yearfeed
studies, there was equivocal evidence ofcarcinogenic
activity ofPETN, NF, formale andfemale F344/N rats,
basedonamarginalincreaseinneoplasms oftheZymbal
gland. Female rats might have tolerated a higher dose.
There was no evidence of carcinogenic activity of
PETN, NF, for male or female B6C3F1 mice fed diets
containing 25,000, or 50,000 ppm for 2 years. No non-
neoplastic lesions were attributed to PETN, NF, admin-
istration.
Synonyms for PETN: 2,2-bis((nitrooxy)methyl)-1,3-
propanediol dinitrate (ester); 2,2-bisdihydroxy-
methyl-1,3-propanediol tetranitrate; niperyt; nitropen-
taerythritol; pentaerythrityl tetranitrate; penthrit
Trade Names for PETN, NF: Angitet; Cardiacap;
Dilcoran-80; Dipentrate; Hasethrol; Lentrat; Metranil;
Myeardol; Neo-Corovas; Nitropenta; Nitropenton; Pen-